NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1

Abstract

The disclosure provides fusion proteins specific for both CD 137 and PD-L1, which fusion protein can be used to co-stimulate lymphocyte activation in a PD-L1-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.

Description

I. BACKGROUND

Programmed death-ligand 1, or PD-L1 (also known as cluster of differentiation 274 or CD274 and B7 homolog 1 or B7-H1) is a single pass type I membrane protein belonging to the B7 family of co-stimulatory/co-inhibitory molecules of antigen presentation. The extracellular portion of PD-L1 contains two domains, an N-terminal IgV-type domain and an IgC-type domain. PD-L1 has a short cytoplasmatic domain without any obvious signal transduction motif, which led to the initial belief that there is no intrinsic signaling by PD-L1 as receptor. Recent data, however, show that the cytoplasmatic domain of PD-L1 contains non-classical conserved signal transduction motifs capable of inhibiting interferon (IFN) transduction and protecting cancer cells from IFN cytotoxicity (Gato-Canas et al., Cell Rep, 2017).

PD-L1 plays a crucial role in the suppression of the immune system during pregnancy, chronic infections, tissue allografts, autoimmune diseases, and cancer. PD-L1 is expressed on a variety of cell types including B cells, T cells, macrophages, myeloid dendritic cells, mast cells, epithelial, and vascular endothelial cells. It is also expressed in several cancer types including but not limited to melanoma, lung, bladder, colon, and breast cancer. High PD-L1 expression levels are associated with increased tumor aggressiveness by mediating the exhaustion and anergy of tumor infiltrating T cells, the secretion of immuno-suppressive cytokines, and protection from lysis by cytotoxic T cells.

PD-L1 is a ligand of the programmed cell death protein 1 (PD-1), a key immune checkpoint inhibitory receptor that is primarily expressed on activated T cells but also on other cells of the immune system including B cells and monocytes. PD-1 is a member of the immunoglobulin family containing an IgV-like extracellular domain, a transmembrane domain and a cytoplasmatic tail with an ITIM (immunoreceptor tyrosine-based inhibitory motif) and an ITSM (immunoreceptor tyrosine-based switch motif). Engagement of PD-1 by PD-L1 leads to the recruitment of src homology 2 domain-containing tyrosine phosphatases 1 and 2 (SHP 1 and 2) to the intracellular switch motifs of PD-1 and to the expression of E3 ubiquitin ligases of the CBL family. These ubiquitin ligases subsequently ubiquitinate and inactivate key TCR signal transduction mediators leading to the removal of TCR's from the cell surface (Karwacz et al., EMBO Mol Med, 2011). The SHP 1 and SHP 2 phosphatases inhibit TCR signaling directly by terminating ZAP70 and PI3K phosphorylation. In addition, PD-L1 engaged PD-1 can cause inhibition of TCR signaling pathways by affecting the expression and activity of CK2 and cyclin-dependent kinases (CDKs) (Arasanz et al., Oncotarget, 2017). It was also shown that PD-1 engagement leads to re-programming of the T cell metabolism from increased glycolysis, which is required to produce energy for effector functions, to fatty acid β-oxidation, which is associated with long-lived cells. This may also explain the survival and persistence of high PD-1 expressing cells in patients with chronic infections and cancer (Patsoukis et al., Nat Commun, 2015).

Blocking the PD-1/PD-L1 interaction by anti-PD-1 or anti-PD-L1 targeting agents can reverse the immune checkpoint function and release the brake on T cell responses. Currently three PD-L1 antibodies, atezolizumab (TECENTRIQ, MPDL3280A, RG7466), avelumab (BAVENCIO, MSB0010718C), and durvalumab (IMFINZI, MEDI4736), are approved for the treatment of cancer. Several successful clinical trials with these antibodies have shown high objective response rates, durability of response, or improved survival rates in bladder cancer, skin cancer and lung cancer (Xu-Monette et al., Front Immunol, 2017).

Cluster of differentiation 137 or CD137 (also known as 4-1BB or TNFRS9) is a co-stimulatory immune receptor and a member of the tumor necrosis factor receptor (TNFR) super-family. It is primarily expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells but can also be found on resting monocytes and dendritic cells (Li and Liu, Clin Pharmacol, 2013), or endothelial cells (Snell et al., Immunol Rev, 2011). CD137 plays an important role in regulation of the immune response and thus is a target for cancer immunotherapy. CD137 ligand (CD137L) is the only known natural ligand of CD137, and is constitutively expressed on several types of antigen presenting cells, such as activated B cells, monocytes, and splenic dendritic cells, and can be induced on T lymphocytes.

CD137L is a trimeric protein that exists as a membrane-bound form and as a soluble variant. The ability of soluble CD137L to activate CD137, e.g., on CD137-expressing lymphocytes is limited, however, and large concentrations are required to elicit an effect (Wyzgol et al., J Immunol, 2009). The natural way of activation of CD137 is via the engagement of a CD137-positive cell with a CD137L-positive cell. CD137 activation is then thought to be induced by clustering through CD137L on the opposing cell, leading to signaling via TRAF1, 2 and 3 (Yao et al., Nat Rev Drug Discov, 2013, Snell et al., Immunol Rev, 2011) and further concomitant downstream effects in the CD137-positive T-cell. In the case of T-cells activated by recognition of their respective cognate targets, the effects elicited by costimulation of CD137 are a further enhanced activation, enhanced survival and proliferation, the production of pro-inflammatory cytokines and an improved capacity to kill.

The benefit of CD137 costimulation for the elimination of cancer cells has been demonstrated in a number of in vivo models. The forced expression of CD137L on a tumor, for example, leads to tumor rejection (Melero et al., Eur J Immunol, 1998). Likewise, the forced expression of an anti-CD137 scFv on a tumor leads to a CD4⁺ T-cell and NK-cell dependent elimination of the tumor (Yang et al., Cancer Res, 2007, Zhang et al., Mol Cancer Ther, 2006, Ye et al., Nat Med, 2002). A systemically administered anti-CD137 antibody has also been demonstrated to lead to retardation of tumor growth (Martinet et al., Gene Ther, 2002).

It has been shown that CD137 is an excellent marker for naturally occurring tumor-reactive T cells in human tumors (Ye et al., Clin Cancer Res, 2014), and that anti-CD137 antibodies can be employed to improve the expansion and activity of CD8⁺ melanoma tumor-infiltrating lymphocytes for the application in adoptive T-cell therapy (Chacon et al., PLoS One, 2013).

The preclinical demonstration of the potential therapeutic benefit of CD137 costimulation has spurred the development of therapeutic antibodies targeting CD137, including BMS-663513 (described in U.S. Pat. No. 7,288,638) and PF-05082566 (Fisher et al., Cancer Immunol immunother, 2012).

The present disclosure provides, among other things, novel approaches for simultaneously engaging CD137 and PD-L1 via one or more fusion proteins having the properties of binding specificity for CD137 and binding specificity for PD-L1.

II. DEFINITIONS

The following list defines terms, phrases, and abbreviations used throughout the instant specification. All terms listed and defined herein are intended to encompass all grammatical forms.

As used herein, unless otherwise specified, “CD137” means human CD137 (huCD137). Human CD137 means a full-length protein defined by UniProt Q07011, a fragment thereof, or a variant thereof. CD137 is also known as 4-1BB, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), and induced by lymphocyte activation (ILA). In some particular embodiments, CD137 of non-human species, e.g., cynomolgus CD137 and mouse CD137, is used.

As used herein, unless otherwise specified, “programmed cell death 1 ligand 1” or “PD-L1” means human PD-L1 (huPD-L1). Human PD-L1 means a full-length protein defined by UniProt Q9NZQ7, a fragment thereof, or a variant thereof. Human PD-L1 is encoded by the CD274 gene. PD-L1 is also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1). In some particular embodiments, PD-L1 of non-human species, e.g., cynomolgus PD-L1 and mouse PD-L1, is used.

As used herein, “binding affinity” describes the ability of a biomolecule (e.g., a polypeptide or a protein) of the disclosure (e.g., a lipocalin mutein, an antibody, a fusion protein, or any other peptide or protein) to bind a selected target and form a complex. Binding affinity is measured by a number of methods known to those skilled in the art including, but are not limited to, fluorescence titration, enzyme-linked immunosorbent assay (ELISA)-based assays, including direct and competitive ELISA, calorimetric methods, such as isothermal titration calorimetry (ITC), and surface plasmon resonance (SPR). These methods are well-established in the art and some examples of such methods are further described herein. Binding affinity is thereby reported as a value of dissociation constant (K_D), half maximal effective concentration (EC₅₀), or half maximal inhibitory concentration (IC₅₀) measured using such these methods. A lower K_D, EC₅₀, or IC₅₀ value reflects better (higher) binding ability (affinity). Accordingly, the binding affinities of two biomolecules toward a selected target can be measured and compared. When comparing the binding affinities of two biomolecules toward the selected target, the term “about the same,” “substantially the same” or “substantially similar” means one biomolecule has a binding affinity reported as a K_D, an EC₅₀, or an IC₅₀ value that is identical or similar to another molecule within the experimental variability of the binding affinity measurement. The experimental variability of the binding affinity measurement is dependent upon the specific method used and is known to those skilled in the art.

As used herein, the term “substantially” may also refer to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

As used herein, the term “detect,” “detection,” “detectable,” or “detecting” is understood both on a quantitative and a qualitative level, as well as a combination thereof. It thus includes quantitative, semi-quantitative, and qualitative measurements performed on a biomolecule of the disclosure.

As used herein, “detectable affinity” generally means the binding ability between a biomolecule and its target, reported by a K_D, EC₅₀, or IC₅₀ value, is at most about 10⁻⁵ M or lower. A binding affinity, reported by a K_D, EC₅₀, or IC₅₀ value, higher than 10⁻⁵ M is generally no longer measurable with common methods such as ELISA and SPR and is therefore of secondary importance.

It is noted that the complex formation between the biomolecule of the disclosure and its target is influenced by many different factors such as the concentrations of the respective target, the presence of competitors, pH and the ionic strength of the buffer system used, the experimental method used for determination of the binding affinity (e.g., fluorescence titration, competitive ELISA (also called competition ELISA), and surface plasmon resonance), and even the mathematical algorithm used for evaluation of the experimental data. Therefore, it is clear to the skilled person that binding affinity reported by a K_D, EC₅₀, or IC₅₀ value may vary within a certain experimental range, depending on the method and experimental setup. This means that there may be a slight deviation in the measured K_D, EC₅₀, or IC₅₀ values or a tolerance range depending, for example, on whether such values were determined by ELISA (including direct or competition ELISA), by SPR, or by another method.

As used herein, “specific for,” “specific binding,” “specifically bind,” or “binding specificity” relates to the ability of a biomolecule to discriminate between the desired target (for example, CD137 and PD-L1) and one or more reference targets (for example, cellular receptor for neutrophil gelatinase-associated lipocalin). It is understood that such specificity is not an absolute but a relative property and can be determined, for example, in accordance with SPR, western blots, ELISA, fluorescence activated cell sorting (FACS), radioimmunoassay (RIA), electrochemiluminescence (ECL), immunoradiometric assay (IRMA), ImmunoHistoChemistry (IHC), and peptide scans.

When used herein in the context of the fusion protein of the present disclosure that bind to CD137 and PD-L1, the term “specific for,” “specific binding,” “specifically bind,” or “binding specificity” means that the fusion protein binds to, reacts with, or is directed against CD137 and PD-L1, as described herein, but does not essentially bind another protein. The term “another protein” includes any proteins that are not CD137 or PD-L1 or proteins closely related to or being homologous to CD137 or PD-L1. However, CD137 or PD-L1 from species other than human and fragments and/or variants of CD137 or PD-L1 are not excluded by the term “another protein.” The term “does not essentially bind” means that the fusion proteins of the present disclosure bind another protein with lower binding affinity than CD137 and/or PD-L1, i.e., shows a cross-reactivity of less than 30%, preferably 20%, more preferably 10%, particularly preferably less than 9, 8, 7, 6, or 5%. Whether the fusion protein specifically reacts as defined herein above can easily be tested, inter alia, by comparing the reaction of a fusion protein of the present disclosure with CD137 and/or PD-L1 and the reaction of said fusion protein with (an)other protein(s).

As used herein, the term “lipocalin” refers to a monomeric protein of approximately 18-20 kDa in weight, having a cylindrical β-pleated sheet supersecondary structural region comprising a plurality of β-strands (preferably eight β-strands designated A to H) connected pair-wise by a plurality of (preferably four) loops at one end to thereby comprise a ligand-binding pocket and define the entrance to the ligand-binding pocket. Preferably, the loops comprising the ligand-binding pocket used in the present invention are loops connecting the open ends of β-strands A and B, C and D, E and F, and G and H, and are designated loops AB, CD, EF, and GH. It is well-established that the diversity of the said loops in the otherwise rigid lipocalin scaffold gives rise to a variety of different binding modes among the lipocalin family members, each capable of accommodating targets of different sizes, shape, and chemical character (reviewed, e.g. in Skerra, Biochim Biophys Acta, 2000, Flower et al., Biochim Biophys Acta, 2000, Flower, Biochem J, 1996). It is understood that the lipocalin family of proteins has naturally evolved to bind a wide spectrum of ligands, sharing unusually low levels of overall sequence conservation (often with sequence identities of less than 20%) yet retaining a highly conserved overall folding pattern. The correspondence between positions in various lipocalins is also well-known to one of skill in the art (see, e.g., U.S. Pat. No. 7,250,297). Proteins fall in the definition of “lipocalin” as used herein include, but not limited to, human lipocalins including tear lipocalin (Tic, Lcn1), Lipocalin-2 (Lcn2) or neutrophil gelatinase-associated lipocalin (NGAL), apolipoprotein D (ApoD), apolipoprotein M, α₁-acid glycoprotein 1, α₁-acid glycoprotein 2, α₁-microglobulin, complement component 8γ, retinol-binding protein (RBP), the epididymal retinoic acid-binding protein, glycodelin, odorant-binding protein IIa, odorant-binding protein IIb, lipocalin-15 (Lcn15), and prostaglandin D synthase.

As used herein, unless otherwise specified, “tear lipocalin” refers to human tear lipocalin (hTlc) and further refers to mature human tear lipocalin. The term “mature” when used to characterize a protein means a protein essentially free from the signal peptide. A “mature hTlc” of the instant disclosure refers to the mature form of human tear lipocalin, which is free from the signal peptide. Mature hTlc is described by residues 19-176 of the sequence deposited with the SWISS-PROT Data Bank under Accession Number P31025, and the amino acid of which is indicated in SEQ ID NO: 1.

As used herein, “Lipocalin-2” or “neutrophil gelatinase-associated lipocalin” refers to human Lipocalin-2 (hLcn2) or human neutrophil gelatinase-associated lipocalin (hNGAL) and further refers to the mature human Lipocalin-2 or mature human neutrophil gelatinase-associated lipocalin. The term “mature” when used to characterize a protein means a protein essentially free from the signal peptide. A “mature hNGAL” of the instant disclosure refers to the mature form of human neutrophil gelatinase-associated lipocalin, which is free from the signal peptide. Mature hNGAL is described by residues 21-198 of the sequence deposited with the SWISS-PROT Data Bank under Accession Number P80188, and the amino acid of which is indicated in SEQ ID NO: 2.

As used herein, a “native sequence” refers to a protein or a polypeptide having a sequence that occurs in nature or having a wild-type sequence, regardless of its mode of preparation. Such native sequence protein or polypeptide can be isolated from nature or can be produced by other means, such as by recombinant or synthetic methods.

The “native sequence lipocalin” refers to a lipocalin having the same amino acid sequence as the corresponding polypeptide derived from nature. Thus, a native sequence lipocalin can have the amino acid sequence of the respective naturally-occurring (wild-type) lipocalin from any organism, in particular, a mammal. The term “native sequence”, when used in the context of a lipocalin specifically encompasses naturally-occurring truncated or secreted forms of the lipocalin, naturally-occurring variant forms such as alternatively spliced forms and naturally-occurring allelic variants of the lipocalin. The terms “native sequence lipocalin” and “wild-type lipocalin” are used interchangeably herein.

As used herein, a “mutein,” a “mutated” entity (whether protein or nucleic acid), or “mutant” refers to the exchange, deletion, or insertion of one or more amino acids or nucleotides, compared to the naturally-occurring (wild-type) protein or nucleic acid. Said term also includes fragments of a mutein as described herein. The present disclosure explicitly encompasses lipocalin muteins, as described herein, having a cylindrical β-pleated sheet supersecondary structural region comprising eight β-strands connected pair-wise by four loops at one end to thereby comprise a ligand-binding pocket and define the entrance of the ligand-binding pocket, wherein at least one amino acid of each of at least three of said four loops has been mutated as compared to the native sequence lipocalin. Lipocalin muteins of the present invention thereof preferably have the function of binding CD137 as described herein.

As used herein, the term “fragment,” in connection with the lipocalin muteins of the disclosure, refers to proteins or polypeptides derived from full-length mature hTlc or hNGAL or lipocalin muteins that are N-terminally and/or C-terminally truncated, i.e., lacking at least one of the N-terminal and/or C-terminal amino acids. Such fragments may include at least 10 or more, such as 20 or 30 or more consecutive amino acids of the primary sequence of mature hTlc or hNGAL or the lipocalin mutein it is derived and are usually detectable in an immunoassay of mature hTlc or hNGAL. Such a fragment may lack up to 2, up to 3, up to 4, up to 5, up to 10, up to 15, up to 20, up to 25, or up to 30 (including all numbers in between) of the N-terminal and/or C-terminal amino acids. As an illustrative example, such a fragment may lack the one, two, three, or four N-terminal (His-His-Leu-Leu) and/or one or two C-terminal amino acids (Ser-Asp) of mature hTlc. It is understood that the fragment is preferably a functional fragment of mature hTlc or hNGAL or the lipocalin mutein from which it is derived, which means that it preferably retains the binding specificity, preferably to CD137, of mature hTlc/hNGAL or lipocalin mutein it is derived from. As an illustrative example, such a functional fragment may comprise at least amino acids at positions 5-153, 5-150, 9-148, 12-140, 20-135, or 26-133 corresponding to the linear polypeptide sequence of mature hTlc. As another illustrative example, such a functional fragment may comprise at least amino acids at positions 13-157, 15-150, 18-141, 20-134, 25-134, or 28-134 corresponding to the linear polypeptide sequence of mature hNGAL.

A “fragment” with respect to the corresponding target CD137 or PD-L1 of a fusion protein of the disclosure, refers to N-terminally and/or C-terminally truncated CD137 or PD-L1 or protein domains of CD137 or PD-L1. Fragments of CD137 or fragments of PD-L1 as described herein retain the capability of the full-length CD137 or PD-L1 to be recognized and/or bound by a fusion protein of the disclosure. As an illustrative example, the fragment may be an extracellular domain of CD137 or PD-L1. As an illustrative example, such an extracellular domain may comprise amino acids of the extracellular subdomains of CD137, such as the individual or combined amino acid sequences of domain 1 (residues 24-45 of UniProt Q07011), domain 2 (residues 46-86), domain 3 (87-118) and domain 4 (residues 119-159). As another illustrative example, such an extracellular domain may comprise amino acids residues 19-238 of UniProt Q9NZQ7.

As used herein, the term “variant” relates to derivatives of a protein or polypeptide that include mutations, for example by substitutions, deletions, insertions, and/or chemical modifications of an amino acid sequence or nucleotide sequence. In some embodiments, such mutations and/or chemical modifications do not reduce the functionality of the protein or peptide. Such substitutions may be conservative, i.e., an amino acid residue is replaced with a chemically similar amino acid residue. Examples of conservative substitutions are the replacements among the members of the following groups: 1) alanine, serine, threonine, and valine; 2) aspartic acid, glutamic acid, glutamine, and asparagine, and histidine; 3) arginine, lysine, glutamine, asparagine, and histidine; 4) isoleucine, leucine, methionine, valine, alanine, phenylalanine, threonine, and proline; and 5) isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan. Such variants include proteins or polypeptides, wherein one or more amino acids have been substituted by their respective D-stereoisomers or by amino acids other than the naturally occurring 20 amino acids, such as, for example, ornithine, hydroxyproline, citrulline, homoserine, hydroxylysine, norvaline. Such variants also include, for instance, proteins or polypeptides in which one or more amino acid residues are added or deleted at the N- and/or C-terminus. Generally, a variant has at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95% or at least about 98% amino acid sequence identity with the native sequence protein or polypeptide. A variant preferably retains the biological activity, e.g. binding the same target, of the protein or polypeptide it is derived.

The term “variant”, as used herein with respect to the corresponding protein ligand CD137 or PD-L1 of a fusion protein of the disclosure, relates to CD137 or PD-L1 or fragment thereof, respectively, that has one or more such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 40, 50, 60, 70, 80 or more amino acid substitutions, deletions and/or insertions in comparison to the native sequence of CD137 or PD-L1 (wild-type CD137 or PD-L1), such as CD137 as deposited with UniProt Q07011 or PD-L1 as deposited with UniProt Q9NZQ7 as described herein. A CD137 variant or a PD-L1 variant, respectively, has preferably an amino acid identity of at least 50%, 60%, 70%, 80%, 85%, 90% or 95% with a wild-type CD137 or PD-L1. A CD137 variant or a PD-L1 variant as described herein retains the ability to bind fusion proteins specific to CD137 and PD-L1 disclosed in the instant invention.

The term “variant”, as used herein with respect to a lipocalin mutein, relates to a lipocalin mutein or fragment thereof of the disclosure, wherein the sequence has mutations, including substitutions, deletions, and insertions, and/or chemical modifications. A variant of lipocalin mutein as described herein retains the biological activity, e.g., binding to CD137, of the lipocalin mutein from which it is derived. Generally, a lipocalin mutein variant has at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% amino acid sequence identity with the lipocalin mutein from which it is derived.

As used herein, the term “mutagenesis” refers to the introduction of mutations into a polynucleotide or amino acid sequence. Mutations are preferably introduced under experimental conditions such that the amino acid naturally occurring at a given position of the protein or polypeptide sequence of can be altered, for example substituted by at least one amino acid. The term “mutagenesis” also includes the (additional) modification of the length of sequence segments by deletion or insertion of one or more amino acids. Thus, it is within the scope of the disclosure that, for example, one amino acid at a chosen sequence position is replaced by a stretch of three amino acids, leading to an addition of two amino acid residues compared to the length of the respective segment of the native protein or polypeptide amino acid sequence. Such an insertion or deletion may be introduced independently from each other in any of the sequence segments that can be subjected to mutagenesis in the disclosure. In one exemplary embodiment of the disclosure, an insertion may be introduced into amino acid sequence segment corresponding to the loop AB of the native sequence lipocalin (cf. International Patent Publication No. WO 2005/019256, which is incorporated by reference in its entirety herein).

As used herein, the term “random mutagenesis” means that no predetermined mutation (alteration of amino acid) is present at a certain sequence position but that at least two amino acids can be incorporated with a certain probability at a predefined sequence position during mutagenesis.

As used herein, the term “sequence identity” or “identity” denotes a property of sequences that measures their similarity or relationship. The term “sequence identity” or “identity” as used in the present disclosure means the percentage of pair-wise identical residues—following (homologous) alignment of a sequence of a protein or polypeptide of the disclosure with a sequence in question—with respect to the number of residues in the longer of these two sequences. Sequence identity is measured by dividing the number of identical amino acid residues by the total number of residues and multiplying the product by 100.

As used herein, the term “sequence homology” or “homology” has its usual meaning and homologous amino acid includes identical amino acids as well as amino acids which are regarded to be conservative substitutions at equivalent positions in the linear amino acid sequence of a protein or polypeptide of the disclosure (e.g., any fusion proteins or lipocalin muteins of the disclosure).

A skilled artisan will recognize available computer programs, for example BLAST (Altschul et al., Nucleic Acids Res, 1997), BLAST2 (Altschul et al., J Mol Biol, 1990), and Smith-Waterman (Smith and Waterman, J Mol Biol, 1981), for determining sequence homology or sequence identity using standard parameters. The percentage of sequence homology or sequence identity can, for example, be determined herein using the program BLASTP, version 2.2.5 (Nov. 16, 2002; (Altschul et al., Nucleic Acids Res, 1997). In this embodiment, the percentage of homology is based on the alignment of the entire protein or polypeptide sequences (matrix: BLOSUM 62; gap costs: 11.1; cutoff value set to 10⁻³) including the propeptide sequences, preferably using the wild-type protein scaffold as reference in a pairwise comparison. It is calculated as the percentage of numbers of “positives” (homologous amino acids) indicated as result in the BLASTP program output divided by the total number of amino acids selected by the program for the alignment.

Specifically, in order to determine whether an amino acid residue of the amino acid sequence of a lipocalin mutein is different from a wild-type lipocalin corresponding to a certain position in the amino acid sequence of a wild-type lipocalin, a skilled artisan can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as BLAST 2.0, which stands for Basic Local Alignment Search Tool, or ClustalW, or any other suitable program which is suitable to generate sequence alignments. Accordingly, a wild-type sequence of lipocalin can serve as “subject sequence” or “reference sequence,” while the amino acid sequence of a lipocalin mutein different from the wild-type lipocalin described herein serves as “query sequence.” The terms “wild-type sequence,” “reference sequence,” and “subject sequence” are used interchangeably herein. A preferred wild-type sequence of lipocalin is the sequence of hTLc as shown in SEQ ID NO: 1 or hNGAL as shown in SEQ ID NO: 2.

“Gaps” are spaces in an alignment that are the result of additions or deletions of amino acids. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved, and have deletions, additions, or replacements, may have a lower degree of sequence identity.

As used herein, the term “position” means the position of either an amino acid within an amino acid sequence depicted herein or the position of a nucleotide within a nucleic acid sequence depicted herein. It is to be understood that when the term “correspond” or “corresponding” as used herein in the context of the amino acid sequence positions of one or more lipocalin muteins, a corresponding position is not only determined by the number of the preceding nucleotides or amino acids. Accordingly, the absolute position of a given amino acid in accordance with the disclosure may vary from the corresponding position due to deletion or addition of amino acids elsewhere in a (mutant or wild-type) lipocalin. Similarly, the absolute position of a given nucleotide in accordance with the present disclosure may vary from the corresponding position due to deletions or additional nucleotides elsewhere in a mutein or wild-type lipocalin 5′-untranslated region (UTR) including the promoter and/or any other regulatory sequences or gene (including exons and introns).

A “corresponding position” in accordance with the disclosure may be the sequence position that aligns to the sequence position it corresponds to in a pairwise or multiple sequence alignment according to the present disclosure. It is preferably to be understood that for a “corresponding position” in accordance with the disclosure, the absolute positions of nucleotides or amino acids may differ from adjacent nucleotides or amino acids but said adjacent nucleotides or amino acids which may have been exchanged, deleted, or added may be comprised by the same one or more “corresponding positions”.

In addition, for a corresponding position in a lipocalin mutein based on a reference sequence in accordance with the disclosure, it is preferably to be understood that the positions of nucleotides or amino acids of a lipocalin mutein can structurally correspond to the positions elsewhere in a reference lipocalin (wild-type lipocalin) or another lipocalin mutein, even if they may differ in the absolute position numbers, as appreciated by the skilled in light of the highly-conserved overall folding pattern among lipocalins.

As used interchangeably herein, the terms “conjugate,” “conjugation,” “fuse,” “fusion,” or “linked” refer to the joining together of two or more subunits, through all forms of covalent or non-covalent linkage, by means including, but not limited to, genetic fusion, chemical conjugation, coupling through a linker or a cross-linking agent, and non-covalent association.

The term “fusion polypeptide” or “fusion protein” as used herein refers to a polypeptide or protein comprising two or more subunits. In some embodiments, a fusion protein as described herein comprises two or more subunits, at least one of these subunits being capable of specifically binding to CD137, and a further subunit capable of specifically binding to PD-L1. Within the fusion protein, these subunits may be linked by covalent or non-covalent linkage. Preferably, the fusion protein is a translational fusion between the two or more subunits. The translational fusion may be generated by genetically engineering the coding sequence for one subunit in a reading frame with the coding sequence of a further subunit. Both subunits may be interspersed by a nucleotide sequence encoding a linker. However, the subunits of a fusion protein of the present disclosure may also be linked through chemical conjugation. The subunits forming the fusion protein are typically linked to each other C-terminus of one subunit to the N-terminus of another subunit, or C-terminus of one subunit to C-terminus of another subunit, or N-terminus of one subunit to N-terminus of another subunit, or N-terminus of one subunit to C-terminus of another subunit. The subunits of the fusion protein can be linked in any order and may include more than one of any of the constituent subunits. If one or more of the subunits is part of a protein (complex) that consists of more than one polypeptide chain, the term “fusion protein” may also refer to the protein comprising the fused sequences and all other polypeptide chain(s) of the protein (complex). As an illustrative example, where a full-length immunoglobulin is fused to a lipocalin mutein via a heavy or light chain of the immunoglobulin, the term “fusion protein” may refer to the single polypeptide chain comprising the lipocalin mutein and the heavy or light chain of the immunoglobulin. The term “fusion protein” may also refer to the entire immunoglobulin (both light and heavy chains) and the lipocalin mutein fused to one or both of its heavy and/or light chains.

As used herein, the term “subunit” of a fusion protein disclosed herein refers to a single protein or a separate polypeptide chain, which may form a stable folded structure by itself and define a unique function of providing binding motif towards a target. In some embodiments, a preferred subunit of the disclosure is a lipocalin mutein. In some other embodiments, a preferred subunit of the disclosure is a full-length immunoglobulin or an antigen-binding domain thereof.

A “linker” that may be comprised by a fusion protein of the present disclosure joins together two or more subunits of a fusion protein as described herein. The linkage can be covalent or non-covalent. A preferred covalent linkage is via a peptide bond, such as a peptide bond between amino acids. A preferred linker is a peptide linker. Accordingly, in a preferred embodiment, said linker comprises one or more amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids. Preferred peptide linkers are described herein, including glycine-serine (GS) linkers, glycosylated GS linkers, and proline-alanine-serine polymer (PAS) linkers. In some preferred embodiments, a GS linker is a (G₄S)₃ as described in SEQ ID NO: 13 is used to join together the subunits of a fusion protein. Other preferred linkers include chemical linkers.

As used herein, the term “albumin” includes all mammal albumins such as human serum albumin or bovine serum albumin or rat serum albumin.

As used herein, the term “organic molecule” or “small organic molecule” denotes an organic molecule comprising at least two carbon atoms, but preferably not more than 7 or 12 rotatable carbon bonds, having a molecular weight in the range between 100 and 2,000 daltons, preferably between 100 and 1,000 daltons, and optionally including one or two metal atoms.

A “sample” is defined as a biological sample taken from any subject. Biological samples include, but are not limited to, blood, serum, urine, feces, semen, or tissue, including tumor tissue.

A “subject” is a vertebrate, preferably a mammal, more preferably a human. The term “mammal” is used herein to refer to any animal classified as a mammal, including, without limitation, humans, domestic and farm animals, and zoo, sports, or pet animals, such as sheep, dogs, horses, cats, cows, rats, pigs, apes such as cynomolgus monkeys, to name only a few illustrative examples. Preferably, the “mammal” used herein is human.

An “effective amount” is an amount sufficient to yield beneficial or desired results. An effective amount can be administered in one or more individual administrations or doses.

As used herein, “antibody” includes whole antibodies or any antigen binding fragment (i.e., “antigen-binding portion”) or single chain thereof. An whole antibody refers to a glycoprotein comprising at least two heavy chains (HCs) and two light chains (LCs) inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable domain (V_H or HCVR) and a heavy chain constant region (C_H). The heavy chain constant region is comprised of three domains, C_H1, C_H2 and C_H3. Each light chain is comprised of a light chain variable domain (V_L or LCVR) and a light chain constant region (C_L). The light chain constant region is comprised of one domain, C_L. The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each V_H and V_L is composed of three CDRs and four FRs, arranged in the following order from the amino-terminus to the carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen (for example, PD-L1). The constant regions of the antibodies may optionally mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

As used herein, “antigen binding fragment” of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., PD-L1). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include (i) a Fab fragment consisting of the V_H, V_L, C_L and C_H1 domains; (ii) a F(ab′)₂ fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab′ fragment consisting of the V_H, V_L, C_L and C_H1 domains and the region between C_H1 and C_H2 domains; (iv) a Fd fragment consisting of the V_H and C_H1 domains; (v) a single-chain Fv fragment consisting of the V_H and V_L domains of a single arm of an antibody, (vi) a dAb fragment (Ward et al., Nature, 1989) consisting of a V_H domain; and (vii) an isolated complementarity determining region (CDR) or a combination of two or more isolated CDRs which may optionally be joined by a synthetic linker; (viii) a “diabody” comprising the V_H and V_L connected in the same polypeptide chain using a short linker (see, e.g., patent documents EP 404,097; WO 93/11161; and Holliger et al., Proc Natl Acad Sci USA, 1993); (ix) a “domain antibody fragment” containing only the V_H or V_L, where in some instances two or more V_H regions are covalently joined.

Antibodies may be polyclonal or monoclonal; xenogeneic, allogeneic, or syngeneic; or modified forms thereof (e.g., humanized, chimeric, or multispecific). Antibodies may also be fully human.

As used herein, “framework” or “FR” refers to the variable domain residues other than the hypervariable region (CDR) residues.

“Fragment crystallizable region” or “Fc region” refers to the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof numbering according to EU index of Kabat (Johnson and Wu, Nucleic Acids Res, 2000). The C-terminal lysine (residue 447 according to EU index of Kabat) of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody. Accordingly, a composition of intact antibodies may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue. Suitable native-sequence Fc regions for use in the antibodies of the invention include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.

“Fc receptor” or “FcR” refers to a receptor that binds to the Fc region of an antibody.

As used herein, “isolated antibody” refers to an antibody that is substantially free of its natural environment. For instance, an isolated antibody is substantially free of cellular material and other proteins from the cell or tissue source from which it is derived. An “isolated antibody” further refers to an antibody that is substantially free of other antibodies having different antigenic specificities. In the present case, an isolated antibody that binds specifically PD-L1 is substantially free of antibodies that specifically bind antigens other than PD-L1. However, an isolated antibody that specifically binds PD-L1 may have cross-reactivity to other antigens, such as PD-L1 molecules from other species.

As used herein, “monoclonal antibody” refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

As used herein, “humanized antibody” refers to an antibody that consists of the CDR of antibodies derived from mammals other than human, and the FR region and the constant region of a human antibody or derived from a human antibody. In some embodiments a humanized antibody comprises a variable domain that has a variable region amino acid sequence which, analyzed as a whole, is closer to human than to other species as assessed using the Immunogenetics Information System (IMGT) DomainGapAlign tool, as described by Ehrenmann et al. (2010). In some embodiments, a humanized antibody may be useful as an effective component in a therapeutic agent due to the reduced antigenicity. The term “therapeutic agent” or “therapeutically active agent”, as used herein, refers to an agent which is therapeutically useful. A therapeutic agent may be any agent for the prevention, amelioration, or treatment of a diseases, a physiological condition, a symptom, or for the evaluation or diagnosis thereof.

As used herein, “human antibody” includes antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

III. DESCRIPTIONS OF FIGURES

FIG. 1: provides an overview over the design of the representative fusion proteins described in this application that are bispecific for the targets CD137 and PD-L1. Representative fusion proteins were made based on an antibody specific for PD-L1 (e.g. an antibody whereby heavy chains are provided by SEQ ID NO: 86, or comprise a heavy chain variable domain of SEQ ID NO: 77, or comprise the CDR sequences of GFSLSNYD (HCDR1, SEQ ID NO: 60), IWTGGAT (HCDR2, SEQ ID NO: 61), and VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 62), and light chains are provided by SEQ ID NO: 87, or comprise a heavy chain variable domain of SEQ ID NO: 82, or comprise the CDR sequences of QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), and QQSNSWPYT (LCDR3; SEQ ID NO: 64)) and one or more lipocalin mutein specific for CD137 (e.g., the lipocalin mutein of SEQ ID NO: 42). One or more lipocalin muteins were genetically fused to the C- and/or the N-terminus of either the heavy chain or the light chain of a PD-L1 specific antibody as depicted in FIG. 1A-11, resulting in the fusion proteins, e.g., SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91. The generated fusion proteins can be bivalent to CD137 (e.g., as depicted in FIG. 1A-1D), or tetravalent to CD137 (e.g., as depicted in FIG. 1E-1H), or have even higher valency to CD137 (e.g., as depicted in FIG. 1I). Additional monospecific fusion proteins were generated by fusing one or more CD137 specific lipocalin muteins (e.g., as depicted in FIG. 1J-1K) to the C-terminus of the Fc region of an antibody provided as described herein via a peptide linker. The resulting monospecific fusion proteins are provided in, e.g., SEQ ID NO: 88 and SEQ ID NO: 89.

FIG. 2: shows the results of ELISA experiments in which the binding to PD-L1 or CD137 of representative fusion proteins was determined as described in Example 4. PD-L1 or CD137 (with C-terminal His or Fc tag) was coated on a microtiter plate, and the tested agents were titrated starting with the highest concentration of 100 nM. Bound agents under study were detected via anti-human IgG Fc-HRP or anti-NGAL-HRP respectively. The data was fit with a 1:1 binding model with EC₅₀ value and the maximum signal as free parameters, and a slope that was fixed to one. The resulting EC₅₀ values are provided in Table 4.

FIG. 3: illustrates the results of an ELISA experiment in which the ability of representative fusion proteins to simultaneously bind both targets, PD-L1 and CD137, was determined as described in Example 5. Recombinant huPD-L1-His or huCD137-His was coated on a microtiter plate, followed by a titration of the fusion proteins starting with the highest concentration of 100 nM. Subsequently, a constant concentration of biotinylated huCD137-His or biotinylated huPD-L1-His, respectively, was added, which was detected via ExtrAvidin-Peroxidase.

FIG. 4: shows the results of an assessment of the target binding of fusion proteins by flow cytometry using human or cynomolgus CD137 (FIG. 4A-4B) as well as human or cynomolgus PD-L1 (FIG. 4C-4D) expressing Flp-In-CHO cells as described in Example 6. No binding was observed when using mock transfected Flp-In-CHO cells (FIG. 4E). The geometric means of the fluorescence intensity were used to calculate EC₅₀ values using nonlinear regression (shared bottom, SLOPE=1). EC₅₀ values are provided in Table 6.

FIG. 5: shows the binding of fusion proteins to PD-L1-positive tumor cells evaluated using flow cytometry by incubating RKO cells and fusion proteins as described in Example 7.

FIG. 6: provides examples of a multi-binding SPR-based experiment designed to investigate whether the fusion protein interactions with CD137 are hampered by the binding of CD137L to CD137, as described in Example 8. This is assessed by generating a complex of huCD137 (C-terminal Fc fusion) and huCD137L (with a C-terminal His tag) on the SPR sensor chip, and checking whether the fusion proteins can still bind the complex of huCD137 and CD137L. As a reference, huCD137 in the absence of huCD137L is also incubated with the tested fusion proteins. The SPR trace for the binding of the respective fusion protein to huCD137 alone is marked with an arrow with a solid stem. The SPR trace for the binding of the respective fusion protein to huCD137 that has been saturated with huCD137L is marked with an arrow with a broken stem. As controls, blank injections without fusion proteins were used. The experiment shows that all tested fusion proteins were able to bind CD137 in the presence of CD137L.

FIG. 7: shows that the fusion proteins compete with PD-L1 for binding to PD-1, depicted in competitive ELISA studies as described in Example 9. A constant concentration of huPD-1-His was coated on a microtiter plate, followed by adding a mixture of testing molecules at different concentrations and tracer huPD-L1-Fc at a fixed concentration. Bound tracer was detected using a HRP-labelled anti-IgG Fc antibody. The dose dependent inhibition of huPD-L1-Fc binding to PD-1 by the CD137 and PD-L1 bispecific fusion proteins or PD-L1 specific antibodies were observed.

FIG. 8: The potential of representative fusion proteins to co-stimulate T-cell activation in a PD-L1-target-dependent manner was assessed using a CD137 Bioassay. NFκB-luc2/CD137 Jurkat cells were co-cultured with the PD-L1 expressing tumor cell line RKO in the presence of various concentrations of the fusion proteins or controls. After 4 h, Luciferase assay reagent was added and luminescent signals were measured. Four-parameter logistic curve analysis was performed with GraphPad Prism® to calculate EC₅₀ values (see Table 9). The fusion proteins only co-stimulate T-cell activation in the presence of PD-L1 (FIGS. 8A and 8C) but not in the absence of PD-L1 (FIGS. 8B and 8D). In contrast, the reference anti-CD137 mAb (SEQ ID NOs: 28 and 29) displays similar activation in the presence and absence of PD-L1 positive RKO cells.

FIG. 9: shows the results of a representative experiment in which the ability of selected fusion proteins to induce T-cell activation was investigated. PD-L1 antibodies, including the respective PD-L1 antibody building block, CD137 binding lipocalin muteins as Fc fusions, and an anti-CD137 benchmark antibody were tested alone and in combination as an anti-PD-L1/anti-CD137 cocktail. In the experiment, human peripheral blood mononuclear cells (PBMCs) were incubated with the fusion proteins, antibodies, lipocalin mutein Fc fusions, cocktails, or control in the presence of 1 ng/mL staphylococcal enterotoxin B (SEB). Levels of secreted interleukin 2 (IL-2), reflective of T-cell activation, were determined by an electrochemoluminescence-based assay as readout for T-cell activation and normalized to the levels of corresponding IgG4 control, as described in Example 11. All fusion proteins are capable of inducing T-cell activation, and more strongly or at least comparable to single building blocks or a cocktail of benchmark anti-PD-L1/anti-CD137 antibodies.

FIG. 10: shows the ability of representative fusion proteins to co-stimulate T-cell activation in a PD-L1-target-dependent manner. PD-L1 antibodies, including the respective PD-L1 antibody building block, CD137 binding lipocalin muteins as Fc fusions, and an anti-CD137 benchmark antibody were tested alone and in combination as an anti-PD-L1/anti-CD137 cocktail. Various tumor cell lines expressing different PD-L1 levels (High: RKO; Moderate: HCC827; Negative: HepG) were seeded into anti-human CD3 coated plates. Pan T cells and various concentrations of fusion proteins and single building blocks were added and incubated for 3 days. Levels of secreted IL-2 were determined by an electrochemoluminescence-based assay, as described in Example 12. All fusion proteins are capable of increasing IL-2 secretion in a PD-L1 dependent manner.

FIG. 11: illustrates the storage stability of fusion proteins in PBS or 25 mM histidine, 60 mM NaCl, 200 mM arginine pH 6 after 1-, 2-, 3-, or 4-week incubation at 37° C. or 40° C. at the concentration of 1 mg/ml or 20 mg/mL. The stability is assessed by the recovery of monomers from analytical size exclusion or by recovery of functional proteins from quantitative ELISA, as described in Example 13.

FIG. 12: shows the ability of a representative fusion protein (SEQ ID NOs: 90 and 87) to stimulate IL-2 secretion in a mixed lymphocyte reaction (MLR) with CD4⁺ T cells. The fusion proteins, the PD-L1 antibody building block (SEQ ID NOs: 86 and 87), the CD137 binding lipocalin mutein as an Fc fusion (SEQ ID NO: 89), and an anti-CD137 benchmark antibody or anti-PD-L1 benchmark antibody alone or in combination as an anti-PD-L1/anti-CD137 cocktail, were tested at equimolar concentrations, as described in Example 14. IL-2 secretion was measured in the supernatants after 6 days of incubation with total human CD4⁺ T cells and monocyte derived dendritic cells (moDCs) from different healthy donors. FIG. 12A illustrates that the fusion protein SEQ ID NOs: 90 and 87 showed significant increase in IL-2 secretion as compared to the building block alone (the PD-L1 antibody SEQ ID NOs: 86 and 87 or CD137 specific lipocalin mutein SEQ ID NO: 89) and a reference anti-PD-L1 or anti-CD137 antibody (SEQ ID NOs: 26 and 27 or SEQ ID NOs: 28 and 29, respectively), at equimolar concentrations (equivalent to 10 or 0.1 μg/ml of the tested fusion protein). Data from 8 independent experiments are shown. FIG. 12B shows the fusion protein SEQ ID NOs: 90 and 87 was able to induce a dose-dependent secretion of IL-2, over concentrations ranging from 0.001 to 20 μg/mL. The IL-2 levels induced by the fusion protein were higher as compared to equimolar concentrations of the cocktail of a reference anti-PD-L1 antibody (SEQ ID NOs: 26 and 27) and a reference anti-CD137 antibody (SEQ ID NOs: 28 and 29). Data from a representative donor are shown.

FIG. 13: shows the ability of an exemplary fusion protein (SEQ ID NOs: 90 and 87) to induce secretion of CD8⁺ T-cell effector molecules. The fusion protein was cultured with moDCs and CD8⁺ T cells from mismatching healthy donors for 6 days, after which the secretion of IL-2 and CD8⁺ T-cell effector molecules in the supernatants were quantified using a Luminex assay as described in Example 15. The fusion protein SEQ ID NOs: 90 and 87 showed increase in the secretion of IL-2 and cytotoxic factors (perforin, granzyme B, and granzyme A) at 10 μg/mL, as compared to the reference anti-PD-L1 antibody (SEQ ID NOs: 26 and 27) and reference anti-CD137 antibody (SEQ ID NOs: 28 and 29) when used alone or as a cocktail.

FIG. 14: shows that the fusion proteins bind overlapping epitopes with a clinically active CD137 antibody (SEQ ID NOs: 28 and 29), depicted in the competitive ELISA studies as described in Example 17. A constant concentration of SEQ ID NOs: 28 and 29 was coated on a microtiter plate, followed by adding a mixture of testing molecules at different concentrations and the tracer of biotinylated huCD137-Fc at a fixed concentration. Bound tracer was detected via ExtrAvidin-Peroxidase. The fusion proteins compete with the CD137 antibody for CD137 binding.

FIG. 15: shows the potential of representative fusion proteins to block the inhibitory signal mediated by PD-1/PD-L1 interaction, evaluated using a PD-1/PD-L1 blockade bioassay as described in Example 18. PD-1-NFAT-luc Jurkat T cells (a Jurkat cell line expressing PD-1 and a NFAT-mediated luciferase gene under the NFAT promoter control) were co-cultured with PD-L1 aAPC/CHO-K1 cells in presence of various concentrations of testing molecules. After 6 hours, luciferase assay reagent was added and luminescent signals measured. Background signal is PD-1-NFAT-luc Jurkat T cells co-cultured with only PD-L1 aAPC/CHO-K1 cells. The fusion protein of SEQ ID NOs: 90 and 87 blocks the PD-1/PD-L1 pathway, comparable to tested PD-L1 antibodies, including the building block PD-L1 antibody shown in SEQ ID NOs: 86 and 87 and the reference PD-L1 antibody shown in SEQ ID NOs: 26 and 27.

FIG. 16: shows the ability of a representative fusion protein to induce T-cell activation. The PD-L1 antibody building block and a reference CD137 antibody, when used alone and in combination with a PD-L1 antibody, were tested as well. In the experiment, human PBMCs were incubated with the fusion protein, antibodies, cocktails, or control in the presence of 0.1 ng/mL SEB. Levels of secreted IL-2 were determined by an electrochemoluminescence-based assay as readout for T-cell activation, as described in Example 19 and depicted in FIG. 16A. FIG. 16B displays the fold increase in IL-2 secretion levels induced by the testing molecules when compared to the level of background IL-2 secretion (PBMCs stimulated with 0.1 ng/mL SEB and without any testing molecules). The fusion protein leads to a dose-dependent increase in IL-2 secretion, which is stronger than a PD-L1 antibody or a CD137 antibody alone or in combination.

FIG. 17: demonstrates the ability of a representative fusion protein to co-stimulate T-cell activation in the presence of PD-L1. The PD-L1 antibody building block, a reference CD137 antibody, and a cocktail of the CD137 antibody and a reference PD-L1 antibody were tested in parallel. CHO cells either transfected with human PD-L1 (FIG. 17A) or mock transfected (human PD-L1 negative, FIG. 17B) were seeded into anti-human anti-CD3 coated plates. Pan T cells as well as various concentrations of testing molecules were added and incubated for 2 days. Levels of secreted IL-2 in the supernatant were determined by an electrochemoluminescence-based assay, as described in Example 20. The IL-2 secretion levels were normalized to background levels (Pan T cells+anti-CD3+CHO cells) to depict the fold increase in IL-2 secretion in the presence of human PD-L1 expressing CHO cells (FIG. 17C) or mock transfected CHO cells (FIG. 17D). The fusion protein induces a strong dose-dependent increase in IL-2 secretion only in the presence of PD-L1, more strongly than the reference CD137 antibody alone or in combination with the reference PD-L1 antibody.

FIG. 18: provides the result of pharmacokinetic analyses of the bispecific fusion proteins and the building block PD-L1 antibody (SEQ ID NOs: 86 and 87) in mice, as described in Example 21. Male CD-1 mice (3 mice per timepoint) were injected intravenously with fusion proteins at a dose of 10 mg/kg. Drug levels were detected using a Sandwich ELISA detecting the full molecule via the targets PD-L1 and CD137. The anti-PD-L1 antibody plasma levels were determined using a Sandwich ELISA with targets PD-L1 and human Fc.

FIG. 19: provides the results of a pharmacokinetic analysis of a representative fusion protein (SEQ ID NOs: 90 and 87) in comparison with two previously described CD137- and PD-L1-binding fusion proteins (SEQ ID NO: 147 and SEQ ID NO: 148) in mice as described in Example 22. Male CD-1 mice (2 mice per timepoint) were injected intravenously with testing molecules at a dose of 2 mg/kg. Drug levels were detected using an ELISA at the indicated time points. The data were plotted in a time vs. concentration graph. SEQ ID NOs: 90 and 87 described herein, but not SEQ ID NO: 147 or SEQ ID NO: 148, displays a favorable pharmacokinetic profile or antibody-like pharmacokinetics.

IV. DETAILED DESCRIPTION OF THE DISCLOSURE

As is described herein, the present disclosure encompasses the recognition that a bivalent CD137-binder, such as an antibody, may not be sufficient by itself to cluster CD137 on T cells or NK cells and lead to efficient activation, similar to the lack of activity of the trivalent soluble CD137L. In recent publications utilizing preclinical mouse models, in vivo evidence has been presented that the mode of action of other anti-TNFR antibodies requires the interaction of the antibodies via their Fc-part with Fc-gamma receptors on Fc-gamma-receptor expressing cells (Bulliard et al., Immunol Cell Biol, 2014, Bulliard et al., J Exp Med, 2013). The mode of action of these anti-TNFR antibodies may therefore be dominated by a non-targeted clustering via Fc-gamma receptors, depending on the presence of Fc-gamma receptor-expressing cells, which may not necessarily overexpress in the targeted tumor microenvironment as compared to normal tissues.

Thus, there is unmet need for the generation of therapeutics that cluster and activate CD137 with a specific, tumor-targeted mode of action.

To meet this unmet need, the present disclosure provides, among other things, novel approaches for simultaneously engaging CD137 and PD-L1 via one or more fusion proteins having binding specificity for CD137 and binding specificity for PD-L1. Provided fusion proteins are designed to promote CD137 clustering by bridging CD137-positive T cells with PD-L1 expressed in the tumor microenvironment. Such bispecific molecules may combine CD137-induced T-cell activation and expansion with anti-PD-L1 mediated immune checkpoint blockade and thus may overcome certain limitations of single agent therapy and offer benefits to, for example, resistant or non-responsive patients. The fusion proteins are also designed to provide potentials of a combinatorial therapy in one molecule and at the same time allow the localized induction of antigen-specific T cells in the tumor microenvironment, potentially reducing peripheral toxicity.

In some aspects, the present disclosure provides fusion proteins that bind CD137 and PD-L1, as well as methods and useful applications therefor. The disclosure also provides methods of making CD137 and PD-L1 binding fusion proteins described herein as well as compositions comprising such proteins. CD137 and PD-L1 binding fusion proteins of the disclosure as well as compositions thereof may be used in methods of detecting CD137 and/or PD-L1 in a sample, in methods of binding of CD137 and/or PD-L1 in a subject, or in methods of modulating immune responses in a subject. No such fusion proteins having these features attendant to the uses provided by present disclosure have been previously described. In contrast to fusion proteins provided herein, previously known fusion proteins targeting both CD137 and PD-L1 suffered from one or more of poor pharmacokinetics, an unacceptable degree of off-target binding, reduced or otherwise degraded ability to bind to one or both of the targets of a particular fusion protein (e.g., PD-L1 and/or CD137), and/or an unacceptable degree of non-specific (e.g., PD-L1 independent) activation of e.g., the immune system.

A. Exemplary Fusion Proteins Specific for CD137 and PD-L1 of the Disclosure.

In some embodiments, a provided fusion protein contains at least two subunits in any order: (1) a first subunit that comprises a full-length immunoglobulin or an antigen-binding domain thereof specific for PD-L1, and (2) a second subunit that comprises a lipocalin mutein specific for CD137.

In some embodiments, a provided fusion protein also may contain at least one additional subunit, for example, a third subunit. For instance, a fusion protein may contain a third subunit specific for CD137. In some embodiments, a third subunit may be or comprise a lipocalin mutein specific for CD137. For example, two lipocalin muteins may be fused to a first immunoglobulin subunit, one at the C-terminus and one at the N-terminus of the immunoglobulin. In some embodiments, lipocalin muteins may be fused to the heavy chain or light chain of an immunoglobulin.

In some embodiments, provided fusion proteins may comprise one or more additional subunits (e.g., a fourth, fifth, or sixth subunit).

In some embodiments, at least one subunit may be fused at its N-terminus and/or its C-terminus to another subunit.

In some embodiments, at least one subunit can be linked to another subunit via a linker. In some further embodiments, a linker is a peptide linker, for example, an unstructured glycine-serine (GS) linker, a glycosylated GS linker, or a proline-alanine-serine polymer (PAS) linker. In some embodiments, a GS linker is a (Gly₄Ser)₃ linker ((G₄S)₃) as shown in SEQ ID NO: 13. Other exemplary linkers are shown in SEQ ID NOs: 14-23. In some embodiments, a peptide linker may have from 1 to 50 amino acids, such as 1, 2, 3, 4, 5, 10, 11, 12, 13, 14, 15, 16, 17 18, 19, 20, 25, 30, 35, 40, 45 or 50 amino acids. For example, when a first subunit comprises a full-length immunoglobulin, a second subunit may be linked via a peptide linker between the N-terminus of the second subunit and the C-terminus of a heavy chain constant region (CH) of said immunoglobulin. In some further embodiments, a third subunit may be linked via a peptide linker between the N-terminus of the third subunit and the C-terminus of a light chain constant region (CL) of said immunoglobulin.

In some embodiments, one subunit can be linked to another subunit as essentially described in FIG. 1. Generally, one subunit may be fused at its N-terminus and/or its C-terminus to another subunit. For example, in some embodiments, a lipocalin mutein subunit can be fused at its N-terminus and/or its C-terminus to an immunoglobulin subunit. For further example, one lipocalin mutein can be linked, preferably via a peptide bond, to the C-terminus of the immunoglobulin heavy chain domain (HC), the N-terminus of the HC, the C-terminus of the immunoglobulin light chain (LC), and/or the N-terminus of the LC (FIG. 1A-1D).

In some embodiments, a lipocalin mutein subunit can be fused at its N-terminus and/or its C-terminus to an immunoglobulin fragment. For example, in some embodiments, a lipocalin mutein may be linked, preferably via a peptide linker, at the C-terminus of a heavy chain constant region (CH) or the C-terminus of a light chain constant region (CL) of the immunoglobulin.

In some embodiments, when one subunit comprises a full-length immunoglobulin, a second subunit may be linked between the N-terminus of the second subunit and the C-terminus of a heavy chain constant region (CH) of said immunoglobulin.

In some embodiments, a third subunit may be linked between the N-terminus of the third subunit and the C-terminus of a light chain constant region (CL) of said immunoglobulin.

In some embodiments, with respect to a fusion protein of the disclosure, wherein at least one subunit may be or comprise a full-length immunoglobulin, the Fc function of the Fc region of the full-length immunoglobulin to Fc receptor-positive cell may be preserved at the same time while the fusion protein is simultaneously engaging CD137 and PD-L1.

In some embodiments, wherein at least one subunit of a provided fusion protein may be or comprise a full-length immunoglobulin, the Fc function of the Fc region of the full-length immunoglobulin to Fc receptor-positive cell may be reduced or fully suppressed by protein engineering while the fusion protein is simultaneously engaging CD137 and PD-L1. In some embodiments, this may be achieved, for example, by switching from the IgG1 backbone to IgG4, as IgG4 is known to display reduced Fc-gamma receptor interactions compared to IgG1. In some embodiments, to further reduce the residual binding to Fc-gamma receptors, mutations may be introduced into the IgG4 backbone such as F234A and L235A. In some embodiments, an S228P mutation may also be introduced into the IgG4 backbone to minimize the exchange of IgG4 half-antibody (Silva et al., J Biol Chem, 2015). In some embodiments, F234A and L235A mutations may be introduced for decreased ADCC and ADCP (Glaesner et al., Diabetes Metab Res Rev, 2010) and/or M428L and N434S mutations or M252Y, S254T, and T256E mutations for extended serum half-life (Dall'Acqua et al., J Biol Chem, 2006, Zalevsky et al., Nat Biotechnol, 2010). In some embodiments, an additional N297A mutation may be present in the immunoglobulin heavy chain of the fusion protein in order to remove the natural glycosylation motif.

In some embodiments, the Fc portion of an immunoglobulin included in a fusion protein of the disclosure may contribute to maintaining the serum levels of the fusion protein. For example, when the Fc portion binds to Fc receptors on endothelial cells and phagocytes, the fusion protein may become internalized and recycled back to the bloodstream, enhancing its half-life within the body.

In one aspect, fusion proteins of the disclosure bind CD137 with high affinity. In another aspect, provided fusion proteins bind PD-L1 with high affinity. In some preferred embodiments, provided fusion proteins simultaneously bind CD137 and PD-L1. In some embodiments, the simultaneous binding to CD137 and PD-L1 allows provided fusion proteins to exhibit a durable anti-tumor or anti-infection response.

In some embodiments, a fusion protein of the disclosure may be able to bind PD-L1 with a K_D value of at most about 2 nM or even lower, such as about 1.5 nM or lower, about 1 nM or lower, about 0.6 nM or lower, or about 0.4 nM or lower. In some embodiments, a fusion protein of the disclosure may be able to bind PD-L1 with a K_D value comparable to or lower than the K_D value of the immunoglobulin specific for PD-L1 as included in such fusion protein, such as the antibody having the heavy and light chains provided by SEQ ID NOs: 86 and 87. The K_D values of provided fusion proteins may be measured, for example, in a surface-plasmon-resonance (SPR) assay, such as an SPR assay as essentially described in Example 3.

In some embodiments, a fusion protein of the disclosure may be able to bind CD137 with a K_D value of at most about 10 nM or even lower, such as about 7 nM, about 6 nM, or about 5 nM, about 4 nM, about 3 nM, about 2 nM or even lower. In some embodiments, a fusion protein of the disclosure may be able to bind CD137 with a K_D value comparable to or lower than the K_D value of the lipocalin mutein specific for CD137 that is included in a particular fusion protein, e.g., SEQ ID NO: 42, or the lipocalin mutein fused to the Fc region of an antibody, e.g., SEQ ID NO: 89. The K_D values of provided fusion proteins may be measured, for example, in an SPR assay, such as an SPR assay as essentially described in Example 3.

In some embodiments, a fusion protein of the disclosure may be able to bind PD-L1 with an EC₅₀ value of at most about 0.5 nM or even lower, such as about 0.3 nM or lower, about 0.2 nM or lower, about 0.15 nM or lower, or about 0.1 nM or lower. In some embodiments, a fusion protein of the disclosure may be able to bind PD-L1 with an EC₅₀ value comparable to or lower than the EC₅₀ value of the immunoglobulin specific for PD-L1 that is included in a particular fusion protein, such as the antibody having the heavy and light chains provided by SEQ ID NOs: 86 and 87. The EC₅₀ values of provided fusion proteins may be measured, for example, in an enzyme-linked immunosorbent assay (ELISA) assay, such as an ELISA assay as essentially described in Example 4.

In some embodiments, a fusion protein of the disclosure may be able to bind CD137 with an EC₅₀ value of at most about 0.6 nM or even lower, such as about 0.5 nM or lower, about 0.2 nM or lower, about 0.15 nM or lower, or about 0.1 nM or lower. In some embodiments, a fusion protein of the disclosure may be able to bind CD137 with an EC₅₀ value comparable to or lower than the EC₅₀ value of the lipocalin mutein specific for CD137 that is included in a particular fusion protein, e.g., SEQ ID NO: 42, or the lipocalin mutein fused to the Fc region of an antibody, e.g., SEQ ID NO: 89. The EC₅₀ values of provided fusion proteins may be measured, for example, in an ELISA assay, such as an ELISA assay as essentially described in Example 4.

In some embodiments, fusion proteins of the disclosure are cross-reactive with cynomolgus PD-L1. In some embodiments, a provided fusion protein may be able to bind cynomolgus PD-L1 with an EC₅₀ value of at most about 0.5 nM or even lower, such as about 0.2 nM or lower, about 0.1 nM or lower, or about 0.05 nM or lower. The EC₅₀ values of provided fusion proteins may be measured, for example, measured in an ELISA assay, such as an ELISA assay as essentially described in Example 4.

In some embodiments, fusion proteins of the disclosure are cross-reactive with cynomolgus CD137. In some embodiments, a provided fusion protein may be able to bind cynomolgus CD137 with an EC₅₀ value of at most about 15 nM or even lower, such as about 10 nM or lower, about 8 nM or lower, about 6 nM or lower, about 3 nM or lower, about 1 nM or lower, about 0.5 nM or lower, about 3 nM or lower, or about 0.1 nM or lower. The EC₅₀ values of provided fusion proteins may be measured, for example, in an ELISA assay, such as an ELISA assay as essentially described in Example 4. In some embodiments, the binding of a provided fusion protein to cynomolgus CD137 may be enhanced by an avidity effect as described in Example 22.

In some embodiments, fusion proteins of the disclosure may be able to simultaneously bind CD137 and PD-L1. In some embodiments, a provided fusion protein may be able to simultaneously bind CD137 and PD-L1, with an EC₅₀ value of at most about 1 nM or even lower, such as 0.8 nM or lower, 0.6 nM or lower, or 0.4 nM or lower. In some other embodiments, a provided fusion protein may be able to simultaneously bind CD137 and PD-L1, with an EC₅₀ value of at most about 10 nM or even lower, such as 8 nM or lower, 6 nM or lower, 3 nM or lower, or 2 nM or lower. The simultaneous binding may be determined, for example, in and ELISA assay, such as an ELISA assay as essentially described in Example 5.

In some embodiments, a fusion protein of the disclosure may be able to bind CD137 expressed on a cell with an EC₅₀ value of at most about 60 nM or even lower, such as about 50 nM or even lower, about 40 nM or even lower, about 30 nM or lower, about 10 nM or lower, about 7 nM or lower, about 5 nM or lower, about 3 nM or lower, or about 1 nM or even lower. The EC₅₀ value of a provided fusion protein may be measured, for example, in a flow cytometric analysis as essentially described in Example 6. The cell expressing CD137 may be, for example, a CHO cell transfected with human CD137 or cynomolgus CD137.

In some embodiments, a fusion protein of the disclosure may be able to bind PD-L1 expressed on a cell with an EC₅₀ value of at most about 10 nM or even lower, such as about 8 nM or lower, about 6 nM or lower, about 4 nM or lower, about 2 nM or lower, or about 1 or even lower. The EC₅₀ value of a provided fusion protein may be measured, for example, in a flow cytometric analysis as essentially described in Example 6. The cell expressing PD-L1 may be, for example, be a CHO cell transfected with human PD-L1 or cynomolgus PD-L1.

In some embodiments, fusion proteins of the disclosure may be able to bind PD-L1 expressed on tumor cells. In some embodiments, a provided fusion protein may be able to bind PD-L1 expressed on a tumor cell with an EC₅₀ value of at most about 2 nM or even lower, such as about 1.5 nM or lower, about 1 nM or lower, about 0.6 nM or lower, or about 0.3 nM or even lower. The EC₅₀ value of a fusion protein to bind PD-L1 expressing tumor cells may be measured, for example, in a flow cytometric analysis as essentially described in Example 7. The tumor cells expressing PD-L1 may be, for example, RKO cells.

In some embodiments, fusion proteins of the disclosure do not essentially affect the binding of CD137 to CD137L. In some embodiments, fusion proteins of the disclosure may be able to bind CD137 when in complex with CD137L. In some embodiments, fusion proteins of the disclosure may be able to bind CD137 in a similar mode as an anti-CD137 antibody having the heavy and light chains provided by SEQ ID NO: 28 and 29. The binding mode to CD137 of a fusion protein may be determined, for example, by an SPR assay, such as an SPR assay as essentially described in Example 8.

In some embodiments, fusion proteins of the disclosure may be able to compete with PD-1 for binding to PD-L1. In some embodiments, a provided fusion protein may be able to compete with PD-1 for binding to PD-L1 with an IC₅₀ value of at most about 5 nM or even lower, such as about 3 nM or lower, about 2 nM or lower, or about 1 or even lower. The inhibitory mode of action can be determined, for example, by an ELISA assay, such as an ELISA assay as essentially described in Example 9.

In some embodiments, fusion proteins of the disclosure may be able to compete with an anti-CD137 antibody shown in SEQ ID NOs: 28 and 29 for binding to CD137. Such competition may be assessed by an ELISA assay as essentially described in Example 17. In some embodiments, a provided fusion protein may have overlapping epitope with the anti-CD137 antibody shown in SEQ ID NOs: 28 and 29.

In some embodiments, fusion proteins of the disclosure may be able to co-stimulate T-cell responses. In some embodiments, provided fusion proteins lead to a comparable or stronger T-cell activation as compared to a PD-L1 antibody, such as the building block PD-L1 antibody SEQ ID NOs: 86 and 87 or the reference PD-L1 antibody SEQ ID NOs: 26 and 27, or a CD137 antibody, such as the reference antibody SEQ ID NOs: 28 and 29. In some embodiments, provided fusion proteins lead to T-cell activation with a comparable or better efficiency as compared to the combination of an anti-PD-L1 antibody and a CD137-targeting molecule such as an anti-CD137 antibody or a previously known CD137-specific lipocalin mutein. The stimulated T-cell response or T-cell activation may be measured, for example, in a CD137 Bioassay as essentially described in Example 10, in a PD-1/PD-L1 blockade bioassay as described in Example 18, or in a functional T-cell activation assay as essentially described in Example 11, Example 12, Example 19, and Example 20.

In some embodiments, fusion proteins of the disclosure may be able to induce increased IL-2 secretion. In some preferred embodiments, provided fusion proteins may be able to induce a concentration-dependent IL-2 secretion and/or demonstrate a tendency to induce enhanced IL-2 secretion at higher concentrations, preferably coating concentrations. In some embodiments, provided fusion proteins may lead to increased IL-2 secretion with a comparable or better efficiency as compared to the combination of an anti-PD-L1 antibody and a CD137-targeting molecule such as an anti-CD137 antibody or a previously known CD137-specific lipocalin mutein. IL-2 secretion may be measured, for example, in a functional T-cell activation assay as essentially described in Example 11 and Example 19.

In some embodiments, fusion proteins of the disclosure may be able to co-stimulate T-cell responses in a PD-L1 dependent manner. In some embodiments, provided fusion proteins may lead to local induction of the IL-2 production by T-cells in the vicinity of PD-L1-positive cells, such as PD-L1 transfected cells or PD-L1 positive tumor cells. “In the vicinity of PD-L1-positive cells” when used herein refers to a T-cell and a PD-L1-positive cell are brought close to each other through a provided fusion protein which binds CD137 and PD-L1 simultaneously. The PD-L1 dependent activation of T-cell by provided fusion proteins may be determined, for example, in a CD137 Bioassay essentially described in Example 10, in a PD-1/PD-L1 blockade bioassay essentially described in Example 18, or in a functional T-cell activation assay essentially described in Example 12 and Example 20.

In some preferred embodiments, provided fusion proteins may be able to co-stimulate T-cell responses in the presence of PD-L1 expressing tumor cells and/or in a tumor microenvironment. In some embodiments, a provided fusion protein may be able to co-stimulate T-cell responses in the presence of PD-L1-positive tumor cells with an EC₅₀ value of about 1 nM or lower, about 0.5 nM or lower, about 0.3 nM or lower, about 0.1 nM or lower, or about 0.05 nM or lower. The T-cell activation by provided fusion proteins in the presence of PD-L1 expressing tumor cells and/or in a tumor microenvironment may be assessed, for example, in a CD137-bioassay essentially described in Example 10 or in a functional T-cell activation assay essentially described in Example 12.

In some embodiments, provided fusion proteins are not able to co-stimulate T-cell responses in the absence of PD-L1. In some embodiments, provided fusion proteins are not able to co-stimulate T-cell responses in the absence of PD-L1 expressing cells. In some embodiments, a provided fusion protein may be able to discern the presence of PD-L1 and lead to corresponding T-cell activation better than a CD137 antibody shown in SEQ ID NOs: 28 and 29. The PD-L1 dependent action of the fusion proteins may be determined, for example, in a CD137 Bioassay essentially described in Example 10, in a PD-1/PD-L1 blockade bioassay essentially described in Example 18, or in a functional T-cell activation assay essentially described in Example 12 and Example 20.

In some embodiments, provided fusion proteins may be able to block the inhibitory signal mediated by binding of PD-1 to PD-L1. In some embodiments, a provided fusion protein may be able to release a brake for T-cell activation or lead to successful T-cell activation by blocking the PD-1/PD-L1 interaction. The blockade of PD-1 inhibitory signal may be measured, for example, in a PD-1/PD-L1 blockade bioassay as described in Example 18.

In some embodiments, fusion proteins of the disclosure may be able to stimulate T cell proliferation and/or activation. In some embodiments, provided fusion proteins may be able to stimulate CD4⁺ T cell proliferation and/or activation. In some embodiments, provided fusion proteins may be able to induce IL-2 secretion, preferably dose-dependent IL-2 secretion. In some embodiments, provided fusion proteins may be able to induce higher IL-2 secretion as compared to the combination of an anti-PD-L1 antibody and a CD137-targeting molecule such as an anti-CD137 antibody or a previously known CD137-specific lipocalin mutein. The IL-2 secretion as used herein may be a measure of T-cell activation. The CD4⁺ T cell proliferation and/or activation stimulated by provided fusion proteins may be assessed by, for example, a mixed lymphocyte reaction (MLR) assay as essentially described in Example 14.

In some embodiments, fusion proteins of the disclosure may be able to stimulate CD8⁺ T cell proliferation and/or activation. In some embodiments, provided fusion proteins may be able to induce the production and IL-2 and effector molecules, such as perforin, granzyme A, and granzyme B. In some embodiments, provided fusion proteins may be able to induce increased production of IL-2 and cytotoxic factors, such as perforin, granzyme B, and granzyme A, as compared to the combination of an anti-PD-L1 antibody and a CD137-targeting molecule such as an anti-CD137 antibody or a previously known CD137-specific lipocalin mutein. The CD8⁺ T cell proliferation and/or activation stimulated by provided fusion proteins may be assessed by, for example, an MLR assay as essentially described in Example 15.

In some embodiments, provided fusion proteins have favorable stability and pharmacokinetics profiles. In some embodiments, a provided fusion protein have comparable pharmacokinetics profile as the building block antibody SEQ ID NOs: 86 and 87. In some embodiments, a provided fusion protein has antibody-like pharmacokinetics. In some embodiments, a provided fusion protein has a terminal half-life of about 200 hours or longer, about 250 hours or longer, about 300 hours or longer, about 350 hours or longer, about 400 hours or longer, or even longer. In some embodiments, a provided fusion protein has a more favorable pharmacokinetic profile than SEQ ID NO: 147. In some embodiments, a provided fusion protein has a more favorable pharmacokinetic profile than SEQ ID NO: 148. Pharmacokinetics profiles of provided fusion proteins may be analyzed as described in Example 21 and Example 22. In some embodiments, a favorable pharmacokinetic profile or an antibody-like pharmacokinetics may be considered to be achieved if % of c_max was above 10% after 336 h.

In some embodiments, a provided fusion protein comprises an amino acid sequence shown in any one of SEQ ID NOs: 88-94.

In some embodiments, a provided fusion protein comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to the amino acid sequences shown in any one of SEQ ID NOs: 88-94.

In some embodiments, a provided fusion protein comprises the amino acids shown in SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, or SEQ ID NOs: 90 and 91.

In some embodiments, a provided fusion protein comprises the amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to the amino acid sequences shown in SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, or SEQ ID NOs: 90 and 91.

B. Exemplary Immunoglobulins as Included in the Fusion Proteins.

In some embodiments, with respect to a provided fusion protein, a first subunit may be or comprise a full-length immunoglobulin or an antigen-binding domain thereof specific for PD-L1. In some embodiments, an immunoglobulin, for example, may be IgG1, IgG2 or IgG4. In some embodiments, an immunoglobulin is or comprises IgG4. In some embodiments, an immunoglobulin is a monoclonal antibody against PD-L1.

Illustrative examples of PD-L1-binding antibodies of the disclosure may comprise an antigen-binding region which cross-blocks or binds to the same epitope as a PD-L1-binding antibody comprising the heavy chain variable domain (V_H) and light chain variable domain (V_L) regions of a known antibody such as atezolizumab (also known as MPDL3280A or RG7446, trade name Tecentriq®), avelumab (also known as MSB0010718C, trade name Bavencio®), durvalumab (previously known as MEDI4736, trade name Imfinzi®), and BMS-936559 (also known as MDX-1105), 5C10 (including humanized 5C10), 5F10 (including humanized 5F10), and 9F6 (including humanized 9F6). In some embodiments, a PD-L1-binding antibody of the disclosure may comprise an antigen-binding region, such as any one of the three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and the three light chain CDRs (LCDR1, LCDR2 and LCDR3) from an antibody selected from the group consisting of atezolizumab, avelumab, durvalumab, BMS-936559, 5C10, 5F10, and 9F6.

In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof may have a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 75-79, and/or a light chain variable region (LCVR) selected from the group consisting of SEQ ID NOs: 80-84.

In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof may have a heavy chain that is any one of SEQ ID NOs: 85-86, and/or a light chain that is SEQ ID NO: 87.

In some embodiments, the heavy chain and light chain pair of a provided PD-L1 antibody or antigen-binding domain thereof are or comprise a HCVR and LCVR, respectively, as follows: SEQ ID NOs: 75 and 80, SEQ ID NOs: 76 and 81, SEQ ID NOs: 77 and 82, SEQ ID NOs: 78 and 83, or SEQ ID NOs:79 and 84.

In some embodiments, the heavy chain and light chain pair of a provided PD-L1 antibody are or comprise the amino acid sequences as shown in SEQ ID NOs: 85 and 87 or SEQ ID NO: 86 and 87.

In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof may have a HCVR with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 75-79, and/or a LCVR with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-84. In other embodiments, a provided PD-L1 antibody or antigen-binding domain thereof may have a heavy chain with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-86, and/or a light chain with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or even higher sequence identity to the amino acid sequence of SEQ ID NO: 87.

In some embodiments, the heavy chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: GFSLSNYD (HCDR1, SEQ ID NO: 60), IWTGGAT (HCDR2, SEQ ID NO: 61), VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 62). In some embodiments the heavy chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: GFDIKDTY (HCDR1, SEQ ID NO: 65), IDPADGNT (HCDR2, SEQ ID NO: 66), ARGLGAWFAS (HCDR3; SEQ ID NO: 67). In some embodiments the heavy chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: GFNIKDTY (HCDR1, SEQ ID NO: 70), IDPANGNT (HCDR2, SEQ ID NO: 71), SRGPPGGIGEYIYAMDY (HCDR3; SEQ ID NO: 72).

In some embodiments the light chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), QQSNSWPYT (LCDR3; SEQ ID NO: 64). In some embodiments the light chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: QDITNS (LCDR1, SEQ ID NO: 68), YTS (LCDR2), QQGHTLPPT (LCDR3; SEQ ID NO: 69). In some embodiments the light chain variable region of a provided PD-L1 antibody or antigen-binding domain thereof may have the three CDRs having following sequences: SSVSSSY (LCDR1, SEQ ID NO: 73), STS (LCDR2), HQYHRSPPT (LCDR3; SEQ ID NO: 74).

In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof comprises a heavy chain variably region that has the three CDRs having following sequences: GFSLSNYD (HCDR1, SEQ ID NO: 60), IWTGGAT (HCDR2, SEQ ID NO: 61), VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 62), and a light chain variably region that has the three CDRs having following sequences: QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), QQSNSWPYT (LCDR3; SEQ ID NO: 64). In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof comprises a heavy chain variably region that has the three CDRs having following sequences: GFDIKDTY (HCDR1, SEQ ID NO: 65), IDPADGNT (HCDR2, SEQ ID NO: 66), ARGLGAWFAS (HCDR3; SEQ ID NO: 67), and a light chain variably region that has the three CDRs having following sequences: QDITNS (LCDR1, SEQ ID NO: 68), YTS (LCDR2), QQGHTLPPT (LCDR3; SEQ ID NO: 69). In some embodiments, a provided PD-L1 antibody or antigen-binding domain thereof comprises a heavy chain variably region that has the three CDRs having following sequences: GFNIKDTY (HCDR1, SEQ ID NO: 70), IDPANGNT (HCDR2, SEQ ID NO: 71), SRGPPGGIGEYIYAMDY (HCDR3; SEQ ID NO: 72), and a light chain variably region that has the three CDRs having following sequences: SSVSSSY (LCDR1, SEQ ID NO: 73), STS (LCDR2), HQYHRSPPT (LCDR3; SEQ ID NO: 74).

Unless otherwise indicated, all CDR sequences disclosed herein are defined according to the IMGT method as described in Lefranc, M.-P., The Immunologist, 7, 132-136 (1999). CDR1 consists of positions 27 to 38, CDR2 consists of positions 56 to 65, CDR3 for germline V-genes consists of positions 105 to 116, CDR3 for rearranged V-J-genes or V-D-J-genes consists of positions 105 to 117 (position preceding J-PHE or J-TRP 118) with gaps at the top of the loop for rearranged CDR3-IMGT with less than 13 amino acids, or with additional positions 112.1, 111.1, 112.2, 111.2, etc. for rearranged CDR3-IMGT with more than 13 amino acids. The positions given in this paragraph are according to the IMGT numbering described in Lefranc, M.-P., The Immunologist, 7, 132-136 (1999).

Antibodies specifically binding to PD-L1 as included in fusion proteins of the disclosure may comprise an Fc part which allows for extending the in vivo half-life of the bispecific binding molecule of the disclosure. In some embodiments, such Fc part is preferably from human origin, more preferably a human Fc part of an IgG1 or IgG4 antibody, even more preferably an engineered human Fc part of an IgG1 or IgG4 with activating or silencing effector functions. In some embodiments, silencing effector functions may be preferred over activating effector functions. In some embodiments, such an Fc part is an engineered to silence effector functions with mutation(s) at positions 234 and/or 235, numbering according to EU index of Kabat (Johnson and Wu, Nucleic Acids Res, 2000). In some embodiments, mutations in positions F234 and L235 of a provided anti-PD-L1 antibody may be introduced to silence effector functions. In other embodiments, mutations in positions D265 and P329 of a provided anti-PD-L1 antibody may be introduced, to silence effector function. Numbering for both sets of these potential mutations is according to the EU index of Kabat (Shields et al., J Biol Chem, 2001).

Various techniques for the production of antibodies and fragments thereof are well known in the art and described, e.g., in Altshuler et al. (2010). Thus, for example, polyclonal antibodies can be obtained from the blood of an animal following immunization with an antigen in mixture with additives and adjuvants and monoclonal antibodies can be produced by any technique which provides antibodies produced by continuous cell line cultures. Examples of such techniques are described, e.g., Harlow and Lane (1999), (1988), and include the hybridoma technique originally described by Köhler and Milstein, 1975, the trioma technique, the human B cell hybridoma technique (see e.g. Li et al., Proc Natl Acad Sci USA, 2006, Kozbor and Roder, Immunol Today, 1983) and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., Cancer Res, 1984). Furthermore, recombinant antibodies may be obtained from monoclonal antibodies or can be prepared de novo using various display methods such as phage, ribosomal, mRNA, or cell display. In some embodiments, a suitable system for the expression of the recombinant (humanized) antibodies or fragments thereof may be selected from, for example, bacteria, yeast, insects, mammalian cell lines or transgenic animals or plants (see, e.g., U.S. Pat. No. 6,080,560; Holliger and Hudson, Nat Biotechnol, 2005). Further, techniques described for the production of single chain antibodies (see, inter alia, U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies specific for the target of this invention. Surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies.

C. Exemplary Lipocalin Muteins of the Disclosure.

Lipocalins are proteinaceous binding molecules that have naturally evolved to bind ligands. Lipocalins occur in many organisms, including vertebrates, insects, plants, and bacteria. The members of the lipocalin protein family (Pervaiz and Brew, FASEB J, 1987) are typically small, secreted proteins and have a single polypeptide chain. They are characterized by a range of different molecular-recognition properties: their binding to various, principally hydrophobic small molecules (such as retinoids, fatty acids, cholesterols, prostaglandins, biliverdins, pheromones, tastants, and odorants), and their binding to specific cell-surface receptors and their formation of macromolecular complexes. Although they have, in the past, been classified primarily as transport proteins, it is now clear that the lipocalins fulfill a variety of physiological functions. These include roles in retinol transport, olfaction, pheromone signaling, and the synthesis of prostaglandins. Lipocalins have also been implicated in the regulation of the immune response and the mediation of cell homeostasis (reviewed, e.g., in Flower et al., Biochim Biophys Acta, 2000, Flower, Biochem J, 1996).

Lipocalins share unusually low levels of overall sequence conservation, often with sequence identities of less than 20%. In strong contrast, their overall folding pattern is highly conserved. The central part of the lipocalin structure consists of a single eight-stranded anti-parallel β-sheet closed back on itself to form a continuously hydrogen-bonded β-barrel. This β-barrel forms a central cavity. One end of the barrel is sterically blocked by the N-terminal peptide segment that runs across its bottom as well as three peptide loops connecting the β-strands. The other end of the β-barrel is open to the solvent and encompasses a target-binding site, which is formed by four flexible peptide loops (AB, CD, EF, and GH). It is the diversity of the loops in the otherwise rigid lipocalin scaffold that gives rise to a variety of different binding modes each capable of accommodating targets of different size, shape, and chemical character (reviewed, e.g., in Skerra, Biochim Biophys Acta, 2000, Flower et al., Biochim Biophys Acta, 2000, Flower, Biochem J, 1996).

A lipocalin mutein according to the present disclosure may be a mutein of any lipocalin. Examples of suitable lipocalins (also sometimes designated as “reference lipocalin,” “wild-type lipocalin,” “reference protein scaffolds,” or simply “scaffolds”) of which a mutein may be used include, but are not limited to, tear lipocalin (lipocalin-1, Tlc, or von Ebner's gland protein), retinol binding protein, neutrophil lipocalin-type prostaglandin D-synthase, β-lactoglobulin, bilin-binding protein (BBP), apolipoprotein D (APOD), neutrophil gelatinase-associated lipocalin (NGAL), α2-microglobulin-related protein (A2m), 24p3/uterocalin (24p3), von Ebner's gland protein 1 (VEGP 1), von Ebner's gland protein 2 (VEGP 2), and Major allergen Can f 1 (ALL-1). In related embodiments, a lipocalin mutein is derived from the lipocalin group consisting of human tear lipocalin (hTlc), human neutrophil gelatinase-associated lipocalin (hNGAL), human apolipoprotein D (hAPOD) and the bilin-binding protein of Pieris brassicae.

The amino acid sequence of a lipocalin mutein according to the disclosure may have a high sequence identity as compared to the reference (or wild-type) lipocalin from which it is derived, for example, hTlc or hNGAL, when compared to sequence identities with another lipocalin (see also above). In this general context the amino acid sequence of a lipocalin mutein according to the disclosure is at least substantially similar to the amino acid sequence of the corresponding reference (wild-type) lipocalin, with the proviso that there may be gaps (as defined herein) in an alignment that are the result of additions or deletions of amino acids. A respective sequence of a lipocalin mutein of the disclosure, being substantially similar to the sequences of the corresponding reference (wild-type) lipocalin, has, in some embodiments, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 82%, at least 85%, at least 87%, at least 90% identity, including at least 95% identity to the sequence of the corresponding lipocalin. In this regard, a lipocalin mutein of the disclosure of course may contain substitutions as described herein which renders the lipocalin mutein capable of binding to CD137.

Typically, a lipocalin mutein contains one or more mutated amino acid residues—relative to the amino acid sequence of the wild-type or reference lipocalin, for example, hTlc and hNGAL in—the four loops at the open end that comprise a ligand-binding pocket and define the entrance of ligand-binding pocket (cf. above). As explained above, these regions are essential in determining the binding specificity of a lipocalin mutein for the desired target. In some embodiments, a lipocalin mutein of the disclosure may also contain mutated amino acid residues regions outside of the four loops. In some embodiments, a lipocalin mutein of the disclosure may contain one or more mutated amino acid residues in one or more of the three peptide loops (designated BC, DE, and FG) connecting the β-strands at the closed end of the lipocalin. In some embodiments, a mutein derived from of tear lipocalin, NGAL lipocalin or a homologue thereof, may have 1, 2, 3, 4, or more mutated amino acid residues at any sequence position in the N-terminal region and/or in the three peptide loops BC, DE, and FG arranged at the end of the β-barrel structure that is located opposite to the natural lipocalin binding pocket. In some embodiments, a mutein derived from tear lipocalin, NGAL lipocalin or a homologue thereof, may have no mutated amino acid residues in peptide loop DE arranged at the end of the β-barrel structure, compared to wild-type sequence of tear lipocalin.

In some embodiments, a lipocalin mutein according to the disclosure may include one or more, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or even more mutated amino acid residues in comparison to the amino acid sequence of a corresponding reference (wild-type) lipocalin, provided that such a lipocalin mutein should be capable of binding to CD137. In some embodiments, a lipocalin mutein of the disclosure includes at least two, including 2, 3, 4, 5, or even more, mutated amino acid residues, where a native amino acid residue of the corresponding reference (wild-type) lipocalin is substituted by an arginine residue.

Any types and numbers of mutations, including substitutions, deletions, and insertions, are envisaged as long as a provided lipocalin mutein retains its capability to bind CD137, and/or it has a sequence identity that it is at least 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85% or higher identity to the amino acid sequence of the reference (wild-type) lipocalin, for example, mature hTlc or mature hNGAL.

In some embodiments, a substitution is a conservative substitution. In some embodiments, a substitution is a non-conservative substitution or one or more from the exemplary substitutions below—

Specifically, in order to determine whether an amino acid residue of the amino acid sequence of a lipocalin mutein is different from a reference (wild-type) lipocalin corresponds to a certain position in the amino acid sequence of the reference (wild-type) lipocalin, a skilled artisan can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as BLAST2.0, which stands for Basic Local Alignment Search Tool or ClustalW or any other suitable program which is suitable to generate sequence alignments. Accordingly, the amino acid sequence of a reference (wild-type) lipocalin can serve as “subject sequence” or “reference sequence”, while the amino acid sequence of a lipocalin mutein serves as “query sequence” (see also above).

Conservative substitutions are generally the following substitutions, listed according to the amino acid to be mutated, each followed by one or more replacement(s) that can be taken to be conservative: Ala→Ser, Thr, or Val; Arg→Lys, Gln, Asn, or His; Asn→Gln, Glu, Asp, or His; Asp→Glu, Gln, Asn, or His; Gln→Asn, Asp, Glu, or His; Glu→Asp, Asn, Gln, or His; His→Arg, Lys, Asn, Gln, Asp, or Glu; Ile→Thr, Leu, Met, Phe, Val, Trp, Tyr, Ala, or Pro; Leu→Thr, Ile,Val, Met, Ala, Phe, Pro, Tyr, or Trp; Lys→Arg, His, Gln, or Asn; Met→Thr, Leu, Tyr, Ile, Phe, Val, Ala, Pro, or Trp; Phe→Thr, Met, Leu, Tyr, Ile, Pro, Trp, Val, or Ala; Ser→Thr, Ala, or Val; Thr→Ser, Ala, Val, Ile, Met, Val, Phe, Pro, or Leu; Trp→Tyr, Phe, Met, Ile, or Leu; Tyr→Trp, Phe, Ile, Leu, or Met; Val→Thr, Ile, Leu, Met, Phe, Ala, Ser, or Pro. Other substitutions are also permissible and can be determined empirically or in accord with other known conservative or non-conservative substitutions. As a further orientation, the following groups each contain amino acids that can typically be taken to define conservative substitutions for one another:

• (a) Alanine (Ala), Serine (Ser), Threonine (Thr), Valine (Val)
• (b) Aspartic acid (Asp), Glutamic acid (Glu), Glutamine (Gin), Asparagine (Asn), Histidine (His)
• (c) Arginine (Arg), Lysine (Lys), Glutamine (Gin), Asparagine (Asn), Histidine (His)
• (d) Isoleucine (Ile), Leucine (Leu), Methionine (Met), Valine (Val), Alanine (Ala), Phenylalanine (Phe), Threonine (Thr), Proline (Pro)
• (e) Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp)

If such conservative substitutions result in a change in biological activity, then more substantial changes, such as the following, or as further described below in reference to amino acid classes, may be introduced and the products screened for a desired characteristic. Examples of such more substantial changes are: Ala→Leu or Phe; Arg→Glu; Asn→Ile, Val, or Trp; Asp→Met; Cys→Pro; Gln→Phe; Glu→Arg; His→Gly; Ile→Lys, Glu, or Gln; Leu→Lys or Ser; Lys→Tyr; Met→Glu; Phe→Glu, Gln, or Asp; Trp→Cys; Tyr→Glu or Asp; Val→Lys, Arg, His.

In some embodiments, substantial modifications in the physical and biological properties of the lipocalin (mutein) are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: methionine, alanine, valine, leucine, iso-leucine; (2) neutral hydrophilic: cysteine, serine, threonine, asparagine, glutamine; (3) acidic: aspartic acid, glutamic acid; (4) basic: histidine, lysine, arginine; (5) residues that influence chain orientation: glycine, proline; and (6) aromatic: tryptophan, tyrosine, phenylalanine. In some embodiments. substitutions may entail exchanging a member of one of these classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the respective lipocalin also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond (s) may be added to the lipocalin to improve its stability.

D. Exemplary CD137-Specific Lipocalin Muteins of the Disclosure.

As noted above, a lipocalin is a polypeptide defined by its supersecondary structure, namely cylindrical β-pleated sheet supersecondary structural region comprising eight β-strands connected pair-wise by four loops at one end to define thereby a binding pocket. The present disclosure is not limited to lipocalin muteins specifically disclosed herein. In this regard, the disclosure relates to a lipocalin mutein having a cylindrical β-pleated sheet supersecondary structural region comprising eight β-strands connected pair-wise by four loops at one end to define thereby a binding pocket, wherein at least one amino acid of each of at least three of said four loops has been mutated and wherein said lipocalin is effective to bind CD137 with detectable affinity.

In some embodiments, lipocalin muteins disclosed herein may be or comprise a mutein of mature human tear lipocalin (hTlc). A mutein of mature hTlc may be designated herein as an “hTlc mutein”. In some other embodiments, a lipocalin mutein disclosed herein is a mutein of mature human neutrophil gelatinase-associated lipocalin (hNGAL). A mutein of mature hNGAL may be designated herein as an “hNGAL mutein”.

In one aspect, the present disclosure includes any number of lipocalin muteins derived from a reference (wild-type) lipocalin, preferably derived from mature hTlc or mature hNGAL, that bind CD137 with detectable affinity. In a related aspect, the disclosure includes various lipocalin muteins that are capable of activating the downstream signaling pathways of CD137 by binding to CD137. In this sense, CD137 can be regarded as a non-natural target of the reference (wild-type) lipocalin, preferably hTlc or hNGAL, where “non-natural target” refers to a substance that does not bind to the reference (wild-type) lipocalins under physiological conditions. By engineering reference (wild-type) lipocalins with one or more mutations at certain sequence positions, the present inventors have demonstrated that high affinity and high specificity for the non-natural target, CD137, is possible. In some embodiments, at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or even more nucleotide triplet(s) encoding certain sequence positions on wild-type lipocalins, a random mutagenesis may be carried out through substitution at these positions by a subset of nucleotide triplets, with the aim of generating a lipocalin mutein which is capable of binding CD137.

In some embodiments, lipocalin muteins of the disclosure may have mutated, including substituted, deleted and inserted, amino acid residue(s) at one or more sequence positions corresponding to the linear polypeptide sequence of a reference lipocalin, preferably hTlc or hNGAL. In some embodiments, the number of amino acid residues of a lipocalin mutein of the disclosure that is mutated in comparison with the amino acid sequence of the reference lipocalin, preferably hTlc or hNGAL, is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more such as 25, 30, 35, 40, 45 or 50, with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 being preferred and 9, 10 or 11 being even more preferred. However, it is preferred that a lipocalin mutein of the disclosure is still capable of binding CD137.

In some embodiments, a lipocalin mutein of the present disclosure may lack 1, 2, 3, 4 or more amino acids at its N-terminal end and/or 1, 2 or more amino acids at its C-terminal end, in comparison to the respective reference (wild-type) lipocalin; for example, SEQ ID NOs: 34-40. In some embodiments, the present disclosure encompasses hTlc muteins as defined above, in which the first four one, two, three, or N-terminal amino acid residues of the sequence of mature hTlc (His-His-Leu-Leu; positions 1-4) and/or the last one or two C-terminal amino acid residues (Ser-Asp; positions 157-158) of the linear polypeptide sequence of the mature hTlc have been deleted (e.g., SEQ ID NOs: 34-40). In some embodiments, the present disclosure encompasses hNGAL muteins as defined above, in which amino acid residues (Lys-Asp-Pro, positions 46-48) of the linear polypeptide sequence of the mature hNGAL have be deleted (SEQ ID NO: 45). Further, a lipocalin mutein of the disclosure may include the wild-type (natural) amino acid sequence of the reference (wild-type) lipocalin, preferably hTlc or hNGAL, outside the mutated amino acid sequence positions.

In some embodiments, one or more mutated amino acid residues incorporated into a lipocalin mutein of the disclosure does do not substantially hamper or not interfere with the binding activity to the designated target and the folding of the mutein. Such mutations, including substitution, deletion and insertion, can be accomplished at the DNA level using established standard methods (Sambrook and Russell, 2001, Molecular cloning: a laboratory manual). In some embodiments, a mutated amino acid residue(s) at one or more sequence positions corresponding to the linear polypeptide sequence of the reference (wild-type) lipocalin, preferably hTlc or hNGAL, is introduced through random mutagenesis by substituting the nucleotide triplet(s) encoding the corresponding sequence positions of the reference lipocalin with a subset of nucleotide triplets.

In some embodiments, a provided lipocalin mutein that binds CD137 with detectable affinity may include at least one amino acid substitution of a native cysteine residue by another amino acid, for example, a serine residue. In some embodiments, a lipocalin mutein that binds CD137 with detectable affinity may include one or more non-native cysteine residues substituting one or more amino acids of a reference (wild-type) lipocalin, preferably hTlc or hNGAL. In some embodiments, a lipocalin mutein according to the disclosure includes at least two amino acid substitutions of a native amino acid by a cysteine residue, hereby to form one or more cysteine bridges. In some embodiments, said cysteine bridge may connect at least two loop regions. The definition of these regions is used herein in accordance with (Biochim Biophys Acta, 2000), Flower (1996) and Breustedt et al. (2005).

Generally, a lipocalin mutein of the disclosure may have about at least 70%, including at least about 80%, such as at least about 85% amino acid sequence identity, with the amino acid sequence of the mature hTlc (SEQ ID NO: 1) or mature hNGAL (SEQ ID NO: 2).

In some aspects, the present disclosure provides CD137-binding hTlc muteins. In this regard, the disclosure provides one or more hTlc muteins that are capable of binding CD137 with an affinity measured by a K_D of about 300 nM, 200 nM, 150 nM, 100 nM, or lower. In some embodiments, provided hTlc muteins are capable of binding CD137 with an EC₅₀ value of about 250 nM, 150 nM, 100 nM, 50 nM, 20 nM, or even lower. In some other embodiments, the CD137-binding hTlc muteins may be cross-reactive with cynomolgus CD137 (cyCD137).

In some embodiments, an hTlc mutein of the disclosure may interfere with the binding of CD137L to CD137.

In some embodiments, provided hTlc muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150, and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1).

In some embodiments, provided hTlc muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 26-34, 55-58, 60-61, 65, 104-106, and 108 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1).

In some embodiments, provided hTlc muteins may further comprise a mutated amino acid residue at one or more positions corresponding to positions 101, 111, 114 and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1).

In some embodiments, provided hTlc muteins may comprise a mutated amino acid residue at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or even more positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150 and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1). In some preferred embodiments, the provided hTlc muteins are capable of binding CD137, in particular human CD137.

In some embodiments, provided hTlc muteins may comprise a mutated amino acid residue at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or even more positions corresponding to positions 26-34, 55-58, 60-61, 65, 104-106 and 108 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1). In some preferred embodiments, the provided hTlc muteins are capable of binding CD137, in particular human CD137.

In some embodiments, a lipocalin mutein according to the disclosure may include at least one amino acid substitution of a native cysteine residue by, e.g., a serine residue. In some embodiments, an hTlc mutein according to the disclosure includes an amino acid substitution of a native cysteine residue at positions corresponding to positions 61 and/or 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1) by another amino acid, such as a serine residue. In this context it is noted that it has been found that removal of the structural disulfide bond (on the level of a respective nave nucleic acid library) of wild-type hTlc that is formed by the cysteine residues 61 and 153 (cf. Breustedt et al., J Biol Chem, 2005) may provide hTlc muteins that are not only stably folded but are also able to bind a given non-natural target with high affinity. In some embodiments, the elimination of the structural disulfide bond may provide the further advantage of allowing for the generation or deliberate introduction of non-natural disulfide bonds into muteins of the disclosure, thereby, increasing the stability of the muteins. However, hTlc muteins that bind CD137 and that have the disulfide bridge formed between Cys 61 and Cys 153 are also part of the present disclosure.

In some particular embodiments, an hTlc mutein of the disclosure may include one or more of the amino acid substitutions Cys 61→Ala, Phe, Lys, Arg, Thr, Asn, Gly, Gln, Asp, Asn, Leu, Tyr, Met, Ser, Pro or Trp and/or Cys 153→Ser or Ala, at positions corresponding to positions 61 and/or 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1).

In some embodiments, either two or all three of the cysteine codons at positions corresponding to positions 61, 101 and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1) are replaced by a codon of another amino acid. Further, in some embodiments, an hTlc mutein according to the disclosure includes an amino acid substitution of a native cysteine residue at the position corresponding to position 101 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1) by a serine residue or a histidine residue.

In some embodiments, a mutein according to the disclosure comprises an amino acid substitution of a native amino acid by a cysteine residue at positions corresponding to positions 28 or 105 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1). Further, in some embodiments, a mutein according to the disclosure comprises an amino acid substitution of a native arginine residue at the position corresponding to position 111 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1) by a proline residue. Further, in some embodiments, a mutein according to the disclosure comprises an amino acid substitution of a native lysine residue at the position corresponding to position 114 of the linear polypeptide sequence of mature hTlc (SEQ ID NO:1) by a tryptophan residue or a glutamic acid.

In some embodiments, provided CD137-binding hTlc muteins may comprise, at one or more positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150, and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1), one or more of the following mutated amino acid residues: Ala 5→Val or Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Thr 42→Ser; Gly 46→Asp; Lys 52→Glu; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg or Asn; Thr 71→Ala; Val 85→Asp; Lys 94→Arg or Glu; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; Arg 148→Ser; Ser 150→Ile; and Cys 153→Ser. In some embodiments, an hTlc mutein of the disclosure comprises two or more, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or more, or even all mutated amino acid residues at these sequence positions of mature hTlc (SEQ ID NO: 1).

In some embodiments, provided CD137-binding hTlc muteins may comprise one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1):

• (a) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29 Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58 Asp; Arg 60→Pro; Cys 61→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; and Cys 153→Ser;
• (b) Ala 5→Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg; Val 85→Asp; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;
• (c) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Asn; Lys 94→Arg; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;
• (d) Ala 5→Val; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg; Lys 94→Glu; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;
• (e) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Thr 42→Ser; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ser 150→Ile; and Cys 153→Ser;
• (f) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Lys 52→Glu; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Thr 71→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ala 133→Thr; Arg 148→Ser; Ser 150→Ile; and Cys 153→Ser; and
• (g) Ala 5→Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Gly 46→Asp; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Thr 71→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ser 150→Ile; and Cys 153→Ser.

In some embodiments, the residual region, i.e. the region differing from positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150, and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1), of an hTlc mutein of the disclosure may comprise the wild-type (natural) amino acid sequence of the linear polypeptide sequence of mature hTlc outside the mutated amino acid sequence positions.

In some embodiments, an hTlc mutein of the disclosure has at least 70% sequence identity or at least 70% sequence homology to the sequence of mature hTlc (SEQ ID NO: 1). As an illustrative example, the mutein of the SEQ ID NO: 34 has an amino acid sequence identity or a sequence homology of approximately 84% with the amino acid sequence of the mature hTlc.

In some embodiments, an hTlc mutein of the disclosure comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 34-40 or a fragment or variant thereof.

In some embodiments, an hTlc mutein of the disclosure has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or higher sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-40.

The present disclosure also includes structural homologues of an hTlc mutein having an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-40, which structural homologues have an amino acid sequence homology or sequence identity of more than about 60%, preferably more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 92% and most preferably more than 95% in relation to said hTlc mutein.

In some aspects, the present disclosure provides CD137-binding hNGAL muteins. In this regard, the disclosure provides one or more hNGAL muteins that are capable of binding CD137 with an affinity measured by a K_D of about 800 nM, 700 nM, 200 nM, 140 nM, 100 nM or lower, preferably about 70 nM, 50 nM, 30 nM, 10 nM, 5 nM, 2 nM, or even lower. In some embodiments, provided hNGAL muteins are capable of binding CD137 with an EC₅₀ value of about 1000 nM, 500 nM, 100 nM, 80 nM, 50 nM, 25 nM, 18 nM, 15 nM, 10 nM, 5 nM, or lower.

In some embodiments, provided CD137-binding hNGAL muteins may be cross-reactive with cynomolgus CD137. In some embodiments, provided hNGAL mutiens are capable of binding cynomolgus CD137 with an affinity measured by a K_D of about 50 nM, 20 nM, 10 nM, 5 nM, 2 nM, or even lower. In some embodiments, provided hNGAL muteins are capable of binding cynomolgus CD137 with an EC₅₀ value of about 100 nM, 80 nM, 50 nM, 30 nM, or even lower.

In some embodiments, an hNGAL mutein of the disclosure may interfere or compete with the binding of CD137L to CD137. In some other embodiments, an hNGAL mutein of the disclosure may be capable of binding CD137 in the presence of CD137L and/or binding CD137/CD137L complex.

In some embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2).

In some embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or even more positions corresponding to position 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2). In some preferred embodiments, the provided hNGAL muteins are capable of binding CD137, in particular human CD137.

In some embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 87, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2) In some preferred embodiments, the provided hNGAL muteins are capable of binding CD137, in particular human CD137.

In some embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 36, 87, and 96 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2) and at one or more positions corresponding to positions 28, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 94, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2).

In other some embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2).

In other embodiments, provided hNGAL muteins may comprise a mutated amino acid residue at one or more positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2) and at one or more positions corresponding to positions 20, 25, 33, 44, 59, 71, 78, 80, 82, 87, 92, 98, 101, and 122 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2).

In some embodiments, a lipocalin mutein according to the disclosure may comprise at least one amino acid substitution of a native cysteine residue by, e.g., a serine residue. In some embodiments, an hNGAL mutein according to the disclosure may comprise an amino acid substitution of a native cysteine residue at positions corresponding to positions 76 and/or 175 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2) by another amino acid, such as a serine residue. In this context, it is noted that it has been found that removal of the structural disulfide bond (on the level of a respective nave nucleic acid library) of wild-type hNGAL that is formed by the cysteine residues 76 and 175 (cf. Breustedt et al., J Biol Chem, 2005) may provide hNGAL muteins that are not only stably folded but are also able to bind a given non-natural target with high affinity. In some embodiments, the elimination of the structural disulfide bond may provide the further advantage of allowing for the generation or deliberate introduction of non-natural disulfide bonds into muteins of the disclosure, thereby, increasing the stability of the muteins. However, hNGAL muteins that bind CD137 and that have the disulfide bridge formed between Cys 76 and Cys 175 are also part of the present disclosure.

In some embodiments, provided CD137-binding hNGAL muteins may comprise, at one or more positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg or Lys; Gln 49→Val, Ile, His, Ser or Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Met, Ala or Gly; Leu 70→Ala, Lys, Ser or Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Met, Arg, Thr or Asn; Trp 79→Ala or Asp; Arg 81→Met, Trp or Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu and Lys 134→Tyr. In some embodiments, an hNGAL mutein of the disclosure comprises two or more, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, even more such as 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or all mutated amino acid residues at these sequence positions of mature hNGAL (SEQ ID NO: 2).

In some embodiments, provided CD137-binding hNGAL muteins may comprise, at one or more positions corresponding to positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Gln 20→Arg; Asn 25→Tyr or Asp; Gln 28→His; Val 33→Ile; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Val or Asp; Gln 49→His; Tyr 52→Ser or Gly; Lys 59→Asn; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln or His; Tyr 78→His; Trp 79→Ile; Ile 80→Asn; Arg 81→Trp or Gln; Thr 82→Pro; Cys 87→Ser; Phe 92→Leu or Ser; Asn 96→Phe; Lys 98→Arg; Tyr 100→Asp; Pro 101→Leu; Leu 103→His or Pro; Phe 122→Tyr; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly.

In some embodiments, provided CD137-binding hNGAL muteins may comprise, at one or more positions corresponding to positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser or Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln or His; Trp 79→Ile; Arg 81→Trp or Gln; Asn 96→Phe; Tyr 100→Asp; Leu 103→His or Pro; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly. In some embodiments, provided CD137-binding hNGAL muteins may further comprise, at one or more positions corresponding to positions 20, 25, 33, 44, 59, 71, 78, 80, 82, 87, 92, 98, 101, and 122 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Gln 20→Arg; Asn 25→Tyr or Asp; Val 33→Ile; Glu 44→Val or Asp; Lys 59→Asn; Phe 71→Leu; Tyr 78→His; Ile 80→Asn; Thr 82→Pro; Phe 92→Leu or Ser; Lys 98→Arg; Pro 101→Leu; and Phe 122→Tyr.

In some embodiments, provided CD137-binding hNGAL muteins may comprise one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2):

• (a) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73 Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (b) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Ile; Tyr 52→Met; Asn 65→Asp; Ser 68→Met; Leu 70→Lys; Arg 72→Asp; Lys 73→Asp; Asp 77→Met; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (c) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Ala; Leu 70→Ala; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (d) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Ala; Leu 70→Ala; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (e) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Ser; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Ser; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Met; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (f) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49 Val; Tyr 52→Met; Asn 65→Asp; Ser 68 Gly; Leu 70→Thr; Arg 72→Asp; Lys 73 Asp; Asp 77→Arg; Trp 79→Asp; Arg 81→Ser; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (g) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→His; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103 His; Tyr 106→Ser; Lys 125 Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;
• (h) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr; or
• (i) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Ser; Tyr 52→Met; Asn 65→Asp; Ser 68→Ala; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Asn; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr.

In some further embodiments, in the residual region, i.e. the region differing from positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), an hNGAL mutein of the disclosure may include the wild-type (natural) amino acid sequence of mature hNGAL outside the mutated amino acid sequence positions.

In some other embodiments, provided CD137-binding hNGAL muteins may comprise one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2):

• (a) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132 Trp; and Lys 134→Gly;
• (b) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68 Asp; Leu 70→Met; Arg 72 Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Lys 98→Arg; Tyr 100 Asp; Pro 101→Leu; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (c) Asn 25→Tyr; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52 Gly; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Gln; Phe 92→Ser; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (d) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Tyr 78→His; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (e) Asn 25→Asp; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52 Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (f) Val 33→Ile; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (g) Gln 20→Arg; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Val; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81 Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Phe 122→Tyr; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (h) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Ile 80→Asn; Arg 81→Trp; Thr 82→Pro; Asn 96→Phe; Tyr 100→Asp; Pro 101→Leu; Leu 103→Pro; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;
• (i) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Lys 59→Asn; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly; and
• (j) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Asp; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→His; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly.

In some embodiments, in the residual region, i.e. the region differing from positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), of an hNGAL mutein of the disclosure may include the wild-type (natural) amino acid sequence of mature hNGAL outside the mutated amino acid sequence positions.

In some embodiments, an hNGAL mutein of the disclosure has at least 70% sequence identity or at least 70% sequence homology to the sequence of mature hNGAL (SEQ ID NO: 2). As an illustrative example, the mutein of the SEQ ID NO: 42 has an amino acid sequence identity or a sequence homology of approximately 87% with the amino acid sequence of the mature hNGAL.

In some embodiments, an hNGAL mutein of the disclosure comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 41-59 or a fragment or variant thereof.

In some embodiments, an hNGAL mutein of the disclosure has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or higher sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-59.

The present disclosure also includes structural homologues of an hNGAL mutein having an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-59, which structural homologues have an amino acid sequence homology or sequence identity of more than about 60%, preferably more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 92% and most preferably more than 95% in relation to said hNGAL mutein.

In some embodiments, the present disclosure provides a lipocalin mutein that binds CD137 with an affinity measured by a K_D of about 5 nM or lower, wherein the lipocalin mutein has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or higher sequence identity to the amino acid sequence of SEQ ID NO: 42.

In some embodiments, a lipocalin mutein of the present disclosure can comprise a heterologous amino acid sequence at its N- or C-Terminus, preferably C-terminus, such as a Strep II tag (SEQ ID NO: 12) or a cleavage site sequence for certain restriction enzymes, without affecting the biological activity (binding to its target, e.g., CD137) of the lipocalin mutein.

In some embodiments, further modifications of a lipocalin mutein may be introduced in order to modulate certain characteristics of the mutein, such as to improve folding stability, serum stability, protein resistance or water solubility or to reduce aggregation tendency, or to introduce new characteristics to the mutein. In some embodiments, modification(s) may result in two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) characteristics of a provided mutein being modulated.

For example, it is possible to mutate one or more amino acid sequence positions of a lipocalin mutein to introduce new reactive groups, for example, for the conjugation to other compounds, such as polyethylene glycol (PEG), hydroxyethyl starch (HES), biotin, peptides or proteins, or for the formation of non-naturally occurring disulphide linkages. The conjugated compound, for example, PEG and HES, can in some cases increase the serum half-life of the corresponding lipocalin mutein.

In some embodiments, a reactive group of a lipocalin mutein may occur naturally in its amino acid sequence, such as naturally occurring cysteine residues in said amino acid sequence. In some other embodiments, such reactive group may be introduced via mutagenesis. In case a reactive group is introduced via mutagenesis, one possibility is the mutation of an amino acid at the appropriate position by a cysteine residue. Exemplary possibilities of such a mutation to introduce a cysteine residue into the amino acid sequence of an hTlc mutein include the substitutions Thr 40→Cys, Glu 73→Cys, Arg 90→Cys, Asp 95→Cys, and Glu 131→Cys of the wild-type sequence of hTlc (SEQ ID NO: 1). Exemplary possibilities of such a mutation to introduce a cysteine residue into the amino acid sequence of an hNGAL mutein include the introduction of a cysteine residue at one or more of the sequence positions that correspond to sequence positions 14, 21, 60, 84, 88, 116, 141, 145, 143, 146 or 158 of the wild-type sequence of hNGAL (SEQ ID NO: 2). The generated thiol moiety may be used to PEGylate or HESylate the mutein, for example, in order to increase the serum half-life of a respective lipocalin mutein

In some embodiments, in order to provide suitable amino acid side chains as new reactive groups for conjugating one of the above compounds to a lipocalin mutein, artificial amino acids may be introduced to the amino acid sequence of a lipocalin mutein. Generally, such artificial amino acids are designed to be more reactive and thus to facilitate the conjugation to the desired compound. Such artificial amino acids may be introduced by mutagenesis, for example, using an artificial tRNA is para-acetyl-phenylalanine.

In some embodiments, a lipocalin mutein of the disclosure is fused at its N-terminus or its C-terminus to a protein, a protein domain or a peptide, for instance, an antibody, a signal sequence and/or an affinity tag. In some other embodiments, a lipocalin mutein of the disclosure is conjugated at its N-terminus or its C-terminus to a partner, which is a protein, a protein domain or a peptide; for instance, an antibody, a signal sequence and/or an affinity tag.

Affinity tags such as the Strep-tag or Strep-tag II (Schmidt et al., J Mol Biol, 1996), the c-myc-tag, the FLAG-tag, the His-tag or the HA-tag or proteins such as glutathione-S-transferase, which allow easy detection and/or purification of recombinant proteins, are examples of suitable fusion partners. Proteins with chromogenic or fluorescent properties such as the green fluorescent protein (GFP) or the yellow fluorescent protein (YFP) are suitable fusion partners for lipocalin muteins of the disclosure as well. In general, it is possible to label the lipocalin muteins of the disclosure with any appropriate chemical substance or enzyme, which directly or indirectly generates a detectable compound or signal in a chemical, physical, optical, or enzymatic reaction. For example, a fluorescent or radioactive label can be conjugated to a lipocalin mutein to generate fluorescence or x-rays as detectable signal. Alkaline phosphatase, horseradish peroxidase and β-galactosidase are examples of enzyme labels (and at the same time optical labels) which catalyze the formation of chromogenic reaction products. In general, all labels commonly used for antibodies (except those exclusively used with the sugar moiety in the Fc part of immunoglobulins) can also be used for conjugation to the lipocalin muteins of the disclosure.

In some embodiments, a lipocalin mutein of the disclosure may be fused or conjugated to a moiety that extends the serum half-life of the mutein (in this regard see also International Patent Publication No. WO 2006/056464, where such strategies are described with reference to muteins of human neutrophil gelatinase-associated lipocalin (hNGAL) with binding affinity for CTLA-4). The moiety that extends the serum half-life may be a PEG molecule, a HES molecule, a fatty acid molecule, such as palmitic acid (Vajo and Duckworth, Pharmacol Rev, 2000), an Fc part of an immunoglobulin, a C_H3 domain of an immunoglobulin, a C_H4 domain of an immunoglobulin, an albumin binding peptide, an albumin binding protein, or a transferrin, to name only a few.

In some embodiments, if PEG is used as a conjugation partner, the PEG molecule can be substituted, unsubstituted, linear, or branched. It can also be an activated polyethylene derivative. Examples of suitable compounds are PEG molecules as described in International Patent Publication No. WO 1999/64016, in U.S. Pat. No. 6,177,074, or in U.S. Pat. No. 6,403,564 in relation to interferon, or as described for other proteins such as PEG-modified asparaginase, PEG-adenosine deaminase (PEG-ADA) or PEG-superoxide dismutase (Fuertges and Abuchowski, Journal of Controlled Release, 1990). The molecular weight of such a polymer, such as polyethylene glycol, may range from about 300 to about 70,000 daltons, including, for example, polyethylene glycol with a molecular weight of about 10,000, of about 20,000, of about 30,000 or of about 40,000 daltons. Moreover, as e.g., described in U.S. Pat. No. 6,500,930 or 6,620,413, carbohydrate oligomers and polymers such as HES can be conjugated to a mutein of the disclosure for the purpose of serum half-life extension.

In some embodiments, if an Fc part of an immunoglobulin is used for the purpose to prolong the serum half-life of the lipocalin muteins of the disclosure, the SynFusion™ technology, commercially available from Syntonix Pharmaceuticals, Inc. (MA, USA), may be used. The use of this Fc-fusion technology allows the creation of longer-acting biopharmaceuticals and may, for example, consist of two copies of the mutein linked to the Fc region of an antibody to improve pharmacokinetics, solubility, and production efficiency.

Examples of albumin binding peptides that can be used to extend the serum half-life of a lipocalin mutein are, for instance, those having a Cys-Xaa₁-Xaa₂-Xaa₃-Xaa₄-Cys consensus sequence, wherein Xaa₁ is Asp, Asn, Ser, Thr, or Trp; Xaa₂ is Asn, Gln, His, Ile, Leu, or Lys; Xaa₃ is Ala, Asp, Phe, Trp, or Tyr; and Xaa₄ is Asp, Gly, Leu, Phe, Ser, or Thr as described in U.S. Patent Publication No. 20030069395 or Dennis et al. (2002). The albumin binding protein fused or conjugated to a lipocalin mutein to extend serum half-life may be a bacterial albumin binding protein, an antibody, an antibody fragment including domain antibodies (see U.S. Pat. No. 6,696,245, for example), or a lipocalin mutein with binding activity for albumin. Examples of bacterial albumin binding proteins include streptococcal protein G (Konig and Skerra, J Immunol Methods, 1998).

In some embodiments, if the albumin-binding protein is an antibody fragment it may be a domain antibody. Domain Antibodies (dAbs) are engineered to allow precise control over biophysical properties and in vivo half-life to create the optimal safety and efficacy product profile. Domain Antibodies are for example commercially available from Domantis Ltd. (Cambridge, UK, and MA, USA).

In some embodiments, albumin itself (Osborn et al., J Pharmacol Exp Ther, 2002), or a biologically active fragment of albumin can be used as a partner of a lipocalin mutein of the disclosure to extend serum half-life. The term “albumin” includes all mammal albumins such as human serum albumin or bovine serum albumin or rat albumin. The albumin or fragment thereof can be recombinantly produced as described in U.S. Pat. No. 5,728,553 or European Patent Publication Nos. EP0330451 and EP0361991. Accordingly, recombinant human albumin (e.g., Recombumin® from Novozymes Delta Ltd., Nottingham, UK) can be conjugated or fused to a lipocalin mutein of the disclosure.

In some embodiments, if a transferrin is used as a partner to extend the serum half-life of the lipocalin muteins of the disclosure, the muteins can be genetically fused to the N or C terminus, or both, of non-glycosylated transferrin. Non-glycosylated transferrin has a half-life of 14-17 days, and a transferrin fusion protein will similarly have an extended half-life. The transferrin carrier also provides high bioavailability, biodistribution and circulating stability. This technology is commercially available from BioRexis (BioRexis Pharmaceutical Corporation, PA, USA). Recombinant human transferrin (DeltaFerrin™) for use as a protein stabilizer/half-life extension partner is also commercially available from Novozymes Delta Ltd. (Nottingham, UK).

Yet another alternative to prolong the half-life of the lipocalin muteins of the disclosure is to fuse to the N- or C-terminus of a mutein a long, unstructured, flexible glycine-rich sequences (for example poly-glycine with about 20 to 80 consecutive glycine residues). This approach disclosed in International Patent Publication No. WO2007/038619, for example, has also been term “rPEG” (recombinant PEG).

E. Exemplary Uses and Applications of Fusion Proteins Specific for CD137 and PD-L1

In some embodiments, fusion proteins of the disclosure may produce synergistic effect through dual-targeting of CD137 and PD-L1. In some embodiments, fusion proteins of the disclosure may produce synergistic effect through CD137 co-stimulation and PD-1/PD-L1 pathway blockade. In some embodiments, fusion proteins of the disclosure may produce localized anti-tumor effect through dual-targeting of CD137 and PD-L1. Numerous possible applications for the fusion proteins of the disclosure, therefore, exist in medicine.

In some embodiments, the present disclosure encompasses the use of one or more fusion proteins disclosed herein or of one or more compositions comprising such fusion proteins for simultaneously binding of CD137 and PD-L1.

The present disclosure also involves the use of one or more fusion proteins as described for complex formation with CD137 and/or PD-L1.

Therefore, in one aspect of the disclosure, provided fusion proteins may be used for the detection of CD137 and PD-L1. Such use may include the steps of contacting one or more said fusion proteins, under suitable conditions, with a sample suspected of containing CD137 and/or PD-L1, thereby allowing formation of a complex between the fusion proteins and CD137 and/or PD-L1, and detecting the complex by a suitable signal. The detectable signal can be caused by a label, as explained above, or by a change of physical properties due to the binding, i.e., the complex formation, itself. One example is surface plasmon resonance, the value of which is changed during binding of binding partners from which one is immobilized on a surface such as a gold foil.

Fusion proteins of the disclosure may also be used for the separation of CD137 and/or PD-L1. Such use may include the steps of contacting one or more said fusion proteins, under suitable conditions, with a sample supposed to contain CD137 and/or PD-L1, thereby allowing the formation of a complex between the fusion proteins and CD137 and/or PD-L1 and separating the complex from the sample.

In some aspects, the present disclosure provides diagnostic and/or analytical kits comprising one or more fusion proteins according to the disclosure.

In addition to their use in diagnostics, in yet another aspect, the disclosure contemplates pharmaceutical compositions comprising one or more fusion proteins of the disclosure and a pharmaceutically acceptable excipient.

Furthermore, in some embodiments, the present disclosure provides fusion proteins that simultaneously bind CD137 and/or PD-L1 for use such as anti-tumor and/or anti-infection agents, and immune modulators. In some embodiments, fusion proteins of the present disclosure are envisaged to be used in a method of prevention, amelioration, or treatment of human diseases, such as a variety of cancers, including PD-L1-positive cancers. Accordingly, also provided are methods of preventing, ameliorating, or treating human diseases such as a variety of cancers, including PD-L1-positive cancer, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of one or more fusion proteins of the disclosure.

Examples of cancers that may be treated using the fusion proteins of the disclosure, include liver cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, breast cancer, lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally induced cancers including those induced by asbestos, hematologic malignancies including, for example, multiple myeloma, B cell lymphoma, Hodgkin lymphoma/primary mediastinal B-cell lymphoma, non-Hodgkin's lymphomas, acute myeloid lymphoma, chronic myelogenous leukemia, chronic lymphoid leukemia, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, mycosis fungoides, anaplastic large cell lymphoma, T cell lymphoma, and precursor T-lymphoblastic lymphoma, and any combinations of said cancers. In some embodiments, the present invention is also applicable to the treatment of metastatic cancers.

In some embodiments, fusion proteins of the disclosure may simultaneously target tumor cells where PD-L1 is expressed and activate lymphocytes of the host immune system adjacent to such tumor cells. In some embodiments, fusion proteins of the disclosure may increase targeted anti-tumor T cells activity, enhance anti-tumor immunity and, and/or have a direct inhibiting effect on tumor growth, thereby produce synergistic anti-tumor results. In some embodiments, fusion proteins of the disclosure may activate immune responses in a tumor microenvironment. In some embodiments, fusion proteins of the disclosure may reduce side effects of effector lymphocytes towards healthy cells, i.e. off-target toxicity, for example, via locally inhibiting oncogene activity and inducing lymphocyte activation.

In some embodiments, the present disclosure encompasses the use of a fusion protein of the disclosure, or a composition comprising a provided fusion protein, for inducing a localized lymphocyte response in the vicinity of PD-L1-positive tumor cells. Accordingly, in some embodiments, the present disclosure provides methods of inducing a localized lymphocyte response in the vicinity of PD-L1-positive tumor cells, comprising applying one or more fusion proteins of the disclosure or of one or more compositions comprising such fusion proteins. “Localized” means that upon simultaneous binding T-cells via CD137 and engaging PD-L1-positive tumor cells, T-cells produce cytokines, particularly IL-2 and/or IFN gamma in vicinity of the PD-L1-positive cells. Such cytokines reflect activation of T-cells which may then be able to kill PD-L1-positive cells, either directly or indirectly by attracting other killer cells, such as T-cells or NK cells.

In some embodiments, the present disclosure encompasses the use of a fusion protein of the disclosure, or a composition comprising such fusion protein, for co-stimulating T-cells, and/or activating downstream signaling pathways of CD137. Preferably, a provided fusion protein co-stimulates T-cells and/or activating downstream signaling pathways of CD137 when engaging tumor cells where PD-L1 is expressed. Accordingly, the present disclosure provides methods of inducing T lymphocyte proliferation and/or activating downstream signaling pathways of CD137, preferably when engaging tumor cells where PD-L1 is expressed, comprising applying one or more fusion proteins of the disclosure and/or one or more compositions comprising such fusion proteins.

In some embodiments, the present disclosure encompasses the use of a fusion protein of the disclosure, or a composition comprising such fusion protein, for inducing CD137 clustering and activation on T-cells and directing such T-cells to tumor cells where PD-L1 is expressed.

Additional objects, advantages, and features of this disclosure will become apparent to those skilled in the art upon examination of the following Examples and the attached Figures thereof, which are not intended to be limiting. Thus, it should be understood that although the present disclosure is specifically disclosed by exemplary embodiments and optional features, modification and variation of the disclosures embodied therein herein disclosed may be resorted to by those skilled in the art and that such modifications and variations are considered to be within the scope of this disclosure.

F. Production of Exemplary Provided Fusion Proteins Specific for CD137 and PD-L1.

In some embodiments, the present disclosure provides nucleic acid molecules (DNA and RNA) that include nucleotide sequences encoding provided fusion proteins. In some embodiments, the disclosure encompasses a host cell containing a provided nucleic acid molecule. Since the degeneracy of the genetic code permits substitutions of certain codons by other codons specifying the same amino acid, the disclosure is not limited to a specific nucleic acid molecule encoding a fusion protein as described herein, rather, encompassing all nucleic acid molecules that include nucleotide sequences encoding a functional fusion protein. In this regard, the present disclosure also relates to nucleotide sequences encoding provided fusion proteins.

A nucleic acid molecule, such as DNA, is referred to as “capable of expressing a nucleic acid molecule” or “able to allow expression of a nucleotide sequence” if it includes sequence elements that contain information regarding to transcriptional and/or translational regulation, and such sequences are “operably linked” to the nucleotide sequence encoding the protein. An operable linkage is a linkage in which the regulatory sequence elements and the sequence to be expressed are connected in a way that enables gene expression. The precise nature of the regulatory regions necessary for gene expression may vary among species, but in general these regions include a promoter, which, in prokaryotes, contains both the promoter per se, i.e., DNA elements directing the initiation of transcription, as well as DNA elements which, when transcribed into RNA, will signal the initiation of translation. Such promoter regions normally include 5′ non-coding sequences involved in initiation of transcription and translation, such as the −35/−10 boxes and the Shine-Dalgarno element in prokaryotes or the TATA box, CAAT sequences, and 5′-capping elements in eukaryotes. These regions can also include enhancer or repressor elements as well as translated signal and leader sequences for targeting the native protein to a specific compartment of a host cell.

In addition, 3′ non-coding sequences may contain regulatory elements involved in transcriptional termination, polyadenylation or the like. If, however, these termination sequences are not satisfactorily functional in a particular host cell, then they may be substituted with signals functional in that cell.

Therefore, a nucleic acid molecule of the disclosure may be “operably linked” to one or more regulatory sequences, such as a promoter sequence, to allow expression of this nucleic acid molecule. In some embodiments, a nucleic acid molecule of the disclosure includes a promoter sequence and a transcriptional termination sequence. Suitable prokaryotic promoters are, for example, the tet promoter, the lacUV5 promoter or the T7 promoter. Examples of promoters useful for expression in eukaryotic cells are the SV40 promoter or the CMV promoter.

In some embodiments, a nucleic acid molecule encoding a lipocalin mutein disclosed in this application may be “operably linked” to another nucleic acid molecule encoding an immunoglobulin of the disclosure to allow expression of a fusion protein disclosed herein.

In some embodiments, provided methods may include subjecting at least one nucleic acid molecule encoding mature hTlc to mutagenesis at nucleotide triplets coding for one or more positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150 and 153 of the linear polypeptide sequence of hTlc (SEQ ID NO: 1), to obtain lipocalin muteins as included in provided fusion proteins. In some embodiments, provided methods may include subjecting at least one nucleic acid molecule encoding mature hNGAL to mutagenesis at nucleotide triplets coding for one or more positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of hNGAL (SEQ ID NO: 2), to obtain lipocalin muteins as included in provided fusion proteins. In some embodiments, a provided method may include subjecting at least one nucleic acid molecule encoding mature hNGAL to mutagenesis at nucleotide triplets coding for one or more positions corresponding to positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of hNGAL (SEQ ID NO: 2), to obtain lipocalin muteins as included in provided fusion proteins.

In addition, with respect to hTlc muteins or hNGAL muteins of the disclosure as included in the fusion proteins, in some embodiments, the naturally occurring disulfide bond between Cys 61 and Cys 153 or Cys 76 and Cys 175, respectively, may be removed. Accordingly, such muteins can be produced in a cell compartment having a reducing redox milieu, for example, in the cytoplasm of Gram-negative bacteria.

With further respect to provided hTlc muteins or hNGAL muteins of the disclosure as included in the fusion proteins, the disclosure also includes nucleic acid molecules encoding such muteins which, in some embodiments, may include one or more additional mutations outside the indicated sequence positions of experimental mutagenesis. Such mutations are often tolerated or can even prove to be advantageous, for example, if they contribute to an improved folding efficiency, serum stability, thermal stability or ligand binding affinity of the lipocalin muteins and/or the fusion proteins.

In some embodiments, provided nucleic acid molecules can also be part of a vector or any other kind of cloning vehicle, such as a plasmid, a phagemid, a phage, a baculovirus, a cosmid or an artificial chromosome.

In some embodiments, a provided nucleic acid molecule may be included in a phagemid. As used in this context, a phagemid vector denotes a vector encoding the intergenic region of a temperate phage, such as M13 or f1, or a functional part thereof fused to the cDNA of interest. For example, in some embodiments, after superinfection of bacterial host cells with such a provided phagemid vector and an appropriate helper phage (e.g., M13K07, VCS-M13 or R408) intact phage particles are produced, thereby enabling physical coupling of the encoded heterologous cDNA to its corresponding polypeptide displayed on the phage surface (Lowman, Annu Rev Biophys Biomol Struct, 1997, Rodi and Makowski, Curr Opin Biotechnol, 1999).

In accordance with various embodiments, cloning vehicles can include, aside from the regulatory sequences described above and a nucleic acid sequence encoding a fusion protein as described herein, replication and control sequences derived from a species compatible with the host cell that is used for expression as well as selection markers conferring a selectable phenotype on transformed or transfected cells. Large numbers of suitable cloning vectors are known in the art and are commercially available.

The disclosure also relates, in some embodiments, to methods for the production of fusion proteins of the disclosure starting from a nucleic acid coding for a fusion protein or any subunits therein using genetic engineering methods. In some embodiments, a provided method can be carried out in vivo, wherein a provided fusion protein can, for example, be produced in a bacterial or eukaryotic host organism, and then isolated from this host organism or its culture. It is also possible to produce a fusion protein of the disclosure in vitro, for example, using an in vitro translation system.

When producing a fusion protein in vivo, a nucleic acid encoding such fusion protein may be introduced into a suitable bacterial or eukaryotic host organism using recombinant DNA technology well known in the art. In some embodiments, a DNA molecule encoding a fusion protein as described herein (for example, SEQ ID NOs: 138-144), and in particular a cloning vector containing the coding sequence of such a fusion protein can be transformed into a host cell capable of expressing the gene. Transformation can be performed using standard techniques. Thus, the disclosure is also directed to host cells containing a nucleic acid molecule as disclosed herein.

In some embodiments, transformed host cells may be cultured under conditions suitable for expression of the nucleotide sequence encoding a fusion protein of the disclosure. In some embodiments, host cells can be prokaryotic, such as Escherichia coli (E. coli) or Bacillus subtilis, or eukaryotic, such as Saccharomyces cerevisiae, Pichia pastoris, SF9 or High5 insect cells, immortalized mammalian cell lines (e.g., HeLa cells or CHO cells) or primary mammalian cells.

In some embodiments, where a lipocalin mutein of the disclosure, including as comprised in a fusion protein disclosed herein, includes intramolecular disulfide bonds, it may be preferred to direct the nascent protein to a cell compartment having an oxidizing redox milieu using an appropriate signal sequence. Such an oxidizing environment may be provided by the periplasm of Gram-negative bacteria such as E. coli, in the extracellular milieu of Gram-positive bacteria or the lumen of the endoplasmic reticulum of eukaryotic cells and usually favors the formation of structural disulfide bonds.

In some embodiments, it is also possible to produce a fusion protein of the disclosure in the cytosol of a host cell, preferably E. coli. In this case, a provided fusion protein can either be directly obtained in a soluble and folded state or recovered in the form of inclusion bodies, followed by renaturation in vitro. A further option is the use of specific host strains having an oxidizing intracellular milieu, which may thus allow the formation of disulfide bonds in the cytosol (Venturi et al., J Mol Biol, 2002).

In some embodiments, a fusion protein of the disclosure as described herein may be not necessarily generated or produced, in whole or in part, via use of genetic engineering. Rather, such protein can also be obtained by any of the many conventional and well-known techniques such as plain organic synthesis strategies, solid phase-assisted synthesis techniques, commercially available automated synthesizers, or by in vitro transcription and translation. It is, for example, possible that promising fusion proteins or lipocalin muteins included in such fusion proteins are identified using molecular modeling, synthesized in vitro, and investigated for the binding activity for the target(s) of interest. Methods for the solid phase and/or solution phase synthesis of proteins are well known in the art (see e.g. Bruckdorfer et al., Curr Pharm Biotechnol, 2004).

In some embodiments, a fusion protein of the disclosure may be produced by in vitro transcription/translation employing well-established methods known to those skilled in the art.

In some further embodiments, fusion proteins as described herein may also be prepared by conventional recombinant techniques alone or in combination with conventional synthetic techniques.

Moreover, in some embodiments, a fusion protein according to the present disclosure may be obtained by conjugating together individual subunits, e.g., immunoglobulins and muteins as included in the fusion protein. Such conjugation can be, for example, achieved through all forms of covalent or non-covalent linkage using conventional methods.

The skilled worker will appreciate methods useful to prepare fusion proteins contemplated by the present disclosure but whose protein or nucleic acid sequences are not explicitly disclosed herein. As an overview, such modifications of the amino acid sequence include, e.g., directed mutagenesis of single amino acid positions to simplify sub-cloning of a protein gene or its parts by incorporating cleavage sites for certain restriction enzymes. Also, these mutations can be incorporated to further improve the affinity of a fusion protein for its targets (e.g., CD137 and PD-L1). Furthermore, mutations can be introduced to modulate one or more characteristics of the protein such as to improve folding stability, serum stability, protein resistance or water solubility or to reduce aggregation tendency, if necessary.

V. EXAMPLES

Example 1: Expression and Analysis of Representative Fusion Proteins

In this Example, representative antibody-lipocalin mutein fusion proteins were generated by fusing together a PD-L1 specific antibody having the heavy chain provided by SEQ ID NO: 86, or comprise a heavy chain variable domain of SEQ ID NO: 77, or comprising the CDRs of GFSLSNYD (HCDR1, SEQ ID NO: 60), IWTGGAT (HCDR2, SEQ ID NO: 61), VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 62), and light chains provided by SEQ ID NO: 87, or comprise a heavy chain variable domain of SEQ ID NO: 82, or comprising the CDRs of QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), QQSNSWPYT (LCDR3; SEQ ID NO: 64), and the CD137-specific lipocalin mutein of SEQ ID NO: 42, via a linker, such as an unstructured (G₄S)₃ linker of SEQ ID NO: 13, to engage PD-L1 and CD137 at the same time. The different formats that were generated are depicted in FIG. 1. For example, such fusion proteins, e.g., SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91, were generated via fusing the one or more of lipocalin mutein of SEQ ID NO: 42 to either one or more of the four termini of an antibody comprising of the heavy chain provided by the heavy chain provided by SEQ ID NO: 86, or comprise a heavy chain variable domain of SEQ ID NO: 77, or comprising the CDRs of GFSLSNYD (HCDR1, SEQ ID NO: 60), IWTGGAT (HCDR2, SEQ ID NO: 61), VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 62), and light chains provided by SEQ ID NO: 87, or comprise a heavy chain variable domain of SEQ ID NO: 82, or comprising the CDRs of QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), QQSNSWPYT (LCDR3; SEQ ID NO: 64). The generated fusion proteins can be bivalent to CD137 (e.g., as depicted in FIG. 1A-1D) or tetravalent to CD137 (e.g., as depicted in FIG. 1E-1H), or have even higher valency to CD137 (e.g., as depicted in FIG. 1I).

The PD-L1 specific antibodies as well as all antibody lipocalin mutein fusion proteins described in this Example had an engineered IgG4 backbone, which contained a S228P mutation to minimize IgG4 half-antibody exchange in-vitro and in-vivo (Silva et al., J Biol Chem, 2015). Additional mutations in the IgG4 backbones may also exist in all antibodies and fusion proteins described here, including any one or more of mutations F234A, L235A, M428L, N434S, M252Y, S254T, and T256E. F234A and L235A mutations may be introduced to decrease ADCC and ADCP (Glaesner et al., Diabetes Metab Res Rev, 2010). M428L and N434S mutations or M252Y, S254T, and T256E mutations may be introduced for extended serum half-life (Dall'Acqua et al., J Biol Chem, 2006, Zalevsky et al., Nat Biotechnol, 2010). All antibodies were expressed without the carboxy-terminal lysine to avoid heterogeneity.

In addition, monospecific lipocalin mutein Fc fusions were generated by fusing one or more of the CD137 specific lipocalin mutein of SEQ ID NO: 42, via a linker, e.g., an unstructured (G4S)3 linker of SEQ ID NO: 13, to the C-terminus of the Fc region of an antibody provided in SEQ ID NO: 30 as depicted in FIG. 1J-1K. The resulting construct is provided in SEQ ID NOs: 88-89.

The present invention also embodies asymmetrical antibody-lipocalin mutein fusion formats where, for example, one light chain of the antibody may be fused with a lipocalin mutein while the other is not.

The constructs of the fusion proteins were generated by gene synthesis and cloned into a mammalian expression vector. They were then transiently expressed in Expi293FTM cells (Life Technologies). The concentration of fusion proteins in the cell culture medium was measured by HPLC (Agilent Technologies) employing a POROS® protein A affinity column (Applied Biosystems). The titers of the fusion proteins were summarized in Table 1.

The fusion proteins were purified using Protein A chromatography followed by size-exclusion chromatography (SEC) in phosphate-buffered saline (PBS). After SEC purification, the fractions containing monomeric protein are pooled and analyzed again using analytical SEC.

TABLE 1
Transient expression titers
                      Expression titer
SEQ ID NO             [mg/mL]
SEQ ID NOs: 90 and 87 0.05
SEQ ID NOs: 86 and 91 0.07
SEQ ID NOs: 92 and 87 0.06
SEQ ID NOs: 86 and 93 0.09
SEQ ID NOs: 94 and 87 0.06
SEQ ID NOs: 90 and 91 0.10
SEQ ID NO: 88         0.24
SEQ ID NOs: 86 and 87 0.07

Example 2: Expression of the Fusion Proteins

The constructs of exemplary fusion proteins were generated by gene synthesis including codon optimization and cloned into a mammalian expression vector. They were then stably expressed in Chinese hamster ovary (CHO) cells. The concentration of fusion proteins in the cell culture medium was measured using Octet (ForteBio, Pall Corp.) with Protein-A sensors and quantified using human IgG1 standard. The titers of the fusion proteins were summarized in Table 2. The data suggest that the geometry of the fusion proteins may have an influence on product yield and cell productivity.

TABLE 2
Stable expression titers
                      Expression titer
SEQ ID NO             [mg/mL]
SEQ ID NOs: 90 and 87 1.423
SEQ ID NOs: 86 and 91 1.502
SEQ ID NOs: 92 and 87 0.456
SEQ ID NOs: 86 and 93 0.294
SEQ ID NOs: 94 and 87 0.293
SEQ ID NOs: 90 and 91 1.297
SEQ ID NO: 88         0.150
SEQ ID NOs: 86 and 87 1.018

Example 3: Binding of Fusion Proteins Towards PD-L1 or CD137 Determined by Surface Plasmon Resonance (SPR)

The binding kinetics and affinity of exemplary fusion proteins to huPD-L1-His or huCD137-His (human PD-L1 or human CD137 with a C-terminal polyhistidine tag, R&D Systems) were determined by surface plasmon resonance (SPR) using a Biacore 8K or a Biacore T200 (GE Healthcare).

The anti-human IgG Fc antibody (GE Healthcare) was immobilized on a CM5 sensor chip using standard amine chemistry: the carboxyl groups on the chip were activated using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS). Subsequently, anti-human IgG Fc antibody solution (GE Healthcare) at a concentration of 25 μg/mL in 10 mM sodium acetate (pH 5.0) was applied at a flow rate of 5 μL/min until an immobilization level of 6000-10000 resonance units (RU) was achieved. Residual non-reacted NHS-esters were blocked by passing a solution of 1M ethanolamine across the surface. The reference channel was treated in an analogous manner. Subsequently, testing fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89) at 0.25 μg/ml or 0.5 μg/mL in HBS-EP+ buffer was captured by the anti-human IgG-Fc antibody at the chip surface for 180 s at a flow rate of 10 μL/min. After each capture step, the needle was washed. Anti-PD-L1 antibodies, including a reference antibody (SEQ ID NOs: 26 and 27) and an antibody as included in the fusion proteins (SEQ ID NOs: 86 and 87), and a reference anti-CD137 antibody (SEQ ID NOs: 28 and 29) were also tested as controls.

For affinity determination, dilutions of huPD-L1-His (10 nM, 5 nM and 2.5 nM or huCD137-His (900 nM, 300 nM, and 100 nM) were prepared in HBS-EP+ buffer and applied to the prepared chip surface. The binding assay was carried out with a contact time of 180 s, a dissociation time of 900 s and a flow rate of 30 μL/min. All measurements were performed at 25° C. Regeneration of the chip surface was achieved with injections of 3 M MgCl₂ for 120 s. Prior to the protein measurements, three startup cycles were performed for conditioning purposes. Data were evaluated with Biacore T200 Evaluation software (v2.0) or with Biacore 8K Evaluation software (V1.1.1). Double referencing was used and the 1:1 binding model was used to fit the raw data.

The values determined for k_on, k_off, and the resulting equilibrium dissociation constant (K_D) for representative fusion proteins are summarized in Table 3. All bispecific fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91) bind PD-L1 as well as CD137 with subnanomolar to low nanomolar affinity. Monospecific CD137-specific lipocalin mutein-Fc fusions (SEQ ID NO: 88 and SEQ ID NO: 89) only bind CD137 with low nanomolar affinity.

TABLE 3
Kinetic constants and affinities of fusion proteins determined by SPR
	huPD-L1	huCD137
	kon	koff	KD	kon	koff	KD
SEQ ID NO	[M−1 × s−1]	[s−1]	[nM]	[M−1 × s−1]	[s−1]	[nM]
90 and 87	1.30E+06	7.69E−04	0.592	3.93E+04	2.55E−04	6.484
86 and 91	1.32E+06	7.48E−04	0.568	3.42E+04	1.75E−04	5.106
92 and 87	7.87E+05	8.03E−04	1.021	3.48E+04	2.08E−04	5.966
86 and 93	5.46E+05	7.54E−04	1.381	3.68E+04	1.30E−04	3.548
94 and 87	1.51E+06	9.16E−04	0.608	4.07E+04	2.24E−04	5.504
90 and 91	1.60E+06	8.61E−04	0.537	3.91E+04	2.24E−04	5.726
88	N.A.	N.A.	N.A.	3.94E+04	1.63E−04	4.155
86 and 87	1.09E+06	6.49E−04	0.593	N.A.	N.A.	N.A.
89	N.A.	N.A.	N.A.	3.66E+04	1.32E−04	3.595
26 and 27	6.38E+05	2.01E−04	0.314	N.A.	N.A.	N.A.
28 and 29	N.A.	N.A.	N.A.	4.72E+05	2.94E−03	6.237

Example 4. Binding of Fusion Proteins Towards PD-L1 or CD137 in Enzyme-Linked Immunosorbent Assay (ELISA)

An enzyme-linked immunosorbent assay (ELISA) was employed to determine the binding potency of exemplary fusion proteins to human PD-L1 and cynomolgus PD-L1.

Recombinant huPD-L1-His or cyPD-L1-His (human or cynomolgus PD-L1 with a C-terminal polyhistidine tag, R&D Systems or Sino Biologics) at the concentration of 1 μg/mL in PBS was coated overnight on microtiter plates at 4° C. After washing with PBS-0.05% T (PBS supplemented with 0.05% (v/v) Tween 20), the plates were blocked with 2% BSA (w/v) in PBS-0.1% T (PBS supplemented with 0.1% (v/v) Tween 20) for 1 h at room temperature. After washing with 100 μL PBS-0.05% T five times, exemplary fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91), Fc fusions a CD137-specific lipocalin mutein (SEQ ID NOs: 88 and SEQ ID NO: 89), and anti-PD-L1 antibodies (SEQ ID NOs: 26 and 27, SEQ ID NOs: 86 and 87), at different concentrations were added to the wells and incubated for 1 h at room temperature, followed by another wash step. Bound molecules under study were detected by incubation with 1:5000 diluted anti-human IgG Fc-HRP (Jackson Laboratory) in PBS-0.1% T-2% BSA. After an additional wash step, fluorogenic HRP substrate (QuantaBlu, Thermo) was added to each well and the fluorescence intensity was detected using a fluorescence microplate reader.

The same ELISA setup was also employed to determine the binding potency of fusion proteins to CD137, where huCD137-His (human CD137 with C-terminal polyhistidine tag, R&D Systems) or cyCD137-Fc (cynomolgus CD137 C-terminally fused to Fc) was instead coated on a microtiter plate. The testing agents were similarly titrated and bound agents were detected via anti-NGAL-HRP.

The results of exemplary experiments are depicted in FIG. 2A-2D, together with the fit curves resulting from a 1:1 binding sigmoidal fit, where the EC₅₀ value and the maximum signal were free parameters, and the slope was fixed to unity. The resulting EC₅₀ values are provided in Table 4.

The observed EC₅₀ values toward the two human targets of provided fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89) were very similar or comparable to tested PD-L1 antibodies (reference PD-L1 antibody of SEQ ID NOs: 26 and 27 and PD-L1 antibody of SEQ ID NOs: 86 and 87 as included in the fusion proteins), and/or the CD137-specific lipocalin mutein as included in the fusion proteins (SEQ ID NO: 42).

All tested fusion proteins show cross-reactivity to cynomolgus PD-L1, with comparable EC₅₀ values to the reference PD-L1 antibody (SEQ ID NOs: 26 and 27) or the PD-L1 antibody included in the fusion proteins (SEQ ID NOs: 86 and 87). Only fusion proteins that are tetravalent to CD137 showed (SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91, and SEQ ID NO: 88) show cross-reactivity to cynomolgus CD137 at a comparable level to human CD137, i.e, bind cynomolgus CD137 with EC₅₀ values in the same range as the corresponding EC₅₀s for human CD137.

TABLE 4
ELISA data for PD-L1 or CD137 binding
	EC50 [nM]	EC50 [nM]	EC50 [nM]	EC50 [nM]
	Binding to	Binding to	Binding to	Binding to
SEQ ID NO	huPD-L1	cyPD-L1	huCD137	cyCD137
90 and 87	0.15	0.13	0.28	5.9
86 and 91	0.23	0.18	0.57	13
92 and 87	0.16	0.15	0.41	9.8
86 and 93	0.19	0.17	0.35	8.1
94 and 87	0.18	0.15	0.16	0.19
90 and 91	0.20	0.17	0.14	0.21
88	N.A.	N.A.	0.15	0.12
86 and 87	0.12	0.1	N.A.	N.A.
89	N.A.	N.A.	0.29	0.82
26 and 27	0.09	0.09	N.A.	N.A.
42	N.A.	N.A.	0.27	N.A.

Example 5. Simultaneous Binding of Fusion Proteins to PD-L1 and CD137 in ELISA

In order to demonstrate the simultaneous binding of exemplary fusion proteins to PD-L1 and CD137, a dual-binding ELISA format was used.

Recombinant huPD-L1-His (R&D Systems) in PBS (1 μg/mL) was coated overnight on microtiter plates at 4° C. The plates were washed five times after each incubation step with 100 μL PBS-0.05% T. The plates were blocked with 2% BSA (w/v) in PBS-0.1% T for 1 h at room temperature and subsequently washed again. Different concentrations of tested fusion proteins were added to the wells and incubated for 1 h at room temperature, followed by a wash step. Subsequently, biotinylated huCD137-His (huCD137-His-Bio, Sino Biological) was added at a constant concentration of 1 μg/mL in PBS-0.1% T-2% BSA for 1 h. After washing, a 1:5000 dilution of ExtrAvidin-HRP (Sigma-Aldrich) in PBS-0.1% T-2% BSA was added to the wells and incubated for 1 h. After an additional wash step, fluorogenic HRP substrate (QuantaBlu, Thermo) was added to each well, and the fluorescence intensity was detected using a fluorescence microplate reader.

The dual binding of exemplary fusion proteins was also tested with a reverse set-up where recombinant 1 μg/ml huCD137-His (R&D Systems) was coated on microtiter plates and the bound fusion proteins were detected via the addition of biotinylated huPD-L1-His (R&D Systems).

Dual binding data of fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91) are shown in FIGS. 3A and 3B, together with the fit curves resulting from a 1:1 sigmoidal binding fit, where the EC₅₀ value and the maximum signal were free parameters, and the slope was fixed to unity. The EC₅₀ values are summarized in Table 5. All bispecific fusion proteins show clear binding signals, demonstrating that the fusion proteins are able to engage PD-L1 and CD137 simultaneously. The data further suggested fusing CD137-specific lipocalin muteins to C-termini of the PD-L1-specific antibodies may be more advantageous than to the N-termini.

TABLE 5
ELISA data for simultaneous target binding of both PD-L1 and CD37
	EC50 [nM]	EC50 [nM]
	PD-L1 capture_CD137	CD137 capture_PD-L1
SEQ ID NO	detection	detection
90 and 87	0.58	2.9
86 and 91	0.59	3.3
92 and 87	1.2	7.2
86 and 93	0.74	6.7
94 and 87	0.48	2.6
90 and 91	0.49	2.3

Example 6. Flow Cytometric Analysis of Fusion Proteins Binding to Cells Expressing Human and Cynomolgus CD137 and PD-L1

Target specific binding of fusion proteins to human and cynomolgus PD-L1-expressing cells and human and cynomolgus CD137-expressing cells was assessed by flow cytometry.

CHO cells were stably transfected with human PD-L1, cynomolgus PD-L1, human CD137, cynomolgus CD137 or a mock control using the Flp-In system (Life technologies) according to the manufacturer's instructions.

Transfected CHO cells were maintained in Ham's F12 medium (Life technologies) supplemented with 10% Fetal Calf Serum (Biochrom) and 500 μg/ml Hygromycin B (Roth). Cells were cultured in cell culture flasks according to manufacturer's instruction (37° C., 5% CO2 atmosphere).

For flow cytometric analysis, respective cell lines were incubated with fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89) and detected using a fluorescently labeled anti-human IgG antibody in FACS analysis as described in the following:

5×10⁴ cells per well were incubated for 1 h in ice-cold PBS containing 5% fetal calf serum (PBS-FCS). A dilution series of the fusion proteins and control antibodies were added to the cells and incubated for 1 h on ice. Cells were washed twice with PBS and then incubated with a goat anti-hIgG Alexa647-labeled antibody for 30 min on ice. Cells were subsequently washed and analyzed using iQue Flow cytometer (Intellicyte Screener). Mean geometric fluorescent signals were plotted and fitted with Graphpad software using nonlinear regression (shared bottom, SLOPE=1).

The ability of fusion proteins to bind human and cynomolgus PD-L1 and CD137 is depicted in FIG. 4. Binding affinities (EC₅₀s) of bispecific fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91) to human and cynomolgus PD-L1 expressing cells are in the single digit nanomolar range demonstrating full cyno-crossreactivity (summarized in Table 6). Binding affinities of fusion proteins to human CD137 expressing cells are in the low nanomolar range. Tested fusion proteins are fully cross-reactive to cynomolgus CD137 (SEQ ID NOs: 94 and 87, SEQ ID NOs: 90 and 91, and SEQ ID NO: 88), bind cynomolgus CD137 with 6-13-fold decreased affinities compared to the corresponding binding affinities to human CD137 (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, and SEQ ID NO: 89), or do not bind cynomolgus CD137 (SEQ ID NO: 92 and 87 and 86 and 93). None of the fusion proteins bind to mock transfected cells.

TABLE 6
Binding affinities of the fusion proteins to cells expressing human and cynomolgus
PD-L1 or CD137
	EC50 [nM]	EC50 [nM]	EC50 [nM]	EC50 [nM]
	Flp-In-	Flp-In-	Flp-In-	Flp-In-
SEQ ID NO	CHO::huCD137	CHO::cynoCD137	CHO::huPDL-1	CHO::cynoPDL-1
90 and 87	3.74	51.35	3.64	4.48
86 and 91	6.48	39.15	1.43	1.41
92 and 87	11.91	—	2.95	2.03
86 and 93	12.73	—	4.63	2.03
94 and 87	4.15	6.92	6.99	5.89
90 and 91	4.69	3.66	4.09	3.37
86 and 87	—	—	2.96	3.55
89	5.74	26.70	—	—
88	4.33	3.81	—	—
28 and 29	1.31	—	—	—

Example 7. Binding Affinities of the Fusion Proteins to PD-L1-Positive Tumor Cells

Binding of fusion proteins to tumor cells expressing PD-L1 was assessed by flow cytometry.

PD-L1 expressing colorectal cancer cell line RKO was maintained in RPMI1640 (Life technologies) supplemented with 10% FCS at 37° C. in a humidified 5% CO₂ atmosphere.

For flow cytometric analysis, RKO cells were incubated with fusion proteins and detected using a fluorescently labeled anti-human IgG antibody as described in Example 6.

The ability of fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91) to bind PD-L1-positive tumor cells is depicted in FIG. 5 and the corresponding binding affinities (EC₅₀s) are summarized in Table 7. Binding affinities of fusion proteins to PD-L1-expressing RKO cells were in the low nanomolar or subnanomolar range, comparable to the PD-L1 antibody included in the fusion proteins (SEQ ID NOs: 86 and 87).

TABLE 7
Binding affinities of the fusion proteins
to PD-L1-positive tumor cells
SEQ ID NO EC50 [nM] RKO
90 and 87 0.51
86 and 91 0.45
92 and 87 1.00
86 and 93 1.38
94 and 87 0.69
90 and 91 0.53
86 and 87 0.32

Example 8. Determination of the Competition Between CD137L and Fusion Proteins in Binding to CD137 by SPR

An SPR assay was utilized to investigate the competition between human CD137L (huCD137L-His, R&D Systems) and exemplary fusion proteins to the human CD137. The competition assay was performed at 25° C. on a Biacore T200 instrument (GE Healthcare).

BiotinCAPture reagent (GE Healthcare) was immobilized on a CAP sensor chip at a concentration of 50 μg/ml and a flow rate of 2 μL/min for 300 s. The reference channel was treated in an analogous manner. Biotinylated huCD137-Fc (R&D systems) was captured on the chip surface for 300 s at a concentration of 1 μg/mL and at a flow rate of 5 μL/min on another channel.

To analyze whether the testing fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89) compete with CD137L to bind CD137, either running buffer (HBS-EP+ buffer) or 500 nM huCD137L-His was applied to the chip surface for 180 s with a flow rate of 30 μL/min. Subsequently, the testing fusion proteins were applied to the prepared chip surface in HBS-EP+ buffer at a fixed concentration of 1 μM. The binding assay was carried out with a contact time of 180 s, a dissociation time of 15 s and a flow rate of 30 μL/min. As a control, buffer injections were included with the same parameters. Regeneration of the chip surface was achieved with injections of 6M Gua-HCl, 0.25M NaOH for 120 s at a flow rate of 10 μL/min, followed by an additional wash step with H₂O (120 s, 10 μl/min).

Representative examples for the relevant segment of the resulting sensorgrams are provided in FIG. 6 for the fusion proteins of SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89. The SPR trace for the binding of the respective fusion protein to huCD137-Fc alone is marked with an arrow with a solid stem. The SPR trace for the binding of the fusion protein to huCD137-Fc that has been saturated with huCD137L-His is marked with an arrow with a broken stem. The data shows that all fusion proteins bind to huCD137 in the presence of huCD137L, but with slightly reduced signals as compared to their binding to CD137 in the absence of CD137L. This suggests tested fusion proteins may be sterically hindered by the binding of CD137L to CD137 to some extent. This binding behavior of the fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 90 and 91, SEQ ID NO: 88, and SEQ ID NO: 89) is similar to that of the anti-CD137 antibody SEQ ID NOs: 28 and 29.

Example 9. Competition of the Fusion Proteins with PD-L1 in Binding to PD-1 Determined Using ELISA

In order to demonstrate the ability of the fusion proteins to inhibit the interaction between PD-1 and PD-L1, a competitive ELISA format was used.

Recombinant huPD-1-His (Acrobiosystems) in PBS (1 μg/mL) was coated overnight on microtiter plates at 4° C. The plates were washed five times after each incubation step with 100 μL PBS-0.05% T (PBS supplemented with 0.05% (v/v) Tween 20). The plates were blocked with 2% BSA (w/v) in PBS-0.1% T (PBS supplemented with 0.1% (v/v) Tween 20) for 1 h at room temperature and subsequently washed again. Fusion proteins at different concentrations were mixed with 15 nM of recombinant huPD-L1-Fc (R&D systems) as a tracer and incubated for 1 h at room temperature. The mixtures of fusion proteins and the tracer were added to the plates and incubated for 20 min at room temperature following by five washing steps with 100 μL PBS-0.05% T. Subsequently, a 1:5000 dilution of goat-anti human IgG-Fc HRP (Jackson) was added to the wells and incubated for 1 h. After an additional wash step, fluorogenic HRP substrate (QuantaBlu, Thermo) was added to each well, and the fluorescence intensity was detected using a fluorescence microplate reader.

Competition data of exemplary fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, and SEQ ID NOs: 90 and 91) are shown in FIG. 7, together with the fit curves resulting from a 1:1 sigmoidal binding fit, where the IC₅₀ value and the maximum signal were free parameters, and the slope was fixed to unity. The IC₅₀ values are summarized in Table 9. All bispecific fusion proteins showed clear inhibition of the PD-1/PD-L1 interaction with IC₅₀ values comparable to the antibody building block (SEQ ID NOs: 86 and 87) and a reference PD-L1 antibody (SEQ ID NOs: 26 and 27).

TABLE 8
Competition of fusion proteins with
PD-L1 for binding to PD-1
SEQ ID NO IC50 [nM]
90 and 87 2.3
86 and 91 3.0
92 and 87 3.4
86 and 93 3.2
94 and 87 2.4
90 and 91 2.8
86 and 87 3.5
26 and 27 3.8

Example 10. PD-L1 Dependent T-Cell Co-Stimulation Using a CD137 Bioassay

The potential of selected fusion proteins to induce activation of CD137 signaling pathway in the presence of PD-L1 was assessed using a commercially available double stable transfected Jurkat cell line expressing CD137 and the luc2 gene (humanized version of firefly luciferase) whereas luc2 expression is driven by a NFκB-responsive element. In this bioassay, CD137 engagement results in CD137 intracellular signaling, leading to NFκB-mediated luminescence.

PD-L1 expressing colorectal cancer cell line RKO was cultured as described in Example 7. One day prior to the assay, RKO cells were plated at 1.25×10⁴ cells per well and allowed to adhere overnight at 37° C. in a humidified 5% CO₂ atmosphere.

The next day, 3.75×10⁴ NF-kB-Luc2/CD137 Jurkat cells were added to each well, followed by the addition of various concentration, typically ranging from 0.001 nM to 5 nM, of fusion proteins or a reference CD137 antibody (SEQ ID NOs: 28 and 29). Plates were covered with a gas permeable seal and incubated at 37° C. in a humidified 5% CO₂ atmosphere. After 4 h, 30 μL Bio-Glo™ Reagent was added to each well and the bioluminescent signal was quantified using a luminometer (PHERAstar). Four-parameter logistic curve analysis was performed with GraphPad Prism® to calculate EC₅₀ values (shared bottom, fixed slope) which are summarized in Table 9. To demonstrate the PD-L1 dependency of CD137 engagement by fusion proteins, the same experiment was performed in parallel in the absence of RKO cells. The assay was performed in triplicates.

The results of a representative experiment are depicted in FIG. 8A-8D. The data demonstrate that all tested fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, and SEQ ID NOs: 86 and 93) induced a strong CD137 mediated T-cell co-stimulation. FIGS. 8B and 8D shows that the activation of CD137 by fusion proteins is PD-L1 dependent, because no activation of the NF-kB-Luc2/CD137 Jurkat cells was detected in absence of PD-L1 expressing tumor cells. In contrast, the reference anti-CD137 mAb (SEQ ID NOs: 28 and 29) showed CD137 mediated T-cell co-stimulation regardless of the presence or absence of target cells.

TABLE 9
Assessment of T-cell activation
using a CD137 Bioassay
          EC50 [nM]
SEQ ID NO With RKO cells
90 and 87 0.0809
86 and 91 0.0889
92 and 87 0.1811
86 and 93 0.2636
28 and 29 0.8135

Example 11. Assessment of T-Cell Activation Using Human Peripheral Blood Mononuclear Cells (PBMCs)

A T cell assay was employed to assess the ability of the selected fusion proteins to co-stimulate T-cell responses as well as prevent co-inhibition mediated by PD-L1 binding to PD-1. For this purpose, fusion proteins at different concentrations were added to staphylococcal enterotoxin B (SEB) stimulated human peripheral blood mononuclear cells (PBMCs) and incubated for 4 days at 37° C. IL-2 secretion levels were measured in the supernatants.

PBMCs from healthy volunteer donors were isolated from buffy coats by centrifugation through a polysucrose density gradient (Biocoll, 1.077 g/mL, Biochrom), following Biochrom's protocols. The purified PBMCs were resuspended in a buffer consisting of 90% FCS and 10% DMSO, immediately frozen down and stored in liquid nitrogen until further use. For the assay, PBMCs were thawed and rested in culture media (RPMI 1640, Life Technologies) supplemented with 10% FCS and 1% Penicillin-Streptomycin (Life Technologies) for 16 h at 37° C. in a humidified 5% CO₂ atmosphere.

The following procedure was performed using triplicates for each experimental condition: 2.5×10⁴ PBMCs were incubated in each well of a 384 well flat-bottom tissue culture plates in culture media. A dilution series of fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91), the building block PD-L1 antibody (SEQ ID NOs: 86 and 87), reference PD-L1 antibody (SEQ ID NOs: 26 and 27), reference CD137 antibody (SEQ ID NO: 28 and 29), a cocktail of the reference CD137 antibody (SEQ ID NOs: 28 and 29) and a PD-L1 antibody (SEQ ID NOs: 86 and 87 or SEQ ID NOs: 26 and 27), or an isotype control (SEQ ID NOs: 24 and 25), typically ranging from 10 to 0.002 nM, and SEB at 0.1 ng/ml were added to the respective wells. Plates were covered with a gas permeable seal (4titude) and incubated at 37° C. in a humidified 5% CO₂ atmosphere for four days. Subsequently, IL-2 levels in the supernatant were assessed using the human IL-2 DuoSet kit (R&D Systems) as described in the following procedures.

384 well plates were coated for 2 h at room temperature with 1 μg/mL “Human IL-2 Capture Antibody” in PBS. Subsequently, wells were washed 5 times with 80 μl PBS supplemented with 0.05% Tween (PBS-T). After 1 h blocking in PBS-0.05% T containing 1% casein (w/w), assay supernatants and a concentration series of IL-2 standard diluted in culture medium was transferred to respective wells and incubated overnight at 4° C. The next day, a mixture of 100 ng/mL goat anti-hIL-2-Bio detection antibody (R&D Systems) and 1 μg/mL Sulfotag-labelled streptavidin (Mesoscale Discovery) in PBS-T containing 0.5% casein were added and incubated at room temperature for 1 h. After washing, 25 μL reading buffer (Mesoscale Discovery) was added to each well and the resulting electrochemiluminescence (ECL) signal was detected by a Mesoscale Discovery reader. Analysis and quantification were performed using Mesoscale Discovery software.

The result of a representative experiment is depicted in FIG. 9. Bispecific fusion proteins of SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91 are capable of inducing T-cell activation, which is demonstrated by increased IL-2 secretion levels compared to isotype control (hIgG4, Sigma). The strongest increase in IL-2 secretion is observed by the fusion proteins tetravalent to CD137 (SEQ ID NOs: 94 and 87 and SEQ ID NOs: 90 and 91), followed by the fusion protein bivalent to CD137 with the lipocalin mutein fused to the C-terminus of PD-L1-specific antibody (SEQ ID NOs: 90 and 87 and SEQ ID NOs: 86 and 91). The lowest increase is observed with the fusion proteins bivalent to CD137 with the lipocalin mutein fused to the N-terminus of PD-L1-specific antibody (SEQ ID NOs: 92 and 87 and SEQ ID NOs: 86 and 93), however, still comparable to the cocktail of a reference CD137 antibody (SEQ ID NOs: 28 and 29) and a reference PD-L1 antibody (SEQ ID NOs: 26 and 27). All fusion proteins show higher IL-2 secretion levels than the single building blocks, i.e., CD137-specific lipocalin mutein-Fc (SEQ ID NO: 88 or SEQ ID NO: 89) or the building block PD-L1 mAb (SEQ ID NOs: 86 and 87).

Example 12. Assessment of T-Cell Activation in Presence of Tumor Cells Expressing Different Level of PD-L1

A further T cell assay was employed to assess the ability of the fusion proteins to co-stimulate T-cell activation in a PD-L1 target dependent manner. Fusion proteins were applied at different concentrations to anti-CD3 stimulated T cells, in the presence of tumor cell lines with different PD-L1 expression levels. Tested tumor cell lines include RKO (PD-L1 high), HCC827 (PD-L1 moderate) and Hep-G2 (PD-L1 negative). IL-2 secretion levels were measured in the supernatants.

PBMC from healthy volunteer donors were isolated from buffy coats as described in Example 11. T lymphocytes were further purified from PBMC by magnetic cell sorting using a Pan T cell purification Kit (Miltenyi Biotec GmbH) following the manufacturer's instructions. Purified Pan T cells were resuspended in a buffer consisting of 90% FCS and 10% DMSO, immediately frozen down and stored in liquid nitrogen until further use.

For the assay, T cells were thawed and rested in culture media (RPMI 1640, Life Technologies) supplemented with 10% FCS and 1% Penicillin-Streptomycin (Life Technologies) for 16 h at 37° C. in a humidified 5% CO₂ atmosphere.

The following procedure was performed using triplicates for each experimental condition: flat-bottom tissue culture plates were pre-coated with 0.25 μg/mL anti-CD3 antibody for 1 h at 37° C. and then washed twice with PBS. Tumor cell line RKO, HCC827 or Hep-G2 were treated for 30 min with 30 μg/ml mitomycin C (Sigma Aldrich) in order to block proliferation. Mitomycin treated tumor cells were then washed twice with PBS and plated at 2.5×10⁴ cells per well in culture medium to allow adhesion overnight at 37° C. in a humidified 5% CO₂ atmosphere. The target cells had before been grown under standard conditions, detached using Accutase (PAA Laboratories), and resuspended in culture media.

On the next days, after washing the plates twice with PBS, 1.25×10⁴ T cells per well were added to the tumor cells. A dilution series of fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, and SEQ ID NOs: 86 and 93), reference PD-L1 antibody (SEQ ID NOs: 26 and 27) and reference CD137 antibody (SEQ ID NO: 28 and 29) used alone or in combination, or an isotype control (SEQ ID NOs: 24 and 25), typically ranging from 0.005 nM to 10 nM, were added to corresponding wells. Plates were covered with a gas permeable seal and incubated at 37° C. in a humidified 5% CO₂ atmosphere for 3 days.

After 3 days of co-culturing, IL-2 level in the supernatant were assessed as described in Example 11.

Exemplary data are shown in FIG. 10. Co-culturing of Pan T cells with RKO cells (PD-L1 high) or HCC827 (PD-L1 moderate) in presence of the fusion proteins with the lipocalin mutein fused to the C-terminus of the PD-L1-specific antibody (SEQ ID NOs: 90 and 87 and SEQ ID NOs: 86 and 91) lead to a clear increase in IL-2 secretion compared to hIgG4 isotype control. The increase of IL-2 secretion induced by fusion proteins with the lipocalin mutein fused to the N-terminus of the PD-L1-specific antibody (SEQ ID NOs: 92 and 87 and SEQ ID NOs: 86 and 93) was weaker but still higher than a cocktail of a reference CD137 antibody (SEQ ID NOs: 28 and 29) and a reference PD-L1 antibody (SEQ ID NO: 26 and 27). No increase of IL-2 secretion was observed with a cocktail of the building blocks, CD137-specific lipocalin mutein (Fc fusion, SEQ ID NO: 89) and PD-L1 antibody (SEQ ID NO: 86 and 87). Additionally, co-culturing with Hep-G2 (PD-L1 negative) did no increase IL-2 secretion levels with any fusion proteins, but with the cocktail of a reference CD137 antibody (SEQ ID NO: 28 and 29) and a reference PD-L1 antibody (SEQ ID NO: 26 and 27).

The data indicate that the functional activity of fusion proteins, measured by their ability to activate T cells or increase IL-2 secretion, is PD-L1 dependent. In contrast, the T-cell activation or IL-2 secretion induced by the reference CD137 antibody (SEQ ID NOs: 28 and 29), when used in combination with the reference PD-L1 antibody (SEQ ID NOs: 26 and 27), is not necessarily PD-L1 dependent and hard to predict. Furthermore, the data show that the bispecific format of targeting PD-L1 and CD137 is superior to a cocktail of two separate molecules targeting CD137 and PD-L1 in presence of PD-L1 expressing target cells.

Example 13. Storage Stability Assessment of Fusion Proteins

To assess storage stability, exemplary fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, SEQ ID NO: 88, and SEQ ID NO: 89) were incubated for 1 week at 37° C. at a concentration of 1 mg/ml in PBS. Monomeric fusion proteins were subsequently determined using analytical size exclusion by applying 20 μg of sample onto a Superdex 200, 3.2/300 Increase (GE Healthcare) column at a flow rate of 0.15 ml/min and PBS as running buffer. All testing fusion peptides were stable after incubation of 1 week in PBS at 37° C. Exemplary results are shown in FIG. 11A.

Further storage stability assessments were performed for a selected fusion protein of SEQ ID NOs: 90 and 87. The fusion protein at 20 mg/ml was incubated for four weeks at 40° C. in 25 mM histidine, 60 mM NaCl, 200 mM arginine pH 6. Functional fusion protein content was measured in a quantitative ELISA setting, utilizing the simultaneous binding assay as described Example 5. Exemplary results are shown in FIG. 11B.

Example 14. Mixed Lymphocyte Reaction (MLR) Assessment with CD4⁺ T Cells

A mixed lymphocyte reaction (MLR) assay was utilized to assess the ability of an exemplary fusion protein to induce CD4⁺ T-cell activation in the presence of antigen presenting cells. The fusion protein (SEQ ID NOs: 90 and 87) at various concentrations was tested in presence of monocyte derived dendritic cells (moDCs) and CD4⁺ T cells from mismatching healthy donors. After 6 days of culturing in the presence of tested molecules, the secretion of IL-2 and IFN-gamma were quantified in the supernatants.

PBMCs were purified from platelet apheresis blood pack using a Lymphoprep solution following manufacturer instructions (StemCell). Total CD4⁺ T lymphocytes were purified from PBMC using a Miltenyi kit and frozen in a solution of 90% FBS 10% DMSO. CD14⁺ monocytes were purified using CD14⁺ beads kit (Miltenyi) and used fresh.

MoDCs were obtained by culturing CD14⁺ monocytes in RPMI1640 plus 10% FBS and Pen/Strep (LifeTech) in the presence of 50 ng/mL of IL-4 and 100 ng/mL of GMCSF (Miltenyi) for 6 days at 2×10⁶ cells/mL. At day 3, 10 ml of fresh medium containing cytokines was added. Phenotype (CD14, CD1a, HLADR, PD-L1) was assessed at day 7 of differentiation by FACS.

10000 moDCs were cultured in presence of 50000 CD4 T⁺ cells in U bottom 96 wells in complete RPMI medium, in the presence of tested molecules for 6 days in RPMI in triplicate wells. At the end of the culture, supernatants were immediately frozen and stored for cytokine quantification.

IL-2 level was measured in the supernatants by using Luminex technology and exemplary data are shown in FIG. 12. FIG. 12A shows the fusion protein (SEQ ID NOs: 90 and 87) was significantly better in IL-2 induction at 10 and 0.1 μg/mL as compared to the corresponding building blocks (SEQ ID NO: 89 and SEQ ID NOs: 86 and 87) alone or a reference CD137 or PD-L1 antibody (SEQ ID NOs: 28 and 29 or SEQ ID NOs: 26 and 27) in several sets of MLR experiments (N=8). FIG. 12B indicates that the fusion protein (SEQ ID NOs: 90 and 87) induced a dose-dependent secretion of IL-2 as compared to an isotype antibody control. IL-2 levels induced by the fusion protein SEQ ID NOs: 90 and 87 were higher as compared to equimolar concentrations of the cocktail of a reference PD-L1 antibody (SEQ ID NOs: 26 and 27) and a reference CD137 antibody (SEQ ID NOs: 28 and 29), over concentrations ranging from 0.001 to 20 μg/mL.

Example 15. Mixed Lymphocyte Reaction Assessment with CD8⁺ T Cells

Given reports of CD137 expression and activity in human CD8⁺ T cells, the ability of an exemplary fusion protein to induce CD8⁺ T-cell activation in the presence of antigen presenting cells was assessed in an MLR assay. The fusion protein (SEQ ID NOs: 90 and 87) was tested in presence of moDCs and total CD8⁺ T cells from mismatching healthy donors. After 6 days of culturing in presence of tested molecules, secretion of IL-2 and CD8 effector molecules (perforin, granzyme B, and granzyme A) were quantified in the supernatants.

PBMCs were purified from platelet apheresis blood pack using a Lymphoprep solution following manufacturer instructions (StemCell). Total CD8⁺ T lymphocytes were purified from PBMC using a Miltenyi kit and used fresh. CD14 positive monocytes were purified using CD14⁺ beads kit (Miltenyi) and used fresh.

MoDCs were obtained by culturing CD14⁺ monocytes in RPMI1640 plus 10% FBS and Pen/Strep (LifeTech) in the presence of 50 ng/mL of IL-4 and 100 ng/mL of GMCSF (Miltenyi) for 6 days at 2×10⁶ cells/mL. At day 3, 10 mL of fresh medium containing cytokines was added. Phenotype (CD14, CD1a, HLADR, PD-L1) was assessed at day 7 of differentiation by FACS.

10000 moDCs were cultured with 50000 CD8⁺ T cells, in the presence of tested molecules, in U bottom 96 wells (in triplet wells) in complete RPMI medium for 6 days. At the end of the culture, supernatants were immediately frozen and stored for secreted factor quantification.

IL-2, perforin, granzyme A, and granzyme B were quantified in the supernatants using Luminex technology. Exemplary data are shown in FIG. 13.

FIG. 13 indicates that the fusion protein (SEQ ID NOs: 90 and 87) showed increase in the secretion of IL-2, perforin, granzyme B, and granzyme A as compared to an equimolar concentration of a reference PD-L1 antibody (SEQ ID NOs: 26 and 27), a reference CD137 antibody (SEQ ID NOs: 28 and 29), or the cocktail of the two at 10 μg/mL (N=4). The data further suggest that the fusion protein (SEQ ID NOs: 90 and 87) has activity on cytotoxic CD8⁺ T cells.

Example 16. Assessment of Functional In Vivo Activity in a Xenograft Mouse Model Engrafted with Human PBMCs

In order to investigate the in vivo activity of provided fusion proteins, cell line-derived xenograft mouse model will be used. Accordingly, a human cancer cell line will be implanted subcutaneously in immune deficient female NOG mice, delivered at the age of 4-6 weeks with at least 1 week of quarantine. After the tumors have been reaching volumes of approximately 80-100 mm³, mice will be substitutes with human PBMCs. Test compounds will be injected at least three times and tumor growth and activity will be constantly measured. After reaching study end, mice will be sacrificed. Intratumoral infiltration of CD3-, CD4- and CD8-positive cells will be assessed via immunohistochemistry. IFN-gamma RNAscope will be conducted as further read-out.

Example 17. Epitope Analysis of the Fusion Proteins

In order to evaluate epitopes the fusion proteins recognize, and whether they are clinically relevant, a competitive ELISA format was used to determine the competition between the fusion proteins and a reference CD137 antibody.

Microtiter plates were coated with the reference CD137 antibody SEQ ID NOs: 28 and 29 in PBS (4 μg/mL) at 4° C. overnight. The plates were washed five times after each incubation step with 100 μL PBS-0.05% T (PBS supplemented with 0.05% (v/v) Tween 20). The plates were blocked with 2% BSA (w/v) in PBS-0.1% T (PBS supplemented with 0.1% (v/v) Tween 20) for 1 h at room temperature and subsequently washed again. Fusion proteins (SEQ ID NOs: 90 and 87 and SEQ ID NOs: 86 and 91), the CD137 specific lipocalin mutein (SEQ ID NO: 42), the reference CD137 antibody (SEQ ID NOs: 28 and 29), and a control antibody (SEQ ID NOs: 86 and 87) at different concentrations were mixed with 1 nM of biotinylated human CD137 Fc fusion (huCD137-Fc-bio) as a tracer and incubated for 1 h at room temperature. The mixtures of testing molecules and the tracer were added to the plates and incubated for 20 min at room temperature following by five washing steps with 100 μL PBS-0.05% T. Subsequently, a 1:5000 dilution of ExtrAvidin-HRP (Sigma-Aldrich) in PBS-0.1% T-2% BSA was added to the wells and incubated for 1 h. After an additional wash step, fluorogenic HRP substrate (QuantaBlu, Thermo) was added to each well, and the fluorescence intensity was detected using a fluorescence microplate reader.

Competition data for an exemplary experiment are shown in FIG. 14, where the x-axis represents testing molecule concentration and the y-axis represents the measured trace molecule concentration. The data were fit to a 1:1 sigmoidal curve, where the IC₅₀ value and the maximum signal were free parameters, and the slope was fixed to unity. The results demonstrate that exemplary fusion proteins (SEQ ID NOs: 90 and 87 and SEQ ID NOs: 86 and 91) compete with the CD137 antibody SEQ ID NOs: 28 and 29 for binding to CD137, suggesting the fusion proteins bind overlapping epitopes with the antibody.

TABLE 10
Competition of fusion proteins
SEQ ID NO IC50 [nM]
90 and 87 1.10
86 and 91 0.99
28 and 29 0.20
42        2.60

Example 18. Assessment of T Cell Activation Using a PD-1/PD-L1 Blockade Bioassay

The potential of selected fusion proteins to block PD-1/PD-L1 mediated suppression was assessed using PD-1-NFAT-luc Jurkat T cells (a Jurkat cell line engineered to express PD-1 and the luc gene (firefly luciferase gene) driven by an NFAT response element (NFAT-RE)), co-cultured with PD-L1 aAPC/CHO-K1 cells (CHO-K1 cells expressing human PD-L1 and an engineered cell surface protein designed to activate cognate TCRs in an antigen-independent manner). In this bioassay, when PD-1-NFAT-luc Jurkat T cells and PD-L1 aAPC/CHO-K1 cells are co-cultured, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-RE-mediated luminescence. Addition of a PD-1/PD-L1 blocking agent, such as fusion proteins specific for CD137 and PD-L1 as described herein, releases the inhibitory signal and results in TCR activation and NFAT-RE-mediated luminescence.

PD-L1 aAPC/CHO-K1 cells were grown in Ham's F12 medium supplemented with 10% FCS and plated at 8.00×10³ cells per well and allowed to adhere overnight at 37° C. in a humidified 5% CO₂ atmosphere. On the next day, the culture media was discarded. 1.00×10⁴ PD-1-NFAT-luc Jurkat T cells were added to each well, followed by the addition of various concentrations, typically ranging from 0.005 nM to 50 nM. of a fusion protein (SEQ ID NOs: 90 and 87) or a PD-L1 antibody (SEQ ID NOs: 86 and 87 or SEQ ID NOs: 26 and 27). Plates were covered with a gas permeable seal and incubated at 37° C. in a humidified 5% CO₂ atmosphere. After 6 h, 30 μL Bio-Glo™ Reagent was added to each well and the bioluminescent signal was quantified using a luminometer. Four-parameter logistic curve analysis was performed with GraphPad Prism® to calculate EC₅₀ values which are summarized in Table 11. The assay was performed in triplicates.

The results of a representative experiment are depicted in FIG. 15. The data demonstrate the tested fusion protein inhibits PD-1/PD-L1 blockade and activates T cells in a dose-dependent manner, with an EC50 value comparable to that of a PD-L1 antibody (SEQ ID NOs: 86 and 87 or SEQ ID NOs: 26 and 27). As negative controls, neither the reference CD137 antibody (SEQ ID NOs: 28 and 29) or and the isotype control antibody (SEQ ID NOs: 24 and 25) leads to an increase in luminescence signal.

TABLE 11
Assessment of T-cell activation using
a PD-1/PD-L1 blockade bioassay
SEQ ID NO EC50 [nM]
90 and 87 0.49
86 and 91 0.58
28 and 29 0.46

Example 19. Assessment of T-Cell Activation Using Human PBMCs

An additional T cell assay was employed to assess the ability of the selected fusion proteins to co-stimulate T-cell responses, where fusion proteins at different concentrations were added to SEB stimulated human PBMCs and incubated for 3 days at 37° C. IL-2 secretion levels were measured in the supernatants.

PBMCs from healthy volunteer donors were isolated and stored as described in Example 11. For the assay, PBMCs were thawed and rested in culture media (RPMI 1640, Life Technologies) supplemented with 10% FCS and 1% Penicillin-Streptomycin (Life Technologies) for 24 h at 37° C. in a humidified 5% CO₂ atmosphere.

The following procedure was performed using triplicates for each experimental condition: 2.5×10⁴ PBMCs were incubated in each well of a 384 well flat-bottom tissue culture plates in culture media. A dilution series of a selected fusion protein (SEQ ID NOs: 90 and 87), the building block PD-L1 antibody (SEQ ID NOs: 86 and 87), a reference CD137 antibody (SEQ ID NO: 28 and 29) used alone or in combination with a reference PD-L1 antibody (SEQ ID NOs: 26 and 27), or an isotype control (SEQ ID NOs: 24 and 25), typically ranging from 0.0002 to 10 nM, and 0.1 ng/ml SEB were added to the respective wells. Plates were covered with a gas permeable seal (4titude) and incubated at 37° C. in a humidified 5% CO₂ atmosphere for three days. Subsequently, IL-2 in the supernatant were assessed as described in Example 11.

The results of a representative experiment are depicted in FIG. 16. The EC₅₀ values of the testing molecules for inducing IL-2 secretion are summarized in Table 12. The bispecific fusion protein of SEQ ID NOs: 90 and 87 induces a strong dose-dependent increase in IL-2 secretion, to higher levels as compared to the building block PD-L1 antibody, the reference CD137 antibody and the cocktail of the reference PD-L1 and CD137 antibodies, as well as decreases the effective EC₅₀ value relative to the PD-L1 and CD137 antibodies used alone or in combination.

TABLE 12
Assessment of T-cell activation using human PBMCs
	EC50 [nM]
	SEQ ID NOs:	SEQ ID NOs:	SEQ ID NOs:	SEQ ID NOs: 28 and 29 +
Donor	90 and 87	86 and 87	26 and 27	SEQ ID NOs: 86 and 87
#1	0.019	0.061	0.250	0.279
#2	0.026	0.057	0.134	0.089

Example 20. Assessment of PD-L1 Dependent T-Cell Activation Induced by the Fusion Proteins

The PD-L1 target dependent T-cell costimulation by the fusion proteins was further analyzed using a T-cell activation assay. Fusion proteins were applied at different concentrations to anti-CD3 stimulated T cells, co-cultured with human PD-L1 transfected or mock transfected Flp-In-CHO cells. IL-2 secretion levels were measured in the supernatants.

PBMC from healthy volunteer donors were isolated from buffy coats as described in Example 11. T lymphocytes were further purified and stored as described in Example 12.

For the assay, T cells were thawed and rested in culture media (RPMI 1640, Life Technologies) supplemented with 10% FCS and 1% Penicillin-Streptomycin (Life Technologies) for overnight at 37° C. in a humidified 5% CO₂ atmosphere.

The following procedure was performed using triplicates for each experimental condition: flat-bottom tissue culture plates were pre-coated with 0.25 μg/mL anti-CD3 antibody for 2 h at 37° C. and then washed twice with PBS. CHO cells, transfected with human PD-L1 or mock transfected, were treated for 30 min with 30 μg/ml mitomycin C (Sigma Aldrich) in order to block proliferation. Mitomycin treated cells were then washed twice with PBS and plated at 1.0×10⁷ cells per well in culture medium to allow adhesion overnight at 37° C. in a humidified 5% CO₂ atmosphere. The CHO cells had before been grown under standard conditions, detached using Accutase (PAA Laboratories), and resuspended in culture media.

On the next days, 8.33×10³ T cells per well were added to the CHO cells. A dilution series of an exemplary fusion protein SEQ ID NOs: 90 and 87, the building block PD-L1 antibody (SEQ ID NOs: 86 and 87), reference CD137 antibody (SEQ ID NOs: 28 and 29), and a cocktail of reference PD-L1 antibody (SEQ ID NOs: 26 and 27) and reference CD137 antibody (SEQ ID NO: 28 and 29), or an isotype control (SEQ ID NOs: 24 and 25), typically ranging from 0.003 nM to 50 nM, were added to corresponding wells. Plates were covered with a gas permeable seal and incubated at 37° C. in a humidified 5% CO₂ atmosphere for 2 days.

After 2 days of co-culturing, IL-2 levels in the supernatant were assessed as described in Example 11.

Exemplary data are shown in FIG. 17. Co-culturing of Pan T cells with CHO cells transfected with human PD-L1 in presence of the fusion protein (SEQ ID NOs: 90 and 87 and SEQ ID NOs: 86 and 91) led to strong dose-dependent IL-2 secretion compared to hIgG4 isotype control and is much stronger than the reference antibodies where only slight increase of IL-2 secretion was observed for the reference CD137 antibody or the cocktail of the reference CD137 antibody and reference PD-L1 antibody. When co-culturing with mock-transfected CHO cells (PD-L1 negative), only the reference CD137 antibody and the cocktail of the reference CD137 antibody and reference PD-L1 antibody showed slight dose-dependent increase in IL-2 secretion. The results illustrate that the activation of T cells by fusion proteins is PD-L1 dependent, versus the reference CD137 antibody (SEQ ID NOs: 28 and 29) showed CD137 mediated T-cell co-stimulation regardless of the presence or absence of target cells.

Example 21. Pharmacokinetics of Fusion Proteins in Mice

Analyses of the pharmacokinetics of representative fusion proteins (SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91) were performed in mice. Male CD-1 mice approximately 5 weeks of age (3 mice per timepoint; Charles River Laboratories, Research Models and Services, Germany GmbH) were injected into a tail vein with a fusion protein at a dose of 10 mg/kg. The test articles were administered as a bolus using a volume of 5 mL/kg. Plasma samples from the mice were obtained at the timepoints of 5 min, 1 h, 4 h, 8 h, 24 h, 48 h, 4 d, 8 d, 14 d, 21 d, and 28 d. Sufficient whole blood—taken under isoflurane anesthesia—was collected to obtain at least 100 μL Li-Heparin plasma per animal and time. Drug levels were detected using a Sandwich ELISA detecting the full bispecific construct via the targets PD-L1 and CD137. The data were fitted using a two-compartmental model using Prism GraphPad 5 software.

FIG. 18 shows plots of the plasma concentration over time for the fusion proteins SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, and SEQ ID NOs: 90 and 91, plotted together with the values obtained for the building block PD-L1 antibody (SEQ ID NOs: 86 and 87) as a reference. The pharmacokinetics looked similar in all cases. Starting from a plasma concentration of around 200 μg/mL, plasma levels fell to a level of around 50 μg/mL within 48 hours, and then further decrease at a much slower rate to a level of around 10 μg/mL at the end of the experiment after 28 days. A non-compartmental analysis was applied to this data. The terminal half-lives are summarized in Table 13.

The data demonstrate that the fusion proteins have long, antibody-like terminal half-lives in mice. Because the assay employed to determine fusion proteins plasma concentrations requires a retained activity both towards PD-L1 and CD137, the result also demonstrates that the bispecific molecules remain intact over the time course of 28 days.

TABLE 13
Terminal half-lives in mice determined
using a non-compartmental analysis
SEQ ID NO Terminal half-life [h]
90 and 87 295
92 and 87 346
86 and 93 332
94 and 87 209
90 and 91 250
86 and 87 390

Example 22. Pharmacokinetics of Fusion Proteins in Mice

An analysis of the pharmacokinetics of a representative fusion protein SEQ ID NOs: 90 and 87 were performed in mice and compared with two previously described CD137- and PD-L1-binding fusion proteins (SEQ ID NO: 147 and SEQ ID NO: 148). Male CD-1 mice approximately 5 weeks of age (2 mice per timepoint; Charles River Laboratories, Research Models and Services, Germany GmbH) were injected into a tail vein with the respective molecule at a dose of 2 mg/kg. Plasma samples from the mice were obtained at the timepoints of 5 min, 24 h, 168 h, and 336 h. Sufficient whole blood—taken under isoflurane anaesthesia—was collected to obtain at least 30-50 μL Li-Heparin plasma per animal and time.

Plasma drug levels were then analyzed with ELISA. HuCD137-His (human CD137 with a C-terminal polyhistidine tag) was dissolved in PBS (1 μg/mL) and coated overnight on microtiter plates at 4° C. The plate was washed after each incubation step with 80 μL PBS supplemented with 0.05% (v/v) Tween 20 five times. The plates were blocked with PBS/BSA/Tween (PBS containing 2% BSA (w/v) and 0.1% (v/v) Tween 20) for 1 h at room temperature and subsequently washed. Plasma samples were diluted in PBS/BSA/Tween to 20% plasma concentration, added to the wells, and incubated for 1 h at room temperature. Another wash step followed. Bound agents under study were detected after 1 h incubation with a mixture of biotinylated human PD-L1 and Streptavidin SULFO-TAG (Mesoscale Discovery) at 1 μg/mL each diluted in PBS containing 2% BSA (w/v) and 0.1% (v/v) Tween 20. After an additional wash step, 35 μL reading buffer was added to each well and the electrochemiluminescence (ECL) signal of every well was read using a Mesoscale Discovery reader. Data were transferred to Excel for analysis and quantification. A calibration curve with standard protein dilutions was prepared.

FIG. 19 shows plots of the plasma concentration over time for SEQ ID NOs: 90 and 87, SEQ ID NO: 147, and SEQ ID NO: 148. SEQ ID NOs: 90 and 87 displays a favorable pharmacokinetic profile or an antibody-like pharmacokinetics, while SEQ ID NO: 147 and SEQ ID NO: 148 do not. As described herein, a favorable pharmacokinetic profile or an antibody-like pharmacokinetics may be considered to be achieved if % of c_max was above 10% after 336 h.

Embodiments illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including,” “containing,” etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present embodiments have been specifically disclosed by preferred embodiments and optional features, modification and variations thereof may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. All patents, patent applications, textbooks and peer-reviewed publications described herein are hereby incorporated by reference in their entirety. Furthermore, where a definition or use of a term in a reference, which is incorporated by reference herein is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply. Each of the narrower species and subgeneric groupings falling within the generic disclosure also forms part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. In addition, where features are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group. Further embodiments will become apparent from the following claims.

Equivalents: Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

VI. NON-PATENT REFERENCES

• 1. GATO-CANAS, M., ZUAZO, M., ARASANZ, H., IBANEZ-VEA, M., LORENZO, L., FERNANDEZ-HINOJAL, G., VERA, R., SMERDOU, C., MARTISOVA, E., AROZARENA, I., WELLBROCK, C., LLOPIZ, D., RUIZ, M., SAROBE, P., BRECKPOT, K., KOCHAN, G. & ESCORS, D. 2017. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Rep, 20, 1818-1829.
• 2. KARWACZ, K., BRICOGNE, C., MACDONALD, D., ARCE, F., BENNETT, C. L., COLLINS, M. & ESCORS, D. 2011. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med, 3, 581-92.
• 3. ARASANZ, H., GATO-CANAS, M., ZUAZO, M., IBANEZ-VEA, M., BRECKPOT, K., KOCHAN, G. & ESCORS, D. 2017. PD1 signal transduction pathways in T cells. Oncotarget, 8, 51936-51945.
• 4. PATSOUKIS, N., BARDHAN, K., CHATTERJEE, P., SARI, D., LIU, B., BELL, L. N., KAROLY, E. D., FREEMAN, G. J., PETKOVA, V., SETH, P., LI, L. & BOUSSIOTIS, V. A. 2015. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun, 6, 6692.
• 5. XU-MONETTE, Z. Y., ZHANG, M., LI, J. & YOUNG, K. H. 2017. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol, 8, 1597.
• 6. LI, S. Y. & LIU, Y. 2013. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol, 5, 47-53.
• 7. SNELL, L. M., LIN, G. H., MCPHERSON, A. J., MORAES, T. J. & WATTS, T. H. 2011. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev, 244, 197-217.
• 8. WYZGOL, A., MULLER, N., FICK, A., MUNKEL, S., GRIGOLEIT, G. U., PFIZENMAIER, K. & WAJANT, H. 2009. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol, 183, 1851-61.
• 9. YAO, S., ZHU, Y. & CHEN, L. 2013. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov, 12, 130-46.
• 10. MELERO, I., BACH, N., HELLSTROM, K. E., ARUFFO, A., MITTLER, R. S. & CHEN, L. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol, 28, 1116-21.
• 11. YANG, Y., YANG, S., YE, Z., JAFFAR, J., ZHOU, Y., CUTTER, E., LIEBER, A., HELLSTROM, I. & HELLSTROM, K. E. 2007. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res, 67, 2339-44.
• 12. ZHANG, H., KNUTSON, K. L., HELLSTROM, K. E., DISIS, M. L. & HELLSTROM, I. 2006. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther, 5, 149-55.
• 13. YE, Z., HELLSTROM, I., HAYDEN-LEDBETTER, M., DAHLIN, A., LEDBETTER, J. A. & HELLSTROM, K. E. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med, 8, 343-8.
• 14. MARTINET, O., DIVINO, C. M., ZANG, Y., GAN, Y., MANDELI, J., THUNG, S., PAN, P. Y. & CHEN, S. H. 2002. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther, 9, 786-92.
• 15. YE, Q., SONG, D. G., POUSSIN, M., YAMAMOTO, T., BEST, A., LI, C., COUKOS, G. & POWELL, D. J., JR. 2014. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res, 20, 44-55.
• 16. CHACON, J. A., WU, R. C., SUKHUMALCHANDRA, P., MOLLDREM, J. J., SARNAIK, A., PILON-THOMAS, S., WEBER, J., HWU, P. & RADVANYI, L. 2013. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One, 8, e60031.
• 17. FISHER, T. S., KAMPERSCHROER, C., OLIPHANT, T., LOVE, V. A., LIRA, P. D., DOYONNAS, R., BERGQVIST, S., BAXI, S. M., ROHNER, A., SHEN, A. C., HUANG, C., SOKOLOWSKI, S. A. & SHARP, L. L. 2012. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother, 61, 1721-33.
• 18. SKERRA, A. 2000. Lipocalins as a scaffold. Biochim Biophys Acta, 1482, 337-50.
• 19. FLOWER, D. R., NORTH, A. C. & SANSOM, C. E. 2000. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta, 1482, 9-24.
• 20. FLOWER, D. R. 1996. The lipocalin protein family: structure and function. Biochem J, 318 (Pt 1), 1-14.
• 21. ALTSCHUL, S. F., MADDEN, T. L., SCHAFFER, A. A., ZHANG, J., ZHANG, Z., MILLER, W. & LIPMAN, D. J. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res, 25, 3389-402.
• 22. ALTSCHUL, S. F., GISH, W., MILLER, W., MYERS, E. W. & LIPMAN, D. J. 1990. Basic local alignment search tool. J Mol Biol, 215, 403-10.
• 23. SMITH, T. F. & WATERMAN, M. S. 1981. Identification of common molecular subsequences. J Mol Biol, 147, 195-7.
• 24. WARD, E. S., GUSSOW, D., GRIFFITHS, A. D., JONES, P. T. & WINTER, G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature, 341, 544-6.
• 25. HOLLIGER, P., PROSPERO, T. & WINTER, G. 1993. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA, 90, 6444-8.
• 26. JOHNSON, G. & WU, T. T. 2000. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res, 28, 214-8.
• 27. EHRENMANN, F., KAAS, Q. & LEFRANC, M. P. 2010. IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res, 38, D301-7.
• 28. BULLIARD, Y., JOLICOEUR, R., ZHANG, J., DRANOFF, G., WILSON, N. S. & BROGDON, J. L. 2014. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol, 92, 475-80.
• 29. BULLIARD, Y., JOLICOEUR, R., WINDMAN, M., RUE, S. M., ETTENBERG, S., KNEE, D. A., WILSON, N. S., DRANOFF, G. & BROGDON, J. L. 2013. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med, 210, 1685-93.
• 30. SILVA, J. P., VETTERLEIN, O., JOSE, J., PETERS, S. & KIRBY, H. 2015. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem, 290, 5462-9.
• 31. GLAESNER, W., VICK, A. M., MILLICAN, R., ELLIS, B., TSCHANG, S. H., TIAN, Y., BOKVIST, K., BRENNER, M., KOESTER, A., PORKSEN, N., ETGEN, G. & BUMOL, T. 2010. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev, 26, 287-96.
• 32. DALL'ACQUA, W. F., KIENER, P. A. & WU, H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem, 281, 23514-24.
• 33. ZALEVSKY, J., CHAMBERLAIN, A. K., HORTON, H. M., KARKI, S., LEUNG, I. W., SPROULE, T. J., LAZAR, G. A., ROOPENIAN, D. C. & DESJARLAIS, J. R. 2010. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol, 28, 157-9.
• 34. SHIELDS, R. L., NAMENUK, A. K., HONG, K., MENG, Y. G., RAE, J., BRIGGS, J., XIE, D., LAI, J., STADLEN, A., LI, B., FOX, J. A. & PRESTA, L. G. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem, 276, 6591-604.
• 35. ALTSHULER, E. P., SEREBRYANAYA, D. V. & KATRUKHA, A. G. 2010. Generation of recombinant antibodies and means for increasing their affinity. Biochemistry (Mosc), 75, 1584-605.
• 36. HARLOW, E. & LANE, D. 1999. Using antibodies: a laboratory manual, Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press.
• 37. HARLOW, E. & LANE, D. 1988. Antibodies: a laboratory manual, Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory.
• 38. LI, J., SAI, T., BERGER, M., CHAO, Q., DAVIDSON, D., DESHMUKH, G., DROZDOWSKI, B., EBEL, W., HARLEY, S., HENRY, M., JACOB, S., KLINE, B., LAZO, E., ROTELLA, F., ROUTHIER, E., RUDOLPH, K., SAGE, J., SIMON, P., YAO, J., ZHOU, Y., KAVURU, M., BONFIELD, T., THOMASSEN, M. J., SASS, P. M., NICOLAIDES, N. C. & GRASSO, L. 2006. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc Natl Acad Sci USA, 103, 3557-62.
• 39. KOZBOR, D. & RODER, J. C. 1983. The production of monoclonal antibodies from human lymphocytes. Immunol Today, 4, 72-9.
• 40. COLE, S. P., CAMPLING, B. G., LOUWMAN, I. H., KOZBOR, D. & RODER, J. C. 1984. A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res, 44, 2750-3.
• 41. HOLLIGER, P. & HUDSON, P. J. 2005. Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 23, 1126-36.
• 42. PERVAIZ, S. & BREW, K. 1987. Homology and structure-function correlations between alpha 1-acid glycoprotein and serum retinol-binding protein and its relatives. FASEB J, 1, 209-14.
• 43. SAMBROOK, J. & RUSSELL, D. W. 2001. Molecular cloning: a laboratory manual, Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press.
• 44. FLOWER, D. R. 2000. Beyond the superfamily: the lipocalin receptors. Biochim Biophys Acta, 1482, 327-36.
• 45. BREUSTEDT, D. A., KORNDORFER, I. P., REDL, B. & SKERRA, A. 2005. The 1.8-A crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. 1 Biol Chem, 280, 484-93.
• 46. SCHMIDT, T. G., KOEPKE, J., FRANK, R. & SKERRA, A. 1996. Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. J Mol Biol, 255, 753-66.
• 47. VAJO, Z. & DUCKWORTH, W. C. 2000. Genetically engineered insulin analogs: diabetes in the new millenium. Pharmacol Rev, 52, 1-9.
• 48. FUERTGES, F. & ABUCHOWSKI, A. 1990. The clinical efficacy of poly(ethylene glycol)-modified proteins. Journal of Controlled Release, 11, 139-148.
• 49. DENNIS, M. S., ZHANG, M., MENG, Y. G., KADKHODAYAN, M., KIRCHHOFER, D., COMBS, D. & DAMICO, L. A. 2002. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem, 277, 35035-43.
• 50. KONIG, T. & SKERRA, A. 1998. Use of an albumin-binding domain for the selective immobilisation of recombinant capture antibody fragments on ELISA plates. J Immunol Methods, 218, 73-83.
• 51. OSBORN, B. L., OLSEN, H. S., NARDELLI, B., MURRAY, J. H., ZHOU, J. X., GARCIA, A., MOODY, G., ZARITSKAYA, L. S. & SUNG, C. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther, 303, 540-8.
• 52. LOWMAN, H. B. 1997. Bacteriophage display and discovery of peptide leads for drug development. Annu Rev Biophys Biomol Struct, 26, 401-24.
• 53. RODI, D. J. & MAKOWSKI, L. 1999. Phage-display technology—finding a needle in a vast molecular haystack. Curr Opin Biotechnol, 10, 87-93.
• 54. VENTURI, M., SEIFERT, C. & HUNTE, C. 2002. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol, 315, 1-8.
• 55. BRUCKDORFER, T., MARDER, 0. & ALBERICIO, F. 2004. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr Pharm Biotechnol, 5, 29-43.

Claims

1. A fusion protein that is capable of binding both CD137 and PD-L1, wherein the fusion protein comprises at least two subunits in any order, wherein a first subunit comprises a full-length immunoglobulin or an antigen-binding domain thereof and is specific for PD-L1, and wherein a second subunit comprises a lipocalin mutein and is specific for CD137.

2. The fusion protein of claim 1, further comprising a third subunit, which third subunit comprises a lipocalin mutein specific for CD137.

3. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding PD-L1 with a KD value of at most about 2 nM or comparable to or lower than the KD value of the immunoglobulin or an antigen-binding domain thereof that is included in the first subunit alone.

4. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding CD137 with a KD value of at most about 7 nM or comparable to or lower than the KD value of the lipocalin mutein specific for CD137 that is included in the second subunit alone.

5. The fusion protein of claim 3 or 4, wherein the KD value is determined by a surface-plasmon-resonance (SPR) assay.

6. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding PD-L1 with an EC50 value of at most about 0.5 nM or comparable to or lower than the EC50 value of the immunoglobulin or an antigen-binding domain thereof that is included in the first subunit alone.

7. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding CD137 with an EC50 value of at most about 0.6 nM or comparable to or lower than the EC50 value of the lipocalin mutein specific for CD137 that is included in the second subunit alone.

8. The fusion protein of any one of claims 6-7, wherein the EC50 value is determined by an enzyme-linked immunosorbent assay (ELISA) assay.

9. The fusion protein of claim 1 or 2, wherein the fusion protein is cross-reactive with cynomolgus PD-L1.

10. The fusion protein of claim 1 or 2, wherein the fusion protein is cross-reactive with cynomolgus CD137.

11. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of simultaneously binding CD137 and PD-L1 with an EC50 values of at most about 10 nM, when said fusion protein is measured in an ELISA assay.

12. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding CD137 expressed on a cell with an EC50 values of at most about 60 nM.

13. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding PD-L1 expressed on a cell with an EC50 values of at most about 10 nM, when said fusion protein is measured in a flow cytometric analysis.

14. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding PD-L1 expressing tumor cells.

15. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of binding CD137 in the presence of CD137 ligand.

16. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of competing with PD-1 for binding to PD-L1.

17. The fusion protein of claim 1 or 2, wherein the fusion protein is capable of compete with the antibody shown in SEQ ID NOs: 28 and 29 for binding to CD137.

18. The fusion protein of claim 1 or 2, wherein the fusion protein has overlapping CD137-binding epitope with the antibody shown in SEQ ID NOs: 28 and 29.

19. The fusion protein of any one of claims 1-18, wherein the fusion protein is capable of stimulating T-cell proliferation and/or responses.

20. The fusion protein of any one of claims 1-19, wherein the fusion protein is capable of stimulating CD4+ and/or CD8+ T-cell proliferation.

21. The fusion protein of any one of claims 1-20, wherein the fusion protein is capable of inducing increased secretion of IL-2 and/or IFN-gamma.

22. The fusion protein of any one of claims 1-21, wherein the fusion protein is capable of inducing increased secretion of cytotoxic factors.

23. The fusion protein of any one of claims 1-22, wherein the fusion protein is capable of co-stimulating T-cell responses in a PD-L1-dependent manner.

24. The fusion protein of any one of claims 1-23, wherein the fusion protein is capable of co-stimulating T-cell responses in a tumor microenvironment.

25. The fusion protein of any one of claims 1-24, wherein the fusion protein does not co-stimulate T-cell responses in the absence of PD-L1.

26. The fusion protein of any one of claims 1-25, wherein the fusion protein is capable of blocking the inhibitory signal of PD-1.

27. The fusion protein of any one of claims 1-26, wherein the fusion protein has antibody-like pharmacokinetics profile.

28. The fusion protein of any one of claims 1-27, wherein the fusion protein has a more favorable pharmacokinetic profile than SEQ ID NO: 147 or SEQ ID NO: 148.

29. The fusion protein of any one of claims 1-28, wherein the lipocalin mutein comprises one or more mutated amino acid residues at positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1).

30. The fusion protein of claim 29, wherein the amino acid sequence of the lipocalin mutein comprises, at one or more positions corresponding to positions 5, 26-31, 33-34, 42, 46, 52, 56, 58, 60-61, 65, 71, 85, 94, 101, 104-106, 108, 111, 114, 121, 133, 148, 150, and 153 of the linear polypeptide sequence of mature hTlc (SEQ ID NO: 1), one or more of the following mutated amino acid residues: Ala 5→Val or Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Thr 42→Ser; Gly 46→Asp; Lys 52→Glu; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg or Asn; Thr 71→Ala; Val 85→Asp; Lys 94→Arg or Glu; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; Arg 148→Ser; Ser 150→Ile and Cys 153→Ser.

31. The fusion protein of claim 29 or 30, wherein the amino acid sequence of the lipocalin mutein comprises one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1): (a) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; and Cys 153→Ser;(b) Ala 5→Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg; Val 85→Asp; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;(c) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Asn; Lys 94→Arg; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;(d) Ala 5→Val; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Lys 65→Arg; Lys 94→Glu; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Lys 121→Glu; Ala 133→Thr; and Cys 153→Ser;(e) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Thr 42→Ser; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ser 150→Ile; and Cys 153→Ser;(f) Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Lys 52→Glu; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Thr 71→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ala 133→Thr; Arg 148→Ser; Ser 150→Ile; and Cys 153→Ser; and(g) Ala 5→Thr; Arg 26→Glu; Glu 27→Gly; Phe 28→Cys; Pro 29→Arg; Glu 30→Pro; Met 31→Trp; Leu 33→Ile; Glu 34→Phe; Gly 46→Asp; Leu 56→Ala; Ser 58→Asp; Arg 60→Pro; Cys 61→Ala; Thr 71→Ala; Cys 101→Ser; Glu 104→Val; Leu 105→Cys; His 106→Asp; Lys 108→Ser; Arg 111→Pro; Lys 114→Trp; Ser 150→Ile; and Cys 153→Ser.

32. The fusion protein of any one of claim 29-32, wherein the amino acid sequence of the lipocalin mutein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-40 or of a fragment or variant thereof.

33. The fusion protein of any one of claim 29-32, wherein the amino acid sequence of the lipocalin mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-40.

34. The fusion protein of any one of claims 1-28, wherein the lipocalin mutein comprises one or more mutated amino acid residues at positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature human neutrophil gelatinase-associated lipocalin (hNGAL) (SEQ ID NO: 2).

35. The fusion protein of claim 34, wherein the amino acid sequence of the lipocalin mutein comprises, at positions corresponding to positions 28, 36, 40-41, 49, 52, 65, 68, 70, 72-73, 77, 79, 81, 83, 87, 94, 96, 100, 103, 106, 125, 127, 132 and 134 of the linear polypeptide sequence of mature human neutrophil gelatinase-associated lipocalin (hNGAL) (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg or Lys; Gln 49→Val, Ile, His, Ser or Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Met, Ala or Gly; Leu 70→Ala, Lys, Ser or Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Met, Arg, Thr or Asn; Trp 79→Ala or Asp; Arg 81→Met, Trp or Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu and Lys 134→Tyr.

36. The fusion protein of any one of claims 1-28, wherein the lipocalin mutein comprises one or more mutated amino acid residues at positions corresponding to positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of mature human neutrophil gelatinase-associated lipocalin (hNGAL) (SEQ ID NO: 2).

37. The fusion protein of claim 36, wherein the amino acid sequence of the lipocalin mutein comprises, at positions corresponding to positions 20, 25, 28, 33, 36, 40-41, 44, 49, 52, 59, 68, 70-73, 77-82, 87, 92, 96, 98, 100, 101, 103, 122, 125, 127, 132, and 134 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2), one or more of the following mutated amino acid residues: Gln 20→Arg; Asn 25→Tyr or Asp; Gln 28→His; Val 33→Ile; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Val or Asp; Gln 49→His; Tyr 52→Ser or Gly; Lys 59→Asn; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln or His; Tyr 78→His; Trp 79→Ile; Ile 80→Asn; Arg 81→Trp or Gln; Thr 82→Pro; Cys 87→Ser; Phe 92→Leu or Ser; Asn 96→Phe; Lys 98→Arg; Tyr 100→Asp; Pro 101→Leu; Leu 103→His or Pro; Phe 122→Tyr; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly.

38. The fusion protein of any one of claims 34-37, wherein the amino acid sequence of the lipocalin mutein comprises one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2): (a) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(b) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Ile; Tyr 52→Met; Asn 65→Asp; Ser 68→Met; Leu 70→Lys; Arg 72→Asp; Lys 73→Asp; Asp 77→Met; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(c) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Ala; Leu 70→Ala; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103 His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(d) Gln 28 His; Leu 36 Gln; Ala 40 Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Asn 65 Asp; Ser 68 Ala; Leu 70 Ala; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Asp; Arg 81→Trp; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(e) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Ser; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Ser; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Met; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(f) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Val; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Arg; Trp 79→Asp; Arg 81→Ser; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(g) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→His; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(h) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Lys; Gln 49→Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Gly; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Thr; Trp 79→Ala; Arg 81→Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr;(i) Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg; Gln 49→Ser; Tyr 52→Met; Asn 65→Asp; Ser 68→Ala; Leu 70→Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Asn; Trp 79→Ala; Arg 81→Ser; Cys 87→Ser; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr.(j) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(k) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70 Met; Arg 72→Leu; Lys 73 Asp; Asp 77→Gln; Trp 79 Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Lys 98→Arg; Tyr 100→Asp; Pro 101→Leu; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(l) Asn 25→Tyr; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Gln; Phe 92→Ser; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(m) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Tyr 78→His; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(n) Asn 25→Asp; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(o) Val 33→Ile; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(p) Gln 20→Arg; Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Val; Gln 49→His; Tyr 52→Gly; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Phe 122→Tyr; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(q) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Ile 80→Asn; Arg 81→Trp; Thr 82→Pro; Asn 96→Phe; Tyr 100→Asp; Pro 101→Leu; Leu 103→Pro; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly;(r) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Gln 49→His; Tyr 52→Gly; Lys 59→Asn; Ser 68 Asp; Leu 70 Met; Arg 72→Leu; Lys 73→Asp; Asp 77→Gln; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100 Asp; Leu 103 His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly; and(s) Leu 36→Met; Ala 40→Asn; Ile 41→Leu; Glu 44→Asp; Gln 49→His; Tyr 52→Ser; Ser 68→Asp; Leu 70→Met; Phe 71→Leu; Arg 72→Leu; Lys 73→Asp; Asp 77→His; Trp 79→Ile; Arg 81→Trp; Phe 92→Leu; Asn 96→Phe; Tyr 100→Asp; Leu 103→His; Lys 125→Ser; Ser 127→Ile; Tyr 132→Trp; and Lys 134→Gly.

39. The fusion protein of any one of claims 34-38, wherein the amino acid sequence of the lipocalin mutein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-59 or of a fragment or variant thereof.

40. The fusion protein of any one of claims 34-38, wherein the amino acid sequence of the lipocalin mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-59.

41. The fusion protein of any one of claims 1-40, wherein one subunit is linked to another subunit via a linker.

42. The fusion protein of any one of claims 1-41, wherein the second subunit is linked at the N-terminus via a linker to the N- or C-terminus of each heavy chain constant region (CH) of the first subunit or the N- or C-terminus of each light chain constant region (CL) of the first subunit.

43. The fusion protein of any one of claims 1-42, wherein the third subunit is linked at the N-terminus via a linker to the N- or C-terminus of each heavy chain constant region (CH) of the first subunit, the N- or C-terminus of each light chain constant region (CL) of the first subunit, or the C-terminus of each second subunit.

44. The fusion protein of any one of claims 41-43, wherein the linker is an unstructured (Gly-Gly-Gly-Gly-Ser)3 linker (SEQ ID NO: 13).

45. The fusion protein of any one of claims 41-43, wherein the liker is an unstructured glycine-serine linker, a polyproline linker, a proline-alanine-serine polymer, or a linker selected from the group consisting of SEQ ID NOs: 13-23.

46. The fusion protein of any one of claims 1-45, wherein the first subunit is an antibody.

47. The fusion protein of claim 46, wherein the heavy chain variable region of the antibody is selected from a group consisting of SEQ ID NOs: 75-79, and wherein the light chain variable region of the monoclonal antibody is selected from a group consisting of SEQ ID NOs: 80-84.

48. The fusion protein of claim 46, wherein the antibody comprises a heavy chain that is any one of SEQ ID NOs: 85-86, and a light chain of SEQ ID NO: 87.

49. The fusion protein of claim 46, wherein the antibody comprises a heavy chain variable region and a light chain variable region, respectively, as follows: SEQ ID NOs: 75 and 80, SEQ ID NOs: 76 and 81, SEQ ID NOs: 77 and 82, SEQ ID NOs: 78 and 83, or SEQ ID NOs:79 and 84.

50. The fusion protein of claim 46, wherein the antibody comprises a heavy chain and a light chain, respectively, as follows: SEQ ID NOs: 85 and 87 and SEQ ID NOs: 86 and 87.

51. The fusion protein of claim 46, wherein the heavy chain of the antibody comprises one of the following sets of CDR sequences: (a) GFSLSNYD (HCDR1, SEQ ID NO: 59), IWTGGAT (HCDR2, SEQ ID NO: 60), VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 61);(b) GFDIKDTY (HCDR1, SEQ ID NO: 65), IDPADGNT (HCDR2, SEQ ID NO: 66), ARGLGAWFAS (HCDR3; SEQ ID NO: 67); and(c) GFNIKDTY (HCDR1, SEQ ID NO: 70), IDPANGNT (HCDR2, SEQ ID NO: 71), SRGPPGGIGEYIYAMDY (HCDR3; SEQ ID NO: 72).

52. The fusion protein of claim 46, wherein the light chain of the antibody comprises one of the following sets of CDR sequences: (a) QSIGTN (LCDR1, SEQ ID NO: 63), YAS (LCDR2), QQSNSWPYT (LCDR3; SEQ ID NO: 64);(b) QDITNS (LCDR1, SEQ ID NO: 68), YTS (LCDR2), QQGHTLPPT (LCDR3; SEQ ID NO: 69); and(c) SSVSSSY (LCDR1, SEQ ID NO: 73), STS (LCDR2), HQYHRSPPT (LCDR3; SEQ ID NO: 74).

53. The fusion protein of claim 46, wherein the heavy chain of the antibody comprises the following set of CDR sequences: GFSLSNYD (HCDR1, SEQ ID NO: 59), IWTGGAT (HCDR2, SEQ ID NO: 60), and VRDSNYRYDEPFTY (HCDR3; SEQ ID NO: 61) and the light chain of the antibody comprises the following set of CDR sequences QSIGTN (LCDR1, SEQ ID NO: 62), YAS (LCDR2), and QQSNSWPYT (LCDR3; SEQ ID NO: 63).

54. The fusion protein of claim 46, wherein the monoclonal antibody has an IgG4 backbone.

55. The fusion protein of claim 54, wherein the IgG4 backbone has one or more of the following mutations: S228P, N297A, F234A, L235A, M428L, N434S, M252Y, S254T, and T256E.

56. The fusion protein of any one of claims 1-55, wherein the fusion protein comprises an amino acid sequence shown in any one of SEQ ID NOs: 86-94, or wherein the fusion protein comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or higher sequence identity to the amino acid sequences shown in any one of SEQ ID NOs: 88-94.

57. The fusion protein of any one of claims 1-56, wherein the fusion protein comprises the amino acids shown in SEQ ID NOs: 90 and 87, the amino acids shown in SEQ ID NOs: 86 and 91, the amino acids shown in SEQ ID NOs: 92 and 87, the amino acids shown in SEQ ID NOs: 86 and 93, the amino acids shown in SEQ ID NOs: 94 and 87, or the amino acids shown in SEQ ID NOs: 90 and 91.

58. The fusion protein of any one of claims 1-56, wherein the fusion protein comprises the amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or higher sequence identity to the amino acid sequences shown in SEQ ID NOs: 90 and 87, SEQ ID NOs: 86 and 91, SEQ ID NOs: 92 and 87, SEQ ID NOs: 86 and 93, SEQ ID NOs: 94 and 87, or SEQ ID NOs: 90 and 91.

59. A nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of any one of claims 1-58.

60. The nucleic acid molecule of claim 59, wherein the nucleic acid molecule is operably linked to a regulatory sequence to allow expression of said nucleic acid molecule.

61. The nucleic acid molecule of claim 59 or 60, wherein the nucleic acid molecule is comprised in a vector or in a phagemid vector.

62. A host cell containing a nucleic acid molecule of any one of claims 58-60.

63. A method of producing the fusion protein according to any one of claims 1-62, wherein the fusion protein is produced starting from the nucleic acid coding for the fusion protein.

64. The method of claim 63, wherein the fusion protein is produced in a bacterial or eukaryotic host organism and is isolated from this host organism or its culture.

65. A use of the fusion protein according to any one of claims 1-58 or a composition comprising such fusion protein for simultaneously activating downstream signaling pathways of CD137 and engaging PD-L1-positive tumor cells.

66. A method of simultaneously activating downstream signaling pathways of CD137 and engaging PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

67. A method of simultaneously co-stimulating T-cells and engaging PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

68. A method of simultaneously inducing lymphocyte activity and engaging PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

69. A method of inducing CD137 clustering and activation on T-cells and directing said T cells to PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

70. A method of inducing a localized lymphocyte response in the vicinity of PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

71. A method of inducing increased IL-2 and/or cytotoxic factors secretion by T-cells in the vicinity of PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

72. The method of claim 71, wherein the cytotoxic factors are selected from the group consisting of perforin, granzyme B, and granzyme A.

73. A method of inducing increased secretion of cytotoxic factors by T-cells in the vicinity of PD-L1-positive tumor cells, comprising applying one or more fusion proteins of any one of claims 1-58 or one or more compositions comprising such fusion protein to a tissue comprising a tumor.

74. A pharmaceutical composition comprising one or more fusion proteins of any one of claims 1-58.

75. A method of preventing, ameliorating, or treating PD-L1-positive cancers, comprising applying the fusion protein of any one claims 1-58 or one or more a composition comprising such fusion protein to a tissue comprising a tumor.

76. The fusion protein of any one of claims 1-58 for use in a therapy.

77. The fusion protein for use of claim 70, wherein the use is in the treatment of cancer.

78. Use of a fusion protein of any one of claims 1-58 for the manufacture of a medicament.

79. The use of claim 78, wherein the medicament is for the treatment of cancer.